reaction	EC	activators	inhibitors	literature	ligandStructureId	commentary
3OAR140	1.1.1.100		(E)-1-(4-methylpiperidin-1-yl)-3-phenylprop-2-en-1-one	703163	96400	80% residual activity
3OAR140	1.1.1.100		(E)-2-nitrophenyl cinnamate	703163	53976	
3OAR140	1.1.1.100		(E)-3-phenoxybenzyl 3-(benzo[d][1,3]dioxol-5-yl)acrylate	703163	92483	61% residual activity
3OAR140	1.1.1.100		(E)-4-cyanophenyl 3-(benzo[d][1,3]dioxol-5-yl)acrylate	703163	53975	
3OAR140	1.1.1.100		(E)-benzyl 3-(benzo[d][1,3]dioxol-5-yl)acrylate	703163	96399	71% residual activity
3OAR140	1.1.1.100		(E)-phenyl 3-(benzo[d][1,3]dioxol-5-yl)acrylate	703163	53974	69% residual activity
3OAR140	1.1.1.100		1,2,3,4,6-penta-O-galloyl-beta-D-glucose	685704	8498	mixed type of inhibition. IC50 value 0.9 microgramm per ml, Ki value 0.21 microgramm per ml
3OAR140	1.1.1.100		chlorogenic acid	669013	488	IC50: 0.881-0.948 mM
3OAR140	1.1.1.100		epigallocatechin gallate	704337	936	
3OAR140	1.1.1.100		N-(1,3-dioxoisoindolin-2-yl)-2-oxo-2H-chromene-3-carboxamide	703163	53977	69% residual activity
3OAR140	1.1.1.100		NADP+	669013	6	competitive product inhibition
3OAR140	1.1.1.100		quercetin	706142	131	
3OAR140	1.1.1.100		Tannic acid	706142	782	; strongest inhibition on FabG, shows time-dependent irreversible inhibition
IMPD	1.1.1.205		1H-naphtho[2,3-d]imidazol-2-ylmethyl 4-aminobenzoate	711735	5912	not inhibitory to wild-type
IMPD	1.1.1.205		2-[(3-ethyl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(4-methoxyphenyl)acetamide	711735	5911	not inhibitory to wild-type
IMPD	1.1.1.205		2-[2-(Z)-fluorovinyl]-inosine 5'-phosphate	703193	53985	is a time-dependent inactivator
IMPD	1.1.1.205		3-(1H-naphtho[2,3-d]imidazol-2-yl)propyl 4-aminobenzoate	711735	6928	not inhibitory to wild-type
IMPD	1.1.1.205		5,5'-dithiobis(2-nitrobenzoate)	347929	196	
IMPD	1.1.1.205		6-Chloro-9-beta-D-ribofuranosylpurine 5 '-phosphate	347929	12759	covalent modification of the enzyme, total inactivation after 15 min at 0.01 mg/ml Cl-IMP, activity can be restored with 2-mercaptoethanol
IMPD	1.1.1.205		6-chloroinosine 5'-phosphate	701583	12759	
IMPD	1.1.1.205		ADP	347946	8	
IMPD	1.1.1.205		AMP	347946	9	
IMPD	1.1.1.205		ATP	347946	7	
IMPD	1.1.1.205		Ca2+	701583	18	competitive inhibition with respect to both K+ and NAD+
IMPD	1.1.1.205		EAD	703193	53984	
IMPD	1.1.1.205		EICARMP	703193	12760	
IMPD	1.1.1.205		GDP	347946	49	
IMPD	1.1.1.205		GMP	347909	150	competitive with respect to IMP and non competitive with respect to NAD+
IMPD	1.1.1.205		GMP	347938	150	competitive with respect to IMP
IMPD	1.1.1.205		GMP	347941	150	; weak and competitive inhibition, strong binding, dissociation by 3 M urea
IMPD	1.1.1.205		GMP	347939, 347946	150	
IMPD	1.1.1.205		GTP	347946	35	
IMPD	1.1.1.205		imidazo[4,5-e][1,4]diazapine	701583	8129	
IMPD	1.1.1.205		imidazo[4,5-e][1,4]diazapine	703193	8129	fat base nucleotide, inosine 5'-phosphate but not NAD+ protects against inhibition
IMPD	1.1.1.205		iodoacetamide	347929	63	
IMPD	1.1.1.205		iodoacetate	347929	87	
IMPD	1.1.1.205		Li+	701583	142	competitive inhibition with respect to both K+ and NAD+
IMPD	1.1.1.205		Li+	703193	142	
IMPD	1.1.1.205		methyl 3-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate	711735	5910	not inhibitory to wild-type
IMPD	1.1.1.205		methyl methanethiosulfonate	347929	1724	
IMPD	1.1.1.205		Mg2+	347946	25	inhibits K+ activation
IMPD	1.1.1.205		Mg2+	701583	25	competitive inhibition with respect to both K+ and NAD+
IMPD	1.1.1.205		mizoribine	703193	3450	
IMPD	1.1.1.205		mizoribine monophosphate	701583	5261	
IMPD	1.1.1.205		Mycophenolic acid	705494	470	
IMPD	1.1.1.205		N-(4-methoxyphenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide	711735	5909	not inhibitory to wild-type
IMPD	1.1.1.205		N-(4-methoxyphenyl)-2-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]acetamide	711735	5908	not inhibitory to wild-type
IMPD	1.1.1.205		N-(naphthalen-2-yl)-2-[2-(pyridin-2-yl)-5,6-dihydro-1H-benzimidazol-1-yl]acetamide	711735	8182	not inhibitory to wild-type
IMPD	1.1.1.205		Na+	701583	55	competitive inhibition with respect to both K+ and NAD+
IMPD	1.1.1.205		Na+	703193	55	
IMPD	1.1.1.205		p-chloromercuribenzoate	347946	40	
IMPD	1.1.1.205		P1-(thiazofurin-5'-yl)-P2-(adenosyl-5'-yl)-alpha,beta-methylene diphosphate	701583	4752	
IMPD	1.1.1.205		thiazole-4-carboxamide adenine dinucleotide	347911	1595	reversible inhibition
IMPD	1.1.1.205		tiazofurin	347911	1402	
IMPD	1.1.1.205		xanthosine 5'-phosphate	347946	772	
IMPD	1.1.1.205	glutathione		347934, 347946	41	
HISTD	1.1.1.23		HgCl2	286332	104	0.5 mM, 100% inhibition, 0.05 mM 79% inhibition
HISTD	1.1.1.23		Urea	286332	110	2.2 mM, 50% inhibition, reversible
DXPRIi	1.1.1.267		(2R,3R)-2,3,4-trihydroxybutyl dihydrogen phosphate	675580	39699	IC50: 0.310 mM
DXPRIi	1.1.1.267		(2R,3R)-4-amino-2,3-dihydroxybutyl dihydrogen phosphate	675580	39700	very weak inhibitor, IC50: 5 mM, above
DXPRIi	1.1.1.267		(2R,3S)-2,3-dihydroxy-4-(hydroxyamino)-4-oxobutyl dihydrogen phosphate	675580	39697	very weak inhibitor, IC50: 5 mM, above
DXPRIi	1.1.1.267		(2R,3S)-4-amino-2,3-dihydroxy-4-oxobutyl dihydrogen phosphate	675580	39698	IC50: 0.253 mM
DXPRIi	1.1.1.267		(2S,3R)-2,3-dihydroxy-4-phosphonooxybutyric acid	675580	41314	IC50: 0.551 mM
DXPRIi	1.1.1.267		(2S,3R)-methyl 2,3-dihydroxy-4-phosphonooxybutyrate	675580	41315	IC50: 1.024 mM
DXPRIi	1.1.1.267		(3-(hydroxy[(pentafluorophenyl)carbonyl]amino)propyl)phosphonic acid	684769	45954	
DXPRIi	1.1.1.267		(3-[hydroxy(5-oxohexanoyl)amino]propyl)phosphonic acid	684769	45955	
DXPRIi	1.1.1.267		(3-[hydroxy(6-phenylhexanoyl)amino]propyl)phosphonic acid	684769	45956	
DXPRIi	1.1.1.267		(3-[hydroxy(hexadecanoyl)amino]propyl)phosphonic acid	684769	45957	
DXPRIi	1.1.1.267		(3S,4R)-3,4-dihydroxy-4-methyl-5-oxohexylphosphonic acid	697249	52037	
DXPRIi	1.1.1.267		(4-[[3-(hydroxymethyl)phenyl]amino]-4-oxobutyl)phosphonic acid	724558	62202	26.8% inhibition
DXPRIi	1.1.1.267		[(1-isoquinolinylamino)methylene]-1,1-bisphosphonate	655787	79763	50% inhibition at 0.004 mM
DXPRIi	1.1.1.267		[[(5-chloro-2-pyridinyl)amino]methylene]-1,1-bisphosphonate	655787	47758	50% inhibition at 0.007 mM
DXPRIi	1.1.1.267		[2-[(3-cyanophenyl)amino]-2-oxoethyl]phosphonic acid	724558	103005	20.0% inhibition
DXPRIi	1.1.1.267		[2-[(3-hydroxyphenyl)amino]-2-oxoethyl]phosphonic acid	724558	62199	43.9% inhibition
DXPRIi	1.1.1.267		[2-[(3-methoxyphenyl)amino]-2-oxoethyl]phosphonic acid	724558	62201	17.8% inhibition
DXPRIi	1.1.1.267		[3-(acetyl(hydroxy)amino)propyl]phosphonic acid 3-methylbutyl ester	697335	52051	
DXPRIi	1.1.1.267		[3-(acetyl(hydroxy)amino)propyl]phosphonic acid mono-n-butyl ester	697335	52050	
DXPRIi	1.1.1.267		[3-(acetyl(hydroxy)amino)propyl]phosphonic acid mono-n-propyl ester	697335	52049	
DXPRIi	1.1.1.267		[3-(acetyl(hydroxy)amino)propyl]phosphonic acid mono(2-naphthalen-1-yl-ethyl) ester	697335	52054	
DXPRIi	1.1.1.267		[3-(acetyl(hydroxy)amino)propyl]phosphonic acid mono(2-naphthalen-2-yl-ethyl) ester	697335	52053	
DXPRIi	1.1.1.267		[3-(acetyl(hydroxy)amino)propyl]phosphonic acid monomethyl ester	697335	52047	
DXPRIi	1.1.1.267		[3-(acetyl(hydroxy)amino)propyl]phosphonic acid monophenethyl ester	697335	52052	
DXPRIi	1.1.1.267		[3-(acetyl(hydroxy)amino)propyl]phosphonic monoethyl ester	697335	52048	
DXPRIi	1.1.1.267		[3-[acetyl(hydroxy)amino]-1-(pyridin-3-yl)propyl]phosphonic acid	723812	7036	
DXPRIi	1.1.1.267		[3-[acetyl(hydroxy)amino]-1-(pyridin-4-yl)propyl]phosphonic acid	723812	7037	
DXPRIi	1.1.1.267		[3-[acetyl(hydroxy)amino]-1-phenylpropyl]phosphonic acid	723812	10331	
DXPRIi	1.1.1.267		[3-[formyl(hydroxy)amino]-1-(pyridin-3-yl)propyl]phosphonic acid	723812	7034	
DXPRIi	1.1.1.267		[3-[formyl(hydroxy)amino]-1-(pyridin-4-yl)propyl]phosphonic acid	723812	7035	
DXPRIi	1.1.1.267		[3-[formyl(hydroxy)amino]-1-phenylpropyl]phosphonic acid	723812	19743	
DXPRIi	1.1.1.267		[4-[(3-hydroxyphenyl)amino]-4-oxobutyl]phosphonic acid	724558	62200	49.2% inhibition
DXPRIi	1.1.1.267		[5-[(3-bromophenyl)amino]-5-oxopentyl]phosphonic acid	724558	103004	26.8% inhibition
DXPRIi	1.1.1.267		1-hydroxy-5-phenylpyridin-2(1H)-one	712689	8183	minimal inhibitory concentration for growth 0.1 mM
DXPRIi	1.1.1.267		1,1-difluoro-1-deoxy-D-xylulose 5-phosphoric acid	675577	41312	i.e. CF2-DXP, very low inhibition
DXPRIi	1.1.1.267		1,1,1-trifluoro-1-deoxy-D-xylulose 5-phosphoric acid	675577	41311	i.e. CF3-DXP, very low inhibition
DXPRIi	1.1.1.267		1,2-dideoxy-D-hexulose 6-phosphate	675577	41313	i.e. Et-DXP, very low inhibition
DXPRIi	1.1.1.267		3-([(1H-indol-3-yl)acetyl]amino)propylphosphonic acid	697249	52040	
DXPRIi	1.1.1.267		3-([2-(methoxycarbonyl)benzoyl]amino)propylphosphonic acid	697249	52041	
DXPRIi	1.1.1.267		3-([3-(1H-indol-3-yl)propanoyl]amino)propylphosphonic acid	697249	52039	
DXPRIi	1.1.1.267		3-([4-(1H-indol-3-yl)butanoyl]amino)propylphosphonic acid	697249	52038	
DXPRIi	1.1.1.267		3-(hydroxy([(2-phenylbutanoyl)amino]acetyl)amino)propylphosphonic acid	697249	17925	
DXPRIi	1.1.1.267		3-(hydroxy([(3-methylbutanoyl)amino]acetyl)amino)propylphosphonic acid	697249	17924	
DXPRIi	1.1.1.267		3-(hydroxy([(4-phenoxybutanoyl)amino]acetyl)amino)propylphosphonic acid	697249	17930	
DXPRIi	1.1.1.267		3-(hydroxy([(4-phenylbutanoyl)amino]acetyl)amino)propylphosphonic acid	697249	17926	
DXPRIi	1.1.1.267		3-[(([(3,4-dimethoxyphenyl)acetyl]amino)acetyl)(hydroxy)amino]propylphosphonic acid	697249	17928	
DXPRIi	1.1.1.267		3-[([(cyclopropylcarbonyl)amino]acetyl)(hydroxy)amino]propylphosphonic acid	697249	17927	
DXPRIi	1.1.1.267		3-[(2-hydroxybenzoyl)amino]propylphosphonic acid	697249	52042	
DXPRIi	1.1.1.267		3-[(3,4-diethoxybenzoyl)amino]propylphosphonic acid	697249	52043	
DXPRIi	1.1.1.267		3-[(3,4-dimethoxybenzoyl)amino]propylphosphonic acid	697249	52046	
DXPRIi	1.1.1.267		3-[(4-methylpentanoyl)amino]propylphosphonic acid	697249	52044	
DXPRIi	1.1.1.267		3-[(4-phenoxybenzoyl)amino]propylphosphonic acid	697249	52045	
DXPRIi	1.1.1.267		3-[hydroxy(([3-(trifluoromethoxy)benzoyl]amino)acetyl)amino]propylphosphonic acid	697249	17929	
DXPRIi	1.1.1.267		3-[hydroxy(([4-(1H-indol-3-yl)butanoyl]amino)acetyl)amino]propylphosphonic acid	697249	17923	
DXPRIi	1.1.1.267		3-fluoro-1-deoxy-D-xylulose-5-phosphate	656890	36418	noncompetitive
DXPRIi	1.1.1.267		4-benzylbenzene-1,2-diol	712689	12913	minimal inhibitory concentration for growth 1 mM
DXPRIi	1.1.1.267		4-fluoro-1-deoxy-D-xylulose-5-phosphate	656890	36419	noncompetitive
DXPRIi	1.1.1.267		Arbutus andrachne plant extract	689434		
DXPRIi	1.1.1.267		biphenyl-3,4-diol	712689	10055	minimal inhibitory concentration for growth 0.5 mM
DXPRIi	1.1.1.267		Cercis siliquastrum leaf extract	689434		high inhibitory activity
DXPRIi	1.1.1.267		Cu2+	286427	28	
DXPRIi	1.1.1.267		diethyl (2-[[3-(hydroxymethyl)phenyl]amino]-2-oxoethyl)phosphonate	724558	62198	40.4% inhibition
DXPRIi	1.1.1.267		diethyl (3-[[3-(hydroxymethyl)phenyl]amino]-3-oxopropyl)phosphonate	724558	102999	17.9% inhibition
DXPRIi	1.1.1.267		diethyl [2-[(3-bromophenyl)amino]-2-oxoethyl]phosphonate	724558	103003	21.4% inhibition
DXPRIi	1.1.1.267		diethyl [2-[(3-cyanophenyl)amino]-2-oxoethyl]phosphonate	724558	62197	11.9% inhibition
DXPRIi	1.1.1.267		diethyl [2-[(3-hydroxyphenyl)amino]-2-oxoethyl]phosphonate	724558	62196	24.4% inhibition
DXPRIi	1.1.1.267		diethyl [2-[(3-methoxyphenyl)amino]-2-oxoethyl]phosphonate	724558	103001	11% inhibition
DXPRIi	1.1.1.267		diethyl [3-[(3-hydroxyphenyl)amino]-3-oxopropyl]phosphonate	724558	103000	33.5% inhibition
DXPRIi	1.1.1.267		diethyl [3-[(3-methoxyphenyl)amino]-3-oxopropyl]phosphonate	724558	103002	14.1% inhibition
DXPRIi	1.1.1.267		EDTA	286427	223	
DXPRIi	1.1.1.267		Fe2+	286427	23	
DXPRIi	1.1.1.267		fosmidomycin	655787	1029	50% inhibition at 0.0035 mM
DXPRIi	1.1.1.267		fosmidomycin	656553	1029	model for tight-binding mode of inhibition
DXPRIi	1.1.1.267		fosmidomycin	673073	1029	acts by binding strongly to DXR as a slow tight-binding inhibitor, inhibitor-enzyme interaction and structure analysis for design of inhibitors, possibly mimics a transition state in the reaction coordinate of the substrate, the initial rapid equilibrium is subject to negative cooperativity, overview
DXPRIi	1.1.1.267		fosmidomycin	675580	1029	a phosphonic metabolite from Streptomyces rubellomurinus
DXPRIi	1.1.1.267		fosmidomycin	286428, 675577, 684210, 684769, 697249, 697335, 723812	1029	
DXPRIi	1.1.1.267		fosmidomycin	724558	1029	a natural product isolated from Streptomyces lavendulae
DXPRIi	1.1.1.267		fosmidomycin analogues	673073		synthesis, stereochemistry, and analysis of inhibitory potency of several fosmidomycin analogues, overview
DXPRIi	1.1.1.267		FR 900098	673073	3266	N-acetyl analogue of fosmidomycin
DXPRIi	1.1.1.267		FR-900098	697249	3266	fosmidomycin homologue
DXPRIi	1.1.1.267		FR900098	675577	3266	specific inhibition
DXPRIi	1.1.1.267		FR900098	684769	3266	N-acetyl homologue of fosmidomycin
DXPRIi	1.1.1.267		FR900098	697335	3266	fosmidomycin homologue
DXPRIi	1.1.1.267		FR900098	724558	3266	an acetyl analogue of fosmidomycin
DXPRIi	1.1.1.267		Geranium molle plant extract	689434		
DXPRIi	1.1.1.267		Helianthemum ventosum plant extract	689434		
DXPRIi	1.1.1.267		Helianthemum vesicarium plant extract	689434		
DXPRIi	1.1.1.267		Sarcopoterium spinosum plant extract	689434		
ME2	1.1.1.40		Ca2+	722940	18	
ME2	1.1.1.40		Co2+	722940	21	
ME2	1.1.1.40		Cu2+	722940	28	strong inhibition
ME2	1.1.1.40		Mg2+	687388	25	activates at up to 4 mM, inhibition above, probably due to blockage of substrate binding, Km is 0.19 mM
ME2	1.1.1.40		Zn2+	722940	19	strong inhibition
ICDHyr	1.1.1.42		desferroxamine	698056	3329	
ICDHyr	1.1.1.42		Diethylenetriaminepentaacetic acid	698056	10742	
ICDHyr	1.1.1.42		manganese(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin	698056	52062	a superoxide dismutase mimic, ICD is inactivated by superoxide, but the inactivated enzyme is replaced by de novo protein synthesis
ICDHyr	1.1.1.42		phosphoenolpyruvate	680481	47	allosteric inhibition. Phosphoenolpyruvate enhances the uncompetitive inhibition of isocitrate lyase by increasing isocitrate, which protects isocitrate dehydrogenase from the inhibition, and contributes to the control through the tricarboxylic acid cycle and glyoxylate shunt
GND	1.1.1.44		5,5'-dithiobis(2-nitrobenzoic acid)	286851, 286874, 286882	196	
GND	1.1.1.44		ATP	286861, 286882, 286904	7	
GND	1.1.1.44		D-fructose 1,6-diphosphate	286851, 286861, 286882, 286904	100	
GND	1.1.1.44		NADPH	286851, 286882, 286904	5	
GND	1.1.1.44		p-chloromercuribenzoate	286851, 286882	40	
GND	1.1.1.44		Rose bengal	286851	1008	photooxidation
GND	1.1.1.44		Rose bengal	286882	1008	
G6PDH2r	1.1.1.49		ATP	722473	7	10 mM, 50-75% inhibition, assay without MgCl2
G6PDH2r	1.1.1.49		Cd2+	722473	48	1 mM, 83% inhibition
G6PDH2r	1.1.1.49		Co2+	722473	21	1 mM, 56% inhibition
G6PDH2r	1.1.1.49		Cu2+	722473	28	1 mM, complete inhibition
G6PDH2r	1.1.1.49		Hg2+	722473	31	1 mM, complete inhibition
G6PDH2r	1.1.1.49		Mn2+	722473	26	1 mM, 56% inhibition
G6PDH2r	1.1.1.49		NADH	722577	3	allosteric inhibition, inhibition is not reversed by NAD+, AMP, or spermidine
G6PDH2r	1.1.1.49		NADPH	722244	5	product inhibition with NADP+ or D-glucose 6-phosphate as the varying substrate
G6PDH2r	1.1.1.49		NADPH	722473	5	
G6PDH2r	1.1.1.49		NADPH	722577	5	when NADP+ is the varied substrate, NADPH NADPH is a competitive inhibitor both in the presence and absence of Mg2+, linear competitive inhibition. When glucose 6-phosphate is the varied substrate NADPH causes linear noncompetitive inhibition
G6PDH2r	1.1.1.49	spermidine		722577	140	activation constant: 0.2 mM
G3PD2	1.1.1.94		(NH4)2SO4	287523	334	100 mM, 68% inhibition, 10 mM, 8% inhibition
G3PD2	1.1.1.94		(NH4)2SO4	287523	334	100 mM, 68% inhibition, 10 mM, 8% inhibition
G3PD2	1.1.1.94		2',5'-ADP	669177	1457	
G3PD2	1.1.1.94		2',5'-ADP	669177	1457	
G3PD2	1.1.1.94		3,4-dihydroxybutyl 1-phosphonate	669177	84692	competitive versus dihydroxyacetone phosphate, binding to a regulatory site
G3PD2	1.1.1.94		3,4-dihydroxybutyl 1-phosphonate	669177	84692	competitive versus dihydroxyacetone phosphate, binding to a regulatory site
G3PD2	1.1.1.94		ADP	669177	8	
G3PD2	1.1.1.94		ADP	669177	8	
G3PD2	1.1.1.94		ADP-ribose	669177	337	
G3PD2	1.1.1.94		ADP-ribose	669177	337	
G3PD2	1.1.1.94		AMP	669177	9	
G3PD2	1.1.1.94		AMP	669177	9	
G3PD2	1.1.1.94		ATP	669177	7	
G3PD2	1.1.1.94		ATP	669177	7	
G3PD2	1.1.1.94		dihydroxyacetone phosphate	669175	241	noncompetitive versus NADP+
G3PD2	1.1.1.94		dihydroxyacetone phosphate	669175	241	noncompetitive versus NADP+
G3PD2	1.1.1.94		DL-glycerol 3-phosphate	287523	352	0.05 mM, 26% inhibition
G3PD2	1.1.1.94		DL-glycerol 3-phosphate	287523	352	0.05 mM, 26% inhibition
G3PD2	1.1.1.94		ethylene glycol phosphate	669177	28739	binding to the active site
G3PD2	1.1.1.94		ethylene glycol phosphate	669177	28739	binding to the active site
G3PD2	1.1.1.94		glyceraldehyde-3-phosphate	689802	473	competitive inhibitor
G3PD2	1.1.1.94		glyceraldehyde-3-phosphate	689802	473	competitive inhibitor
G3PD2	1.1.1.94		glyceric acid 2-phosphate	689802	783	competitive inhibitor
G3PD2	1.1.1.94		glyceric acid 2-phosphate	689802	783	competitive inhibitor
G3PD2	1.1.1.94		glycerol 3-phosphate	287523	352	50% inhibition with 0.035 mM, sigmoid inhibition curve, competitive inhibition vs. glycerone phosphate, uncompetitive vs. NADPH
G3PD2	1.1.1.94		glycerol 3-phosphate	287523	352	50% inhibition with 0.035 mM, sigmoid inhibition curve, competitive inhibition vs. glycerone phosphate, uncompetitive vs. NADPH
G3PD2	1.1.1.94		K2PO4-	287523	70513	100 mM, 95% inhibition, 10 mM, 27% inhibition
G3PD2	1.1.1.94		K2PO4-	287523	70513	100 mM, 95% inhibition, 10 mM, 27% inhibition
G3PD2	1.1.1.94		K2SO4	287523	1867	100 mM, 60% inhibition
G3PD2	1.1.1.94		K2SO4	287523	1867	100 mM, 60% inhibition
G3PD2	1.1.1.94		KCl	287523	74	100 mM, 47% inhibition
G3PD2	1.1.1.94		KCl	287523	74	100 mM, 47% inhibition
G3PD2	1.1.1.94		Na2PO4-	287523	2591	100 mM, 92% inhibition, 10 mM, 27% inhibition
G3PD2	1.1.1.94		Na2PO4-	287523	2591	100 mM, 92% inhibition, 10 mM, 27% inhibition
G3PD2	1.1.1.94		Na2SO4	287523	590	100 mM, 63% inhibition
G3PD2	1.1.1.94		Na2SO4	287523	590	100 mM, 63% inhibition
G3PD2	1.1.1.94		NaCl	287523	39	100 mM, 47% inhibition
G3PD2	1.1.1.94		NaCl	287523	39	100 mM, 47% inhibition
G3PD2	1.1.1.94		NAD+	669177	4	
G3PD2	1.1.1.94		NAD+	669177	4	
G3PD2	1.1.1.94		NADP+	669175	6	competitive versus NADPH
G3PD2	1.1.1.94		NADP+	669177	6	
G3PD2	1.1.1.94		NADP+	669175	6	competitive versus NADPH
G3PD2	1.1.1.94		NADP+	669177	6	
G3PD2	1.1.1.94		NADPH	669175	5	competitive versus NADP+
G3PD2	1.1.1.94		NADPH	669175	5	competitive versus NADP+
G3PD2	1.1.1.94		NH4Cl	287523	282	100 mM, 37% inhibition
G3PD2	1.1.1.94		NH4Cl	287523	282	100 mM, 37% inhibition
G3PD2	1.1.1.94		NMN	669177	623	
G3PD2	1.1.1.94		NMN	669177	623	
G3PD2	1.1.1.94		palmitoyl-CoA	287523	122	0.0015 mM, 52% inhibition
G3PD2	1.1.1.94		palmitoyl-CoA	287523	122	0.0015 mM, 52% inhibition
G3PD2	1.1.1.94		phosphoenolpyruvate	689802	47	competitive inhibitor
G3PD2	1.1.1.94		phosphoenolpyruvate	689802	47	competitive inhibitor
G3PD2	1.1.1.94		sn-glycerol-3-phosphate	669175	352	product inhibition at an allosteric, regulatory site, competitive versus dihydroxyacetone phosphate, noncompetitive versus NADPH, the wild-type enzyme is feedback inhibited
G3PD2	1.1.1.94		sn-glycerol-3-phosphate	669177	352	the wild-type enzyme is feedback regulated, competitive versus dihydroxyacetone phosphate, binding to a regulatory site
G3PD2	1.1.1.94		sn-glycerol-3-phosphate	669175	352	product inhibition at an allosteric, regulatory site, competitive versus dihydroxyacetone phosphate, noncompetitive versus NADPH, the wild-type enzyme is feedback inhibited
G3PD2	1.1.1.94		sn-glycerol-3-phosphate	669177	352	the wild-type enzyme is feedback regulated, competitive versus dihydroxyacetone phosphate, binding to a regulatory site
PGCD	1.1.1.95		(R)-2-amino-1-propanol	287548	24967	slightly
PGCD	1.1.1.95		3-phosphoglycerate	287546	174	
PGCD	1.1.1.95		Ag+	287530	71	inhibition can be overcome by addition of dithiothreitol
PGCD	1.1.1.95		amino acids	287525, 287547, 287548	3318	
PGCD	1.1.1.95		beta-Alanine	287548	411	slightly
PGCD	1.1.1.95		glycine	287546	68	
PGCD	1.1.1.95		glycine	287548	68	mutants show less to no inhibition
PGCD	1.1.1.95		hydroxyglutarate	287546	4350	product inhibition of the alpha-ketoglutarate reduction
PGCD	1.1.1.95		iodoacetate	287525	87	
PGCD	1.1.1.95		L-alanine	287525	97	
PGCD	1.1.1.95		L-alanine	287548	97	native enzyme and mutant H344A
PGCD	1.1.1.95		L-allothreonine	287525	2124	
PGCD	1.1.1.95		L-homoserine	287525	294	
PGCD	1.1.1.95		L-Ser	656083	89	binding of the inhibitor to the apoenzyme displays positive cooperativity in the binding of the first two serine molecules and negative cooperativity in the binding of the last two serine molecules. At least two NADH-induced conformational forms of the enzyme bind the inhibitor in the physiological range. Successive binding of NADH to the enzyme results in an increase in the affinity for the first inhibitor ligand bound and a lessening of both the positive and negative cooperativity of inhibitor binding
PGCD	1.1.1.95		L-serine	287525	89	50% inhibition at 0.005 mM and pH 7.5
PGCD	1.1.1.95		L-serine	287530	89	inhibition of enzyme from E. coli, Salmonella typhimurium and Haemophilus influenzae, not of mammalian enzyme, inhibition in both reaction directions
PGCD	1.1.1.95		L-serine	287546, 287547	89	allosteric inhibition, regulates the pathway of serine biosynthesis by end product inhibition interacting with His344, Asn346 and Asn364
PGCD	1.1.1.95		L-serine	287548	89	50% inhibition at 0.008 mM L-serine; allosteric inhibition, regulates the pathway of serine biosynthesis by end product inhibition interacting with His344, Asn346 and Asn364
PGCD	1.1.1.95		L-serine	287550	89	sigmoidal binding curve with mutant G294V/G336V, mutants with decreased sensitivity to serine
PGCD	1.1.1.95		L-serine	663605	89	feedback regulation, positive and negative cooperativity in absence of NADH, positive in presence of NADH, overview
PGCD	1.1.1.95		L-serine	667649	89	the enzyme contains an ACT regulatory domain which binds L-serine for feedback regulation, binding site lies around residues H344-N364
PGCD	1.1.1.95		L-serine	711203	89	physiological inhibitor, exerts its effect on at least two steps in the kinetic mechanism. There is a small but significant effect on the dissociation constant of NADH, increasing the Kd to 5 and 23 microM from 0.6 and 9 microM, respectively, for the two sets of sites in the enzyme. After the second substrate is added, serine reduces the amplitude of the signal without a significant effect on the observed rate constants for binding. The serine concentration that reduces the amplitude by 50% is equal to the K0.5 for serine inhibition. Serine binding eliminates a conformational change subsequent to substrate binding by formation of a dead-end quaternary complex consisting of enzyme, coenzyme, substrate, and effector. The rate data conform to a model in which serine can bind to two forms of the enzyme with different affinities
PGCD	1.1.1.95		L-serine	287551, 687564, 724307	89	
PGCD	1.1.1.95		L-threonine	287525	220	
PGCD	1.1.1.95		Mercurials	287530		inhibition can be overcome by addition of dithiothreitol
PGCD	1.1.1.95		N-ethylmaleimide	287525	46	
PGCD	1.1.1.95		NADH	287525	3	inhibition of phosphoglycerate oxidation
DHDPRy	1.17.1.8		(4S)-4-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinate	390620	4325	
DHDPRy	1.17.1.8		2,6-pyridine dicarboxylate	696300	1090	stable analog of the dihydrodipicolinate substrate, the binding affinity is not affected by the presence of NADH or NAD+
DHDPRy	1.17.1.8		2,6-pyridinedicarboxylic acid	390624	1090	dead-end inhibitor
DHDPRy	1.17.1.8		2,6-pyridinedicarboxylic acid	390623, 390625	1090	
DHDPRy	1.17.1.8		3-acetyl-NAD+	390617	706	
DHDPRy	1.17.1.8		alpha-picolinic acid	390617	3360	
DHDPRy	1.17.1.8		catechol rhodanine acetic acid	696300	94414	binds to the NADH cofactor site
DHDPRy	1.17.1.8		DELTA3-tetrahydroisophthalic acid	390620	71843	moderate inhibition
DHDPRy	1.17.1.8		dipicolinate	390617, 390618	1090	
DHDPRy	1.17.1.8		dipicolinate	390620	1090	reversible, competitive versus substrate (4S)-4-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinate
DHDPRy	1.17.1.8		Isophthalic acid	390617	2475	competitive versus dihydrodipicolinate
DHDPRy	1.17.1.8		Isophthalic acid	390618	2475	
DHDPRy	1.17.1.8		Isophthalic acid	390620	2475	reversible, competitive versus substrate 2,3-dihydrodipicolinate
DHDPRy	1.17.1.8		NAD+	390617	4	
DHDPRy	1.17.1.8		NADP+	390617	6	
DHDPRy	1.17.1.8		NADP+	390624	6	product inhibition
DHDPRy	1.17.1.8		phosphate	390617, 390618	12	
DHDPRy	1.17.1.8	NADH		696300	3	
DHDPRy	1.17.1.8	NADPH		696300	5	similar affinity as NADH
GAPD	1.2.1.12		ADP	287977	8	inhibition of esterase activity with p-nitrophenyl acetate
GAPD	1.2.1.12		AMP	287977	9	inhibition of esterase activity with p-nitrophenyl acetate
GAPD	1.2.1.12		ATP	287977	7	inhibition of esterase activity with p-nitrophenyl acetate
GAPD	1.2.1.12		iodoacetate	287977	87	
G5SD	1.2.1.41		3-(Phosphonoacetylamido)-L-alanine	390307	28827	competitive with respect to DL-pyrroline-5-carboxylic acid, non-competitive with respect to NADP+ and phosphate
G5SD	1.2.1.41		Ba2+	390308	105	50% inhibition at 1 mM
G5SD	1.2.1.41		Co2+	390308	21	50% inhibition at 2.5 mM
G5SD	1.2.1.41		Cu2+	390308	28	75% inhibition at 0.1 mM
G5SD	1.2.1.41		iodoacetamide	390308	63	40% inhibition at 1 mM
G5SD	1.2.1.41		iodoacetate	390308	87	15% inhibition at 1 mM
G5SD	1.2.1.41		NADPH	390307	5	competitive with respect to all three substrates
G5SD	1.2.1.41		Ni2+	390308	36	100% inhibition at 0.1 mM
G5SD	1.2.1.41		p-chloromercuribenzoate	390308	40	100% inhibition at 1 mM
GLUTRR	1.2.1.70		1,10-phenanthroline	656104	58	5 mM, 25% inhibition
GLUTRR	1.2.1.70		2,2'-dipyridyl	656104	317	5 mM, 20% inhibition
GLUTRR	1.2.1.70		5,5'-dithiobis(2-nitrobenzoic acid)	656104	196	1 mM, 80% inhibition
GLUTRR	1.2.1.70		Co2+	656104	21	
GLUTRR	1.2.1.70		EDTA	656104	223	10 mM, 55% inhibition
GLUTRR	1.2.1.70		EGTA	656104	157	10 mM, 35% inhibition
GLUTRR	1.2.1.70		glutamycin	656104	23065	3 mM, 90% inhibition
GLUTRR	1.2.1.70		iodoacetamide	656104	63	0.1 mM, complete inhibition
GLUTRR	1.2.1.70		Ni2+	656104	36	
GLUTRR	1.2.1.70		PtCl4	656104	36432	1 mM, 90% inhibition
PPND	1.3.1.12		2-hydroxyphenylacetate	390524, 654967	4351	
PPND	1.3.1.12		4-hydroxyphenylpyruvate	390529	353	
PPND	1.3.1.12		5,5'-dithiobis(2-nitrobenzoate)	3557, 390522	196	
PPND	1.3.1.12		5,6-dihydro-5,6-dihydroxychorismate	654967	36438	
PPND	1.3.1.12		adamantane analogues	390521, 390524, 390555		
PPND	1.3.1.12		adamantane-1-acetate	654967	36435	
PPND	1.3.1.12		adamantane-1-carboxylate	654967	36434	
PPND	1.3.1.12		adamantane-1-phosphonate	654967	23069	
PPND	1.3.1.12		adamantane-1,3-diacetate	654967	36436	
PPND	1.3.1.12		AMP	390529	9	
PPND	1.3.1.12		chorismate analogues	390521, 390524, 390555		
PPND	1.3.1.12		chorismate-5,6-epoxide	654967	36437	
PPND	1.3.1.12		citrate	390524	125	
PPND	1.3.1.12		Diethylmalonate	390524	20315	
PPND	1.3.1.12		iodoacetamide	3557, 390522	63	
PPND	1.3.1.12		iodoacetamide	390537	63	modification of only one cysteinyl residue results in the inactivation
PPND	1.3.1.12		iodoacetate	390522, 390537	87	
PPND	1.3.1.12		L-tyrosine	3557, 390518, 390522, 390526, 390539	103	
PPND	1.3.1.12		L-tyrosine	655472	103	feed-back inhibition of both enzyme activities
PPND	1.3.1.12		L-tyrosine	671431	103	Tyr263 or residues 354 to 357 of the enzyme are involved in the feedback inhibition
PPND	1.3.1.12		malonate	390524	328	
PPND	1.3.1.12		N-benzenesulfonyl-L-phenylalanine	390532		
PPND	1.3.1.12		N-Benzyloxycarbonyl-L-phenylalanine	390532	6204	
PPND	1.3.1.12		N-bromosuccinimide	390537	185	
PPND	1.3.1.12		N-ethylmaleimide	390537	46	
PPND	1.3.1.12		N-Toluene-p-sulfonyl-L-p-aminophenylalanine	390532	65087	
PPND	1.3.1.12		N-Toluene-p-sulfonyl-L-phenylalanine	390532	65088	
PPND	1.3.1.12		NADH	390529	3	
PPND	1.3.1.12		Tetranitromethane	390537	1100	
PPND	1.3.1.12		trans-2,3-pleiadanedicarboxylic acid	654967	36019	i.e. diacid, 50% inhibition at 0.25 mM, inhibits competitively the prephenate dehydrogenase activity, but not the chorismate mutase activity of the enzyme
PPND	1.3.1.12	Adamantane 1-acetate		390521	36435	
PPND	1.3.1.12	Bovine serum albumin		390521		at low concentrations of prephenate
PPND	1.3.1.12	Bovine serum albumin		390529		formation of an enzyme-albumin complex with MW of 150000
PTPATi	1.3.1.98		1,2-bis(3-chlorophenyl)-3,5-dioxopyrazolidine-4-carboxylic acid (4-chlorophenyl)amide	669810	11962	
PTPATi	1.3.1.98		1,2-bis(3-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-trifluoromethylphenyl)amide	669810	11963	
PTPATi	1.3.1.98		1,2-bis(3-chlorophenyl)pyrazolidine-3,5-dione	669810	11938	
PTPATi	1.3.1.98		1,2-bis(3,4-dichlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3,4-dichlorophenyl)amide	669810	11965	
PTPATi	1.3.1.98		1,2-bis(3,4-dichlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 4-tolylamide	669810	11964	
PTPATi	1.3.1.98		1,2-bis(3,4-dichlorophenyl)pyrazolidine-3,5-dione	669810	11937	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-3,5-dioxo-N-phenylpyrazolidine-4-carboxamide	669810	11940	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-4-(3,4-dichlorobenzoyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11967	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-4-cyclohexanecarbonyl-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11975	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (1-naphthalen-2-ylethyl)amide	669810	11958	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (2-chlorophenyl)amide	669810	11945	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3-chlorophenyl)amide	669810	11944	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (3-trifluoromethylphenyl)amide	669810	11942	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-chlorophenyl)amide	669810	11941	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-cyanophenyl)amide	669810	11947	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-hydroxyphenyl)amide	669810	11951	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-methoxyphenyl)amide	669810	11946	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-trifluoromethylphenyl)amide	669810	11943	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [1-(4-bromophenyl)ethyl]amide	669810	11957	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [4(3-(dimethylamino)propylcarbamoyl)-phenyl]amide	669810	11952	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 2-chlorobenzylamide	669810	11955	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 2,4-dichlorobenzylamide	669810	11954	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 3,4-dichlorobenzylamide	669810	11953	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid cyclohexylamide	669810	11948	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid phenethylamide	669810	11956	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-methoxybenzoyl)-1,2-dihydropyrazol-3-one	669810	11968	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-trifluoromethoxybenzoyl)-1,2-dihydropyrazol-3-one	669810	11970	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(4-trifluoromethylbenzoyl)-1,2-dihydropyrazol-3-one	669810	11973	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-4-(thiophene-2-carbonyl)-1,2-dihydropyrazol-3-one	669810	11972	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)-5-hydroxy-4-[2-(4-methoxyphenyl)acetyl]-1,2-dihydropyrazol-3-one	669810	11974	
PTPATi	1.3.1.98		1,2-bis(4-chlorophenyl)pyrazolidine-3,5-dione	669810	11936	
PTPATi	1.3.1.98		1,2-bis(4-fluorophenyl)pyrazolidine-3,5-dione	669810	11939	
PTPATi	1.3.1.98		1,2-diphenylpyrazolidine-3,5-dione	669810	11935	slight inhibition
PTPATi	1.3.1.98		3-acetylpyridine adenine dinucleotide phosphate	286065	4537	oxidized form, competitive with respect to NADPH
PTPATi	1.3.1.98		3'-NADP+	286065	21450	noncompetitive with respect to NADPH
PTPATi	1.3.1.98		4-(4-butoxybenzoyl)-1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11969	
PTPATi	1.3.1.98		4-(4-chlorobenzoyl)1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11966	
PTPATi	1.3.1.98		4-(biphenylyl-4-carbonyl)-1,2-bis(4-chlorophenyl)-5-hydroxy-1,2-dihydropyrazol-3-one	669810	11971	
PTPATi	1.3.1.98		4-[1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonyl]aminobenzoic acid	669810	11950	
PTPATi	1.3.1.98		4-[1,2-bis(4-chlorophenyl)-5-hydroxy-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonyl]aminobenzoic acid ethyl ester	669810	11949	
PTPATi	1.3.1.98		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-bromophenyl)amide	669810	11960	
PTPATi	1.3.1.98		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid (4-chlorophenyl)amide	669810	11959	
PTPATi	1.3.1.98		5-hydroxy-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid phenylamide	669810	11961	
PTPATi	1.3.1.98		ADP	286065	8	at high concentration, competitive with respect to NADPH
PTPATi	1.3.1.98		ADP-ribose	286065	337	at high concentration, competitive with respect to NADPH
PTPATi	1.3.1.98		iodoacetate	286059	87	
PTPATi	1.3.1.98		NADP+	286065	6	noncompetitive with respect to NADPH
PTPATi	1.3.1.98		NADP+	722831	6	about 78% inhibition at 0.06 mM
PTPATi	1.3.1.98		NADPH	286065	5	substrate inhibition at pH 7.0, Ki: 1.6 mM
PTPATi	1.3.1.98		nicotinamide 1,N6-ethenoadenine dinucleotide phosphate	286065	11049	oxidized form, noncompetitive with respect to NADPH
PTPATi	1.3.1.98		nicotinamide hypoxanthine dinucleotide phosphate	286065	7467	oxidized form, noncompetitive with respect to NADPH
PTPATi	1.3.1.98		p-chloromercuribenzoate	286059	40	
PTPATi	1.3.1.98		thio-NADP+	286065	1513	noncompetitive with respect to NADPH
PTPATi	1.3.1.98		thio-NADP+	722831	1513	about 80% inhibition at 0.06 mM
PTPATi	1.3.1.98		UDP	286065	24	at high concentration, noncompetitive with respect to NADPH
PTPATi	1.3.1.98		UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine	286065	4911	substrate inhibition at pH 6, Ki 0.01 mM with 0.15 mM NADPH, weaker at more basic pH
PTPATi	1.3.1.98		uridine diphospho-N-acetylglucosamine	286065	120	at very high concentration, noncompetitive with respect to NADPH
PTPATi	1.3.1.98		uridine diphospho-N-acetylmuramic acid	286065	70996	uncompetitive with respect to NADPH
UAPGR	1.3.5.2		deoxycholate	391227	369	
UAPGR	1.3.5.2		Dodecyl sulfate	391227	10561	
UAPGR	1.3.5.2		fatty acids	391227	663	
UAPGR	1.3.5.2		Orotate	390918	373	competitive to dihydroorotate
UAPGR	1.3.5.2		Orotate	391227	373	
GLUDy_reverse	1.4.1.4		AMP	391685	9	inhibitory at higher concentrations than 1 mM
GLUDy_reverse	1.4.1.4		Ca2+	391662	18	at 1 mM 27% inhibition
GLUDy_reverse	1.4.1.4		guanidine hydrochloride	391686	804	complete loss of activity
GLUDy_reverse	1.4.1.4		L-homoserine	391686	294	competitive inhibitor with respect to both ammonia and glutamine
GLUDy_reverse	1.4.1.4		pyridoxal 5'-phosphate	391667	30	at 10 mM, 90% inhibition, complete protection when 16.8 mM 2-oxoglutarate and 1.68 mM NADP+ are added
GLUDy_reverse	1.4.1.4		Urea	391685	110	at 8 M stable for 10 min
GLUDy_reverse	1.4.1.4		Zn2+	391662	19	at 1 mM, 40% inhibition
GLUDy_reverse	1.4.1.4	AMP		391685	9	slight activation up to 1 mM
GLUDy_reverse	1.4.1.4	ATP		391685	7	at 2 mM, 50% activation
GLUDy_reverse	1.4.1.4	UTP		391675	61	activates up to 70%
PDX5POi	1.4.3.5		4-deoxypyridoxine 5'-phosphate	391903	11700	competitive inhibition
PDX5POi	1.4.3.5		pyridoxal 5'-phosphate	391903	30	competitive inhibition
PDX5POi	1.4.3.5		pyridoxal 5'-phosphate	391904, 654870	30	
PDX5POi	1.4.3.5		pyridoxal 5'-phosphate	724427	30	competitive inhibitor
PDX5POi	1.4.3.5		pyridoxine 5'-phosphate	654870	795	substrate inhibition
P5CR	1.5.1.2		NADH	392126	3	above 0.16 mM
P5CR	1.5.1.2		NADH	392126	3	above 0.16 mM
P5CR	1.5.1.2		NADP+	392126	6	
P5CR	1.5.1.2		NADP+	392126	6	
P5CR	1.5.1.2		NADPH	392126	5	above 0.13 mM
P5CR	1.5.1.2		NADPH	392126	5	above 0.13 mM
P5CR	1.5.1.2		p-chloromercuribenzoate	392126	40	complete inhibition at 0.125 mM, can be prevented by addition of dithiothreitol
P5CR	1.5.1.2		p-chloromercuribenzoate	392126	40	complete inhibition at 0.125 mM, can be prevented by addition of dithiothreitol
P5CR	1.5.1.2		proline	392126	215	
P5CR	1.5.1.2		proline	392126	215	
P5CR	1.5.1.2		thiazolidine-4-carboxylic acid	392140	10694	42% inhibition at 10 mM, L-isomer
P5CR	1.5.1.2		thiazolidine-4-carboxylic acid	392140	10694	42% inhibition at 10 mM, L-isomer
MTHFR2	1.5.1.20		5,10-methylenetetrahydrofolate	696353	336	
MTHFR2	1.5.1.20		LY309887	672154	7882	i.e. 6R-2√Ç¬í,5√Ç¬í-thienyl-5,10-dideazatetrahydrofolate monoglutamate
MTHFR2	1.5.1.20		methylenetetrahydrofolate	654771	727	
MTHFR2	1.5.1.20		NADH	654771	3	
GF6PTA	1.5.1.5		ATP	392307, 392308	7	
GF6PTA	1.5.1.5		GTP	392307, 392308	35	
GF6PTA	1.5.1.5		N10-formyltetrahydrofolate	392307, 392308	2297	
METS	2.1.1.13	cyanocobalamin		441196	692	supports methyltransferase in extracts of animal tissues and Escherichia coli
METS	2.1.1.13	K+		441179	37	at 67 mM 1.4 fold activity
METS	2.1.1.13	Li+		441179	142	at 67 mM, 1.3fold activity
METS	2.1.1.13	Na+		441179	55	at 67 mM 1.5 fold activity
METS	2.1.1.13	NH4+		441179	50	at 67 mM 1.5 fold activity
METS	2.1.1.13	S-adenosyl-L-methionine		659993	22	required
METS	2.1.1.13	S-adenosylmethionine		441179	22	at about 0.0001 mM
METS	2.1.1.13	TrisHCl		441179	1644	at 67 mM 1.2 fold activity
TMDS	2.1.1.45		(+)tetrahydropteroylglutamate	485375	72260	
TMDS	2.1.1.45		(2S)-2-[([4-[(2-amino-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)sulfanyl]phenyl]carbonyl)amino]pentanedioic acid	688294	8030	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
TMDS	2.1.1.45		(S)-2-(5(((1,2-dihydro-3-methyl-1-oxobenzo(f)quinazolin-9-yl)methyl)amino)1-oxo-2-isoindolinyl)glutaric acid	692639	12511	BW1843U89, U89, distorts the thymidylate synthase active site
TMDS	2.1.1.45		10-propargyl-5,8-dideazafolate	688294	109179	PDDF
TMDS	2.1.1.45		10-propargyl-5,8-dideazafolate	692639	109179	PDDF, folate-like TS inhibitor
TMDS	2.1.1.45		10-propargyl-5,8-dideazafolate	693567	109179	i.e. PDDF. Dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
TMDS	2.1.1.45		10-propargyl-5,8-dideazafolate	485415, 705044	109179	
TMDS	2.1.1.45		2-amino-5-[(2-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9969	
TMDS	2.1.1.45		2-amino-5-[(2,5-dimethoxyphenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9960	
TMDS	2.1.1.45		2-amino-5-[(3-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9967	
TMDS	2.1.1.45		2-amino-5-[(3,4-dichlorophenyl)sulfanyl]-6-methylthieno[2,3-d]pyrimidin-4(3H)-one	693567	4266	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
TMDS	2.1.1.45		2-amino-5-[(3,4-dichlorophenyl)thio]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9961	
TMDS	2.1.1.45		2-amino-5-[(3,5-dichlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]-pyrimidin-4(3H)-one	705044	9962	
TMDS	2.1.1.45		2-amino-5-[(3,5-dimethoxyphenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9968	
TMDS	2.1.1.45		2-amino-5-[(4-bromophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	9966	
TMDS	2.1.1.45		2-amino-5-[(4-chlorophenyl)sulfanyl]-6-ethylthieno[2,3-d]pyrimidin-4(3H)-one	705044	4306	
TMDS	2.1.1.45		2-amino-6-ethyl-5-(2-naphthylthio)thieno[2,3-d]pyrimidin-4(3H)-one	705044	9963	
TMDS	2.1.1.45		2-amino-6-ethyl-5-(phenylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one	705044	4305	
TMDS	2.1.1.45		2-amino-6-ethyl-5-(pyridin-4-ylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one	705044	9964	
TMDS	2.1.1.45		2-amino-6-ethyl-5-[(4-fluorophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one	705044	9965	
TMDS	2.1.1.45		2-amino-6-ethyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one	705044	4307	
TMDS	2.1.1.45		2-amino-6-methyl-5-(2-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one	693567	4267	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
TMDS	2.1.1.45		2-amino-6-methyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one	693567	4268	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
TMDS	2.1.1.45		2'-deoxy-2',2'-difluorouridine 5'-dihydrogen	702544	54024	classic inhibitor (no time dependence of inhibition observed)
TMDS	2.1.1.45		2'-fluoro-ara-UMP	702544	54023	classic inhibitor (no time dependence of inhibition observed)
TMDS	2.1.1.45		2',5-difluoro-ara-UMP	702544	54025	slow-binding (time-dependent) inhibitor
TMDS	2.1.1.45		4-amino-N10-methylfolic acid	705044	213	
TMDS	2.1.1.45		5-fluoro-2'-deoxyuridylic acid	485358, 485359, 485369, 485375, 485383, 485397, 485402, 485413, 485417, 485419, 485423, 485430	640	
TMDS	2.1.1.45		5-fluorouracil	485374, 485397, 485413, 485419, 485423	651	
TMDS	2.1.1.45		5-Formyl-2'-deoxyuridylic acid	485365, 485375	6103	
TMDS	2.1.1.45		5-Mercapto-2'-deoxyuridylic acid	485375	7101	
TMDS	2.1.1.45		5,10-methylenetetrahydrofolate	485397	336	
TMDS	2.1.1.45		Chloroacetamide	485357	7150	
TMDS	2.1.1.45		diglutamate	485375	5463	
TMDS	2.1.1.45		dihydrofolate	485358, 485415	173	
TMDS	2.1.1.45		ethylene glycol	485431	1064	
TMDS	2.1.1.45		folic acid oligoglutamate	485371		
TMDS	2.1.1.45		glutamate	485375	38	
TMDS	2.1.1.45		glycerol	485431	129	
TMDS	2.1.1.45		iodoacetate	485357	87	
TMDS	2.1.1.45		methopterin	485365, 485372, 485376	213	
TMDS	2.1.1.45		methotrexate	705044, 711474	213	
TMDS	2.1.1.45		N-(4-((2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo(3,2-d)pyrimidin-5-yl)methyl)benzoyl)-L-glutamic acid	688294	9594	
TMDS	2.1.1.45		N-(4-((2-amino-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo(2,3-d)pyrimidin-5-yl)thio)benzoyl)-L-glutamic acid	688294	8030	
TMDS	2.1.1.45		N-[4-[(2-amino-6-ethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)thio]benzoyl]-L-glutamic acid	705044	9985	
TMDS	2.1.1.45		N-[4-[(2-amino-6-methyl-4-oxo-3,4-dihydro-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl]benzoyl]-L-glutamic acid	688294	9594	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Escherichia coli enzyme; dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
TMDS	2.1.1.45		N-[4-[(2-amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)sulfanyl]benzoyl]-L-glutamic acid	693567	4269	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
TMDS	2.1.1.45		N-[4-[(2-amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)sulfanyl]benzoyl]-L-glutamic acid	705044	4269	potent inhibitor of thymidylate synthase
TMDS	2.1.1.45		N-[4-[(2,4-diamino-5-methyl-furo[2,3-d]pyrimidin-6-yl)thio]-benzoyl]-L-glutamic acid	711474	6941	
TMDS	2.1.1.45		N-ethylmaleimide	485357	46	
TMDS	2.1.1.45		N5-formiminotetrahydropteroyltriglutamate	485371	29830	
TMDS	2.1.1.45		N5-formyltetrahydropteroyloligoglutamate	485371, 485375	32842	
TMDS	2.1.1.45		pemetrexed	693567	873	dual inhibitor of thymidylate synthase and dihydrofolate reductase. Comparison with inhibitory effect on human and Toxoplasma gondii enzyme
TMDS	2.1.1.45		pemetrexed	688294, 705044, 711474	873	
TMDS	2.1.1.45		piritrexim	705044	3911	
TMDS	2.1.1.45		plevitrexed	705044	9958	
TMDS	2.1.1.45		pteroylhexaglutamate	485375	8819	
TMDS	2.1.1.45		raltitrexed	705044, 711474	2263	
TMDS	2.1.1.45		tetrahydrohomofolate	485375	73309	
TMDS	2.1.1.45		tetrahydromethotrexate	485373, 485383	5672	
TMDS	2.1.1.45		thymidine phosphate	485358, 485363, 485415	1952	
TMDS	2.1.1.45		trimethoprim	705044, 711474	418	
TMDS	2.1.1.45		trimetrexate	705044, 711474	2328	
TMDS	2.1.1.45	2,3-Dimercaptopropanol		485358	1854	absolute requirement for a thiol, synthetase shows greatly dimished activity in absence
TMDS	2.1.1.45	dithiothreitol		485359, 485381, 485402, 485425	42	
TMDS	2.1.1.45	KCN		485358	149	
GHMT2r	2.1.2.1		4-chloro-L-threonine	441427, 441434	3227	
GHMT2r	2.1.2.1		5-formyltetrahydrofolate monoglutamate	441418	32280	
GHMT2r	2.1.2.1		5-methyltetrahydrofolate monoglutamate	441418	14207	
GHMT2r	2.1.2.1		5-Methyltetrahydrofolate triglutamate	441418	20101	
GHMT2r	2.1.2.1		5,5-dithiobis(2-nitrobenzoic acid)	441412	196	
GHMT2r	2.1.2.1		beta-trifluoroallothreonine	441427		
GHMT2r	2.1.2.1		beta-trifluorothreonine	441427		
GHMT2r	2.1.2.1		D-alanine	441412, 441424	151	inactivates enzyme by converting the enzyme bound pyridoxal 5'-phosphate to pyridoxamine phosphate in a transamination reaction
GHMT2r	2.1.2.1		methyl methanethiosulfonate	441412	1724	
GHMT2r	2.1.2.1		substituted hydroxylamine derivates	441427		
GHMT2r	2.1.2.1		sulfonyl fluoride triazine derivates	441427	8781	
GHMT2r	2.1.2.1		Thiosemicarbazide	441427	2487	
GHMT2r	2.1.2.1		Urea	703674	110	in 1 M urea, almost all the cofactor is bound to the enzyme as internal aldimine, indicating that the loss of activity does not result from the denaturation of the active site, these observations suggest that urea might act as an enzyme inhibitor
GHMT2r	2.1.2.1	L-serine		718984	89	stabilizes the dimeric form of the enzyme
MOHMT	2.1.2.11		3-Methyl-2-butanone	485700	7441	5 mM, 27% inhibition
MOHMT	2.1.2.11		coenzyme A	485700, 485701	10	above 1 mM
MOHMT	2.1.2.11		D-valine	485700	1427	5 mM, 16% inhibition
MOHMT	2.1.2.11		formaldehyde	485700	124	0.8 mM, partial inhibition
MOHMT	2.1.2.11		formaldehyde	485701	124	0.8 mM, partial inhibition; forward reaction
MOHMT	2.1.2.11		Isovalerate	485700	2843	5 mM, 39% inhibition
MOHMT	2.1.2.11		L-valine	485700	217	5 mM, 23% inhibition
MOHMT	2.1.2.11		Pantoate	485700, 485701	1878	0.05 mM or above
MOHMT	2.1.2.11		pantothenate	485700, 485701	1139	0.5 mM or above
MOHMT	2.1.2.11		pyruvate	485700	29	5 mM, 38% inhibition
MOHMT	2.1.2.11		tetrahydrofolate	485700	184	0.38 mM, partial inhibition
MOHMT	2.1.2.11		tetrahydrofolate	485701	184	0.38 mM, partial inhibition; forward reaction
CHORS	2.1.2.2		(6S)-N10-formyltetrahydrofolate	485718	72285	
CHORS	2.1.2.2		10-trifluoroacetyl-DDACTHF	672527	5140	
CHORS	2.1.2.2		4-carbamoyl-2-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid	672527	24283	
CHORS	2.1.2.2		4-carbamoyl-4-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid	672527	24284	
CHORS	2.1.2.2		5,10-dideaza-5,6,7,8-tetrahydrofolate	485715, 485719	7613	
CHORS	2.1.2.2		5,10-dideazatetrahydrofolate	485715, 485719, 485731, 485735	3415	
CHORS	2.1.2.2		5,8-Dideazafolate	485720, 485731	8296	
CHORS	2.1.2.2		beta-thioglycinamide dideazafolate	485718	72771	
CHORS	2.1.2.2		DDACTHF	672526, 672527	3265	
CHORS	2.1.2.2		dideazafolate	485718	8296	
CHORS	2.1.2.2		N10-(Bromoacetyl)-5,8-dideazafolate	485718	65101	
CHORS	2.1.2.2		N10-formyl-2,4-diaminodideazafolate	485718	1373	
DXPS	2.2.1.7		D-glyceraldehyde	719975	520	competitive inhibition with respect to pyruvate
DXPS	2.2.1.7		D-glyceraldehyde 3-phosphate	719975	139	substrate inhibition
DXPS	2.2.1.7		pyruvate	719975	29	substrate inhibition
ACGS	2.3.1.1		arginine	486063, 486066	117	0.02 mM, 50% inhibition; L-arginine
ACGS	2.3.1.1		arginine	685805	117	
ACGS	2.3.1.1		Cd2+	486063	48	0.1 mM, 94% inhibition
ACGS	2.3.1.1		coenzyme A	486061, 486063	10	2.5 mM, 50% inhibition
ACGS	2.3.1.1		Cu2+	486063	28	0.1 mM, 68% inhibition
ACGS	2.3.1.1		Hg2+	486063	31	0.1 mM; 50% inhibition
ACGS	2.3.1.1		High ionic strength	486061, 486063		
ACGS	2.3.1.1		KCl	486063	74	100 mM, 36% inhibition after 1 h, 300 mM, 74% inhibition after 1 h, 500 mM, 87% inhibition after 1 h
ACGS	2.3.1.1		L-citrulline	486063	730	10 mM, 75% inhibition
ACGS	2.3.1.1		L-Indospicine	486066	29438	0.2 mM; 50% inhibition
ACGS	2.3.1.1		N-acetylglutamate	486061	450	
ACGS	2.3.1.1		N-acetylglutamate	486063	450	25 mM, 50% inhibition
ACGS	2.3.1.1		N-ethylmaleimide	486063	46	
ACGS	2.3.1.1		O-(L-Norvalyl-5)-isourea	486066	65180	0.02 mM, 50% inhibition
ACGS	2.3.1.1		p-chloromercuribenzoate	486063	40	
ACGS	2.3.1.1		p-hydroxymercuribenzoate	486063	92	
ACGS	2.3.1.1		Zn2+	486063	19	0.1 mM, 43% inhibition
THDPS	2.3.1.117		2-Hydroxytetrahydropyran-2,6-dicarboxylic acid	486149	29918	competitive inhibition
THDPS	2.3.1.117		2-oxopimelic acid	486149	21889	5 mM, 57% inhibition
THDPS	2.3.1.117		2,6-dihydroxypimelic acid	486149	72385	0.54 mM, 66% inhibition
THDPS	2.3.1.117		4-oxo-(2E,5E)-heptadien-1,7-dioic acid	486149	47680	0.5 mM, 32% inhibition
THDPS	2.3.1.117		6-Aminocaproic acid	486149	1969	5 mM, 35% inhibition
THDPS	2.3.1.117		CaCl2	486148	193	1 mM, 3% inhibition
THDPS	2.3.1.117		CoCl2	486148	347	1 mM, 95% inhibition
THDPS	2.3.1.117		CuSO4	486148	228	1 mM, complete loss of activity
THDPS	2.3.1.117		D-2-aminopimelate	486149	11128	competitive vs. L-2-aminopimelate and tetrahydropicolinate
THDPS	2.3.1.117		D-2-hydroxypimelic acid	486149	72820	5 mM, 93% inhibition
THDPS	2.3.1.117		DL-2-amino-5-thiapimelic acid	486149	72865	5 mM, 75% inhibition
THDPS	2.3.1.117		L-2-hydroxypimelic acid	486149	72936	5 mM, 88% inhibition
THDPS	2.3.1.117		MgCl2	486148	176	1 mM, 20% inhibition
THDPS	2.3.1.117		MnCl2	486148	262	1 mM, 9% inhibition
THDPS	2.3.1.117		N-ethylmaleimide	486148	46	16 mM, 42% inhibition
THDPS	2.3.1.117		p-Chloromercuriphenylsulfonate	486148	1069	0.16 mM, 97% inhibition
THDPS	2.3.1.117		pimelic acid	486149	8396	5 mM, 43% inhibition
THDPS	2.3.1.117		ZnCl2	486148	236	1 mM, 88% inhibition
G1PACT	2.3.1.157		(1R,2R)-2-[[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	10263	
G1PACT	2.3.1.157		(1R,2R)-2-[[4-hydroxy-2-methoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	111799	
G1PACT	2.3.1.157		(1R,2R)-2-[[5-(acridin-10(9H)-ylsulfonyl)-2,4-dimethoxyphenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	10262	
G1PACT	2.3.1.157		(1R,2R)-2-[[5-(acridin-10(9H)-ylsulfonyl)-4-hydroxy-2-methoxyphenyl]carbamoyl]-3-methylcyclopropanecarboxylic acid	719070	10269	
G1PACT	2.3.1.157		(2E)-4-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobut-2-enoic acid	719064	6990	
G1PACT	2.3.1.157		[[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethyl]sulfanyl]acetic acid	719064	6992	
G1PACT	2.3.1.157		[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethoxy]acetic acid	719064	8210	
G1PACT	2.3.1.157		1-(2-[[([5-[(3-carboxypropanoyl)amino]-2,4-dimethoxyphenyl]sulfonyl)amino]methyl]phenyl)piperidine-4-carboxylic acid	719064	7018	
G1PACT	2.3.1.157		2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethyl acetate	719064	6989	
G1PACT	2.3.1.157		2-(2-cyanopyridin-4-yl)-N-[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]acetamide	719070	10267	
G1PACT	2.3.1.157		2-Nitro-5-thiocyanobenzoic acid	288685, 288686	7067	
G1PACT	2.3.1.157		2'-[[([5-[(3-carboxypropanoyl)amino]-2,4-dimethoxyphenyl]sulfonyl)amino]methyl]biphenyl-4-carboxylic acid	719064	8211	
G1PACT	2.3.1.157		4-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobutanoic acid	719064	6991	
G1PACT	2.3.1.157		4-([2,4-dimethoxy-5-[naphthalen-2-yl(phenyl)sulfamoyl]phenyl]amino)-4-oxobutanoic acid	719070	10258	
G1PACT	2.3.1.157		4-([4-hydroxy-2-methoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-4-oxobutanoic acid	719986	6985	
G1PACT	2.3.1.157		4-([5-[(4-aminophenyl)(phenyl)sulfamoyl]-2,4-dimethoxyphenyl]amino)-4-oxobutanoic acid	719070, 719986	3740	
G1PACT	2.3.1.157		4-([5-[bis(4-methylphenyl)sulfamoyl]-2,4-dimethoxyphenyl]amino)-4-oxobutanoic acid	719070	10257	
G1PACT	2.3.1.157		4-[(2,4-dimethoxy-5-[[2-(piperidin-1-yl)benzyl]sulfamoyl]phenyl)amino]-4-oxobutanoic acid	719064	7015	
G1PACT	2.3.1.157		4-[(5-[[2-(4-[[(carboxyacetyl)oxy]methyl]piperidin-1-yl)benzyl]sulfamoyl]-2,4-dimethoxyphenyl)amino]-4-oxobutanoic acid	719064	7017	
G1PACT	2.3.1.157		4-[[2,4-dimethoxy-5-(10H-phenothiazin-10-ylsulfonyl)phenyl]amino]-4-oxobutanoic acid	719070	10259	
G1PACT	2.3.1.157		4-[[2,4-dimethoxy-5-(10H-phenoxazin-10-ylsulfonyl)phenyl]amino]-4-oxobutanoic acid	719070, 719986	3503	
G1PACT	2.3.1.157		4-[[4-hydroxy-2-methoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]amino]-4-oxobutanoic acid	719070	10268	
G1PACT	2.3.1.157		4-[[5-([2-[4-(carboxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719064	7019	
G1PACT	2.3.1.157		4-[[5-([2-[4-(hydroxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719064	7016	
G1PACT	2.3.1.157		4-[[5-(dibenzo[b,f][1,4]oxazepin-10(11H)-ylsulfonyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719070	10260	
G1PACT	2.3.1.157		4-[[5-(diphenylsulfamoyl)-2,4-dimethoxyphenyl]amino]-4-oxobutanoic acid	719070	10256	
G1PACT	2.3.1.157		4-[2-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]amino)-2-oxoethoxy]benzoic acid	719064	6994	
G1PACT	2.3.1.157		DTNB	288685, 288686	196	
G1PACT	2.3.1.157		iodoacetamide	288686	63	
G1PACT	2.3.1.157		methyl 2-[([[5-(acetylamino)-2,4-dimethoxyphenyl]sulfonyl]amino)methyl]benzoate	719064	7012	
G1PACT	2.3.1.157		N-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]carbamothioyl)glycine	719064	6987	
G1PACT	2.3.1.157		N-([2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]carbamoyl)glycine	719064	6988	
G1PACT	2.3.1.157		N-(2,4-dimethoxy-5-[[2-(piperidin-1-yl)benzyl]sulfamoyl]phenyl)acetamide	719064	7013	
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]-2-(2-fluoropyridin-4-yl)acetamide	719070	10265	
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-(1,2,3,4-tetrahydroquinolin-2-ylsulfonyl)phenyl]-3-(2H-tetrazol-5-yl)propanamide	719070	10261	
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-(phenylsulfamoyl)phenyl]acetamide	719064	6997	
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-(piperidin-1-ylsulfonyl)phenyl]acetamide	719064	7002	
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-[(2-methoxybenzyl)sulfamoyl]phenyl]acetamide	719064	7009	
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-[(2-methyl-2,3-dihydro-1H-indol-1-yl)sulfonyl]phenyl]acetamide	719064	6986	the inhibitor binds at the C-terminal domain of GlmU engaging the A, B and C subunits of the trimer
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]-2-(pyridin-4-ylsulfanyl)acetamide	719064	6993	
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]acetamide	719064, 719986	3291	
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]benzamide	719064	6996	
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-[(2-methyl-3,4-dihydroquinolin-1(2H)-yl)sulfonyl]phenyl]methanesulfonamide	719064	6995	
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-[(2-methylpyrrolidin-1-yl)sulfonyl]phenyl]acetamide	719064	7001	
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-[(3-methylphenyl)sulfamoyl]phenyl]acetamide	719064	7007	
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-[(4-methylphenyl)sulfamoyl]phenyl]acetamide	719064	7008	
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-[methyl(phenyl)sulfamoyl]phenyl]acetamide	719064, 719986	3292	
G1PACT	2.3.1.157		N-[2,4-dimethoxy-5-[phenyl(propan-2-yl)sulfamoyl]phenyl]acetamide	719064	6998	
G1PACT	2.3.1.157		N-[5-([2-[4-(hydroxymethyl)piperidin-1-yl]benzyl]sulfamoyl)-2,4-dimethoxyphenyl]acetamide	719064	7014	
G1PACT	2.3.1.157		N-[5-(acridin-10(9H)-ylsulfonyl)-2,4-dimethoxyphenyl]-2-(2-fluoropyridin-4-yl)acetamide	719070	10266	
G1PACT	2.3.1.157		N-[5-(acridin-10(9H)-ylsulfonyl)-2,4-dimethoxyphenyl]-2-(pyridin-4-yl)acetamide	719070	10264	
G1PACT	2.3.1.157		N-[5-(dimethylsulfamoyl)-2,4-dimethoxyphenyl]acetamide	719064	7003	
G1PACT	2.3.1.157		N-[5-[(1,3-benzodioxol-5-ylmethyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7010	
G1PACT	2.3.1.157		N-[5-[(2-bromobenzyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7011	
G1PACT	2.3.1.157		N-[5-[(2-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7006	
G1PACT	2.3.1.157		N-[5-[(3-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7005	
G1PACT	2.3.1.157		N-[5-[(4-fluorophenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7004	
G1PACT	2.3.1.157		N-[5-[butyl(propan-2-yl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	7000	
G1PACT	2.3.1.157		N-[5-[ethyl(2-methylphenyl)sulfamoyl]-2,4-dimethoxyphenyl]acetamide	719064	6999	
G1PACT	2.3.1.157		N-acetylglucosamine-1-phosphate	288685	1096	acetyltransferase activity inhibited by its reaction product
G1PACT	2.3.1.157		N-ethylmaleimide	288686	46	
G1PACT	2.3.1.157		p-hydroxymercuribenzoate	288686	92	
G1PACT	2.3.1.157		UDP-MurNAc	288685	1441	1 mM, relative enzyme activity 2%
UDPG4E_reverse	2.3.1.30		ATP	657835	7	mixed non-competitive with respect to serine
UDPG4E_reverse	2.3.1.30		CoA	486778	10	
UDPG4E_reverse	2.3.1.30		cysteine	657835	70	competitive versus acetyl-CoA, mixed non-competitive with respect to serine
UDPG4E_reverse	2.3.1.30		cysteine	659391	70	competitive, binds at the serine substrate site, negatively regulates its own synthesis
UDPG4E_reverse	2.3.1.30		glycine	486778	68	competitive against L-serine, noncompetitive against acetyl-CoA
UDPG4E_reverse	2.3.1.30		glycine	657835	68	mixed non-competitive inhibitor of propionyl transfer to serine with respect to propionyl-CoA
UDPG4E_reverse	2.3.1.30		L-alanine	486778	97	noncompetitive against acetyl-CoA
UDPG4E_reverse	2.3.1.30		L-Cys	676935	70	
UDPG4E_reverse	2.3.1.30		L-cysteic acid	486752	2703	
UDPG4E_reverse	2.3.1.30		L-cysteine	486752, 486756, 486757, 486777	70	
UDPG4E_reverse	2.3.1.30		L-serine	486752	89	above 3 mM, weak
UDPG4E_reverse	2.3.1.30		N-acetyl-L-cysteine	486752	1771	
AIRC2	2.3.1.46		D-methionine	487045	743	slight feed-back inhibition
AIRC2	2.3.1.46		diethyldicarbonate	672232	265	inactivation, pH dependence, overview
AIRC2	2.3.1.46		Hydroxyethylclavam	487044	64660	oxygen analogue beta-lactam antibiotic
AIRC2	2.3.1.46		iodoacetamide	487046	63	inhibition is pH-dependent
AIRC2	2.3.1.46		iodoacetamide	672232	63	inactivation, pH dependence, overview
AIRC2	2.3.1.46		L-methionine	487044, 487045	83	feed-back inhibition
AIRC2	2.3.1.46		L-methionine	671413	83	feedback inhibition
AIRC2	2.3.1.46		S-adenosyl-L-methionine	487044	22	feed-back inhibition
AIRC2	2.3.1.46		S-adenosyl-L-methionine	671413	22	feedback inhibition
AIRC2	2.3.1.46		Valclavam	487044	20644	oxygen analogue beta-lactam antibiotic, complete inhibition at 0.2 mM
AOXSr2	2.3.1.47		(R)-8-amino-7-oxononanoic acid	702483	3994	no inhibition up to 15 microM with 94.6% ee (S)-enantiomer as substrate, beyond that strong inhibitor of both enzyme forms, binding to active site
AOXSr2	2.3.1.47		8-Amino-7-oxononanoate	487047	1131	product inhibition in vivo
AOXSr2	2.3.1.47		D/L-histidine	487051	4409	
AOXSr2	2.3.1.47		L-cysteine	487047, 487051	70	
AOXSr2	2.3.1.47		trifluoroalanine	676274	8342	binding structure, irreversible suicide inhibition of the enzyme, involves decarboxylative defluorination of the inhibitor-PLP aldimine followed by attack of the conjugated imine by the amino group of the active site lysine to afford a covalently bound difluorinated intermediate, which can subsequently undergo further HF losses and hydrolysis to afford a 2-(pyridoximine phosphate) acetoyl protein adduct
LPADSS	2.4.1.182		octyl-beta-D-glucoside	638252	1726	
LPADSS	2.4.1.182	Triton X-100		702266	57	between 0 and 0.5 mM Triton X-100 increases the apparent specific activity 5fold
UAGPT3	2.4.1.227		(1R,3S,3aR,6aS)-3-((S)-1,2-dihydroxyethyl)-N-(2-((((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)amino)-2-oxoethyl)-1-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxamide	721824	102379	
UAGPT3	2.4.1.227		(1R,3S,3aR,6aS)-3-(2,3-dimethoxyphenyl)-N-[2-({[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}amino)-2-oxoethyl]-1-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxamide	721824	102378	
UAGPT3	2.4.1.227		(1R,3S,3aR,6aS)-N-[2-({[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}amino)-2-oxoethyl]-1-methyl-4,6-dioxo-3,5-diphenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxamide	721824	102376	
UAGPT3	2.4.1.227		(1R,3S,3aR,6aS)-N-[2-({[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}amino)-2-oxoethyl]-3-(2-methoxyphenyl)-1-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxamide	721824	102377	
UAGPT3	2.4.1.227		(1R,3S,3aR,6aS)-N-[2-({[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}amino)-2-oxoethyl]-3-(2-methoxyphenyl)-2-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxamide	721824	102387	
UAGPT3	2.4.1.227		(2S)-N-{[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}-1-{[(1R,3S,3aR,6aS)-3-(2-methoxyphenyl)-1-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrol-1-yl]carbonyl}pyrrolidine-2-carboxamide	721824		
UAGPT3	2.4.1.227		(2S)-N-{[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}-1-{[(1R,3S,3aR,6aS)-5-ethyl-3-(2-methoxyphenyl)-1-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrol-1-yl]carbonyl}pyrrolidine-2-carboxamide	721824	102390	
UAGPT3	2.4.1.227		5'-({[(2R,3R,3aR,6aR)-3-carboxy-2-(2,3-dihydroxypropyl)-6a-methyl-4,6-dioxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]acetyl}amino)-5'-deoxyuridine	721824	102383	
UAGPT3	2.4.1.227		5'-({[(2S,3R,3aR,6aR)-3-carboxy-2-(2-methoxyphenyl)-6a-methyl-4,6-dioxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]acetyl}amino)-5'-deoxyuridine	721824	102382	
UAGPT3	2.4.1.227		5'-({[(2S,3R,3aS,6aR)-3-carboxy-2-(2-methoxyphenyl)-6a-methyl-4,6-dioxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]acetyl}amino)-5'-deoxyuridine	721824	102385	
UAGPT3	2.4.1.227		5'-({[(2S,3R,3aS,6aR)-3-carboxy-2-(2,3-dimethoxyphenyl)-6a-methyl-4,6-dioxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]acetyl}amino)-5'-deoxyuridine	721824		
UAGPT3	2.4.1.227		5'-({[(2S,3R,3aS,6aR)-3-carboxy-2-(3,4-dimethoxyphenyl)-6a-methyl-4,6-dioxohexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]acetyl}amino)-5'-deoxyuridine	721824	102386	
UAGPT3	2.4.1.227		5'-({[(2S,3R,3aS,6aR)-3-carboxy-6a-methyl-4,6-dioxo-2-phenylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]acetyl}amino)-5'-deoxyuridine	721824	102384	
UAGPT3	2.4.1.227		5'-[(1-{[(2R,3R,4R,5S)-3,4-bis(methoxycarbonyl)-5-(2-methoxyphenyl)-2-methylpyrrolidin-2-yl]carbonyl}-L-prolyl)amino]-5'-deoxyuridine	721824	102389	
UAGPT3	2.4.1.227		5'-[(1-{[(2R,3S,4R,5S)-3,4-bis(methoxycarbonyl)-5-(2-methoxyphenyl)-2-methylpyrrolidin-2-yl]carbonyl}-L-prolyl)amino]-5'-deoxyuridine	721824	102388	
UAGPT3	2.4.1.227		5'-{[(3S,4R,5S)-3,4-bis(methoxycarbonyl)-5-(2-methoxyphenyl)-2-methyl-D-prolylglycyl]amino}-5'-deoxyuridine	721824	102381	
UAGPT3	2.4.1.227		5'-{[(3S5'-{[(3S,4R,5S)-3,4-bis(methoxycarbonyl)-2-methyl-5-phenyl-D-prolylglycyl]amino}-5'-deoxyuridine,4R,5S)-3,4-bis(methoxycarbonyl)-2-methyl-5-phenyl-D-prolylglycyl]amino}-5'-deoxyuridine	721824	102380	
UAGPT3	2.4.1.227		5'-O-(3-{[(1R,3S,3aR,6aS)-3-(2-methoxyphenyl)-1-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrol-1-yl]methoxy}-3-oxopropanoyl)uridine	721824	102391	
UAGPT3	2.4.1.227		5'-O-(4-{[(1R,3S,3aR,6aS)-3-(2-methoxyphenyl)-1-methyl-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrol-1-yl]methoxy}-4-oxobutanoyl)uridine	721824	102392	
UAGPT3	2.4.1.227		cephalosporin C	657559	398	50% inhibition at 0.014 mg/ml
UAGPT3	2.4.1.227		EDTA	488971	223	
UAGPT3	2.4.1.227		methanol	488978	78	
UAGPT3	2.4.1.227		Moenomycin	658448	2590	50% inhibition at 0.0106 mM
UAGPT3	2.4.1.227		N-p-chlorobiphenyl-vancomycin	658448	80653	50% inhibition at 0.00125 mM
UAGPT3	2.4.1.227		NG-p-chlorobiphenyl-vancomycin	658448	80652	50% inhibition at 0.0214 mM
UAGPT3	2.4.1.227		Ni2+	488971	36	
UAGPT3	2.4.1.227		nisin	657559	13919	50% inhibition at 0.016 mg/ml
UAGPT3	2.4.1.227		ramoplanin	488972, 703764	21972	
UAGPT3	2.4.1.227		ramoplanin	721824	21972	90% inhibition at 0.02 mM
UAGPT3	2.4.1.227		trifluoroethanol	488978	7477	
UAGPT3	2.4.1.227		tunicamycin	488972	1243	
UAGPT3	2.4.1.227		tunicamycin	657559	1243	50% inhibition at 0.0003 mg/ml
UAGPT3	2.4.1.227		UDP	488976	24	competitive inhibitor of UDP-GlcNAc donor, noncompetitive inhibitor of lipid I acceptor analogue
UAGPT3	2.4.1.227		UDP	703764	24	
UAGPT3	2.4.1.227		Vancomycin	657559	1560	50% inhibition at 0.009 mg/ml
UAGPT3	2.4.1.227		Vancomycin	658448	1560	50% inhibition at 0.0157 mM
UAGPT3	2.4.1.227		Zn2+	488971	19	
UAGPT3	2.4.1.227	Ca2+		488971	18	
UAGPT3	2.4.1.227	cardiolipin		703764	652	the activity of MurG is increased in the presence of cardiolipin
UAGPT3	2.4.1.227	dimethyl sulfoxide		488978	702	
UAGPT3	2.4.1.227	DMSO		703764	702	high concentration (35%) of dimethylsulfoxide is necessary for maximal enzyme activity
UAGPT3	2.4.1.227	Mg2+		488971, 488973, 488974, 488976, 488978	25	
KDOCT2	2.4.2.10		adenine	489719	136	not inhibitory
KDOCT2	2.4.2.10		adenosine	489719	116	not inhibitory
KDOCT2	2.4.2.10		ADP	489719	8	not inhibitory
KDOCT2	2.4.2.10		AMP	489719	9	not inhibitory
KDOCT2	2.4.2.10		ATP	489719	7	not inhibitory
KDOCT2	2.4.2.10		HgCl2	489719	104	slight inhibition of mutant, not wild-type
KDOCT2	2.4.2.10		iodoacetamide	489719	63	slight inhibition of mutant, not wild-type
KDOCT2	2.4.2.10		NEM	489719	46	slight inhibition of mutant, not wild-type
KDOCT2	2.4.2.10		PCMB	489719	40	reversible by DTT
KDOCT2	2.4.2.10		UTP	489719	61	not inhibitory
KDOCT2	2.4.2.10		Zn2+	489719	19	
GLUPRT	2.4.2.14		1-alpha-diphosphoryl-2-alpha,3-alpha-dihydroxy-4-beta-cyclopentane-methanol-5-phosphate	489766	21880	competitive vs. 5-phospho-alpha-D-ribose 1-diphosphate in wild-type and P410W mutant, competition for the amidotransferase C site
GLUPRT	2.4.2.14		2-amino-4-oxo-5-chloropentanoate	489747	63007	approx. 80% inactivation of NH3-dependent activity after 30 min
GLUPRT	2.4.2.14		5'-p-fluorosulfonylbenzoyladenosine	489763	5401	inactivation follows pseudo-first order kinetic, AMP, GMP and 5-phospho-alpha-D-ribose 1-diphosphate protect
GLUPRT	2.4.2.14		6-diazo-5-oxo-L-norleucine	489747	666	approx. 98% inactivation of amidotransferase activity after 30 min
GLUPRT	2.4.2.14		ADP	489747	8	
GLUPRT	2.4.2.14		AMP	489747	9	approx. 10 mM, complete inhibition, sigmoidal inhibition curve, competitive vs. 5-phospho-alpha-D-ribose 1-diphosphate, GMP and AMP together have a synergistic effect on inhibition
GLUPRT	2.4.2.14		AMP	489763	9	4.7 mM, 50% inhibition
GLUPRT	2.4.2.14		GDP	489747	49	
GLUPRT	2.4.2.14		GMP	489747	150	approx. 2.5 mM, complete inhibition, highly sigmoidal inhibition curve, competitive vs. 5-phospho-alpha-D-ribose 1-diphosphate, GMP and AMP together have an synergistic effect on inhibition
GLUPRT	2.4.2.14		GMP	489763	150	1.2-1.4 mM, 50% inhibition
GLUPRT	2.4.2.14		GTP	489747	35	5 mM, 79% inhibition
GLUPRT	2.4.2.14		IMP	489747	206	5 mM, 86% inhibition
GLUPRT	2.4.2.14		iodoacetamide	489747	63	approx. 60% inactivation of amidotransferase activity after 30 min, very weak inactivation of NH3-dependent activity
GLUPRT	2.4.2.14		N3-AMP	489763	20138	1.2-1.4 mM, 50% inhibition, AMP and GMP protect
GLUPRT	2.4.2.14		p-mercuribenzoate	489747	554	0.001 mM, complete inhibition
GLUPRT	2.4.2.14		XMP	489747	772	51% inhibition; 5 mM
GLUPRT	2.4.2.14	Mg-phosphoribosyldiphosphate		489747		no glutamine-binding site in the absence of Mg-phosphoribosyldiphosphate
GLUPRT	2.4.2.14	phosphoribosyl-5-phosphate		489747	147	3-4fold activation of glutaminase activity in the presence of phosphate or diphosphate
NNDPR	2.4.2.19		D-fructose-1,6-diphosphate	638020	100	competitive with respect to 5-phosphoribosyl-1-diphosphate and noncompetitive with respect to quinolinate
NNDPR	2.4.2.19		diphosphate	638020	13	noncompetitive with respect to both 5-phosphoribosyl-1-diphosphate and quinolinate
NNDPR	2.4.2.19		nicotinate mononucleotide	638020	1045	competitive with respect to 5-phosphoribosyl-1-diphosphate
NNDPR	2.4.2.19		Phthalic acid	638020	2060	dead-end inhibitor, competitive with respect to quinolinate, uncompetitive with respect to 5-phosphoribosyl-1-diphosphate
DHPS2	2.5.1.15		7,8-Dihydropteroic acid	639665, 639666	1459	
DHPS2	2.5.1.15		phosphanilic acid	660716	37633	28% inhibition at 2.0 mM, complete inhibition at 20 mM
DHPS2	2.5.1.15		Sulfadiazine	660716	2226	0.2 mM, complete inhibition
DHPS2	2.5.1.15		sulfamethoxazole	1014	1556	competitive to 4-aminobenzoate
DHPS2	2.5.1.15		sulfanilamide	1014	833	
DHPS2	2.5.1.15		sulfathiazole	1014, 639666, 639676	2304	competitive to 4-aminobenzoate
DHPS2	2.5.1.15		sulfonamide	1014, 639666	4706	competitive to 4-aminobenzoate
PSCVT	2.5.1.19		(3R,4S,5R)-4-hydroxy-5-[(2R)-1-hydroxy-1-oxo-2-phosphono-propan-2-yl]oxy-3-phosphonooxy-cyclohexene-1-carboxylic acid	690885	9610	RP-TI, (R)-phosphonate analogue of the (S)-tetrahedral reaction intermediate, very potent competitive inhibitor of EPSPS forward reaction, binding induces substantial conformational change in enzyme√Ç¬ís backbone and active site (e.g., Glu341 and Arg124)
PSCVT	2.5.1.19		(3R,4S,5R)-4-hydroxy-5-[(2S)-1-hydroxy-1-oxo-2-phosphono-propan-2-yl]oxy-3-phosphonooxy-cyclohexene-1-carboxylic acid	690885	9611	SP-TI, (S)-phosphonate analogue of the (S)-tetrahedral reaction intermediate, moderate competitive inhibitor of EPSPS forward reaction
PSCVT	2.5.1.19		(3R,4S,5R)-5-((R)-1-carboxy-1-phosphono-ethoxy)-4-hydroxy-3-phosphonooxy-cyclohex-1-enecarboxylic acid	658112	9610	analogue of the tetrahedral reaction intermediate, competitive to both substrates, binding structure analysis, binding induces conformational changes to residues Arg124 and Glu341 within the active site, which results in structural alterations in the amino-terminal globular domain of the enzyme
PSCVT	2.5.1.19		(3R,4S,5R)-5-((S)-1-carboxy-1-phosphono-ethoxy)-4-hydroxy-3-phosphonooxy-cyclohex-1-enecarboxylic acid	658112	9611	analogue of the tetrahedral reaction intermediate, competitive to both substrates, binding structure analysis, binding induces no conformational changes
PSCVT	2.5.1.19		(3R,4S,5R)-5-[(2R)-1,1-difluoro-3-hydroxy-3-oxo-2-phosphonooxy-propan-2-yl]oxy-4-hydroxy-3-phosphonooxy-cyclohexene-1-carboxylic acid	690885	9609	2F-TI, (R)-difluoromethyl analogue of the (S)-tetrahedral reaction intermediate, very potent competitive inhibitor of EPSPS forward reaction
PSCVT	2.5.1.19		(Z)-3-fluorophosphoenolpyruvate	638176	2350	competitive vs. phosphoenolpyruvate at saturated shikimate 3-phosphate concentration and vice versa
PSCVT	2.5.1.19		3-Bromopyruvate	638179	1425	0.1 mM, approx. 80% inactivation after 5 min, maximum rate-constant: 0.31/min, substrates or a combination of shikimate 3-phosphat and glyphosate protect from inactivation, bromopyruvate modifies residues C408 and L411
PSCVT	2.5.1.19		5-Deoxy-shikimate 3-phosphate	638176	28992	competitive vs. shikimate 3-phosphate
PSCVT	2.5.1.19		5-enolpyruvylshikimate 3-phosphate	638175	1249	product inhibition
PSCVT	2.5.1.19		Carboxyallenyl phosphate	638176	67083	strong
PSCVT	2.5.1.19		diethyldicarbonate	638177	265	inactivation with a second-order rate constant of 220/M/min, subtstrates protect from inactivation, enzyme activity is recovered by treatment with hydroxylamine
PSCVT	2.5.1.19		glyphosate	658298	633	competitive inhibition of the wild-type enzyme, mutant T42M is less sensitive
PSCVT	2.5.1.19		glyphosate	691087	633	N-(phosphonomethyl)glycine, broad-spectrum herbicide
PSCVT	2.5.1.19		glyphosate	658112, 690885, 693010, 704646	633	
PSCVT	2.5.1.19		N-phosphonomethylglycine	638173	633	inhibition of enolpyruvate transfer, competitive vs. phosphoenolpyruvate
PSCVT	2.5.1.19		N-phosphonomethylglycine	638177	633	0.01 mM, 50% inhibition
PSCVT	2.5.1.19		N-phosphonomethylglycine	638207	633	mechanism of inhibition in atomic detail
PSCVT	2.5.1.19		N-phosphonomethylglycine	638175, 638176, 638178, 638179, 638200, 638203, 638209	633	
PSCVT	2.5.1.19		phosphoenolpyruvate	638176	47	substrate inhibition
PSCVT	2.5.1.19		pyruvate	638178	29	20 mM, 85% inactivation after 1 h in the presence of cyanoborhydride, no inactivation in the absence of cyanoborhydride, preincubation with 5-enolpyruvylshikimate or a combination of shikimate 3-phosphate and glyphosate prevents from inactivation
UDCPDPS	2.5.1.31		(2E,6E)-farnesyl thiodiphosphate	637494	3950	(2E,6E)-farnesyl diphosphate analogue
UDCPDPS	2.5.1.31		(E,E)-[1-3H]-(2-diazo-3-trifluoropropionyloxy)geranyl diphosphate	708911	98810	
UDCPDPS	2.5.1.31		(S)-farnesyl thiodiphosphate	708864	3950	an extremely poor substrate for UPPs
UDCPDPS	2.5.1.31		3-[5-(5,6-dihydrobenzimidazo[1,2-c]quinazolin-6-yl)-2,5-dihydrofuran-2-yl]benzenesulfonamide	699031	5179	barely inhibits UPPS of Escherichia coli; i.e. HTS04781. contrary to Helicobacter pylori, HTS04781 is almost not inhibitory in Escherichia coli
UDCPDPS	2.5.1.31		3-[5-(5,6-dihydrobenzimidazo[1,2-c]quinazolin-6-yl)-2,5-dihydrofuran-2-yl]benzenesulfonamide	704720	5179	barely inhibits UPPS of Escherichia coli
UDCPDPS	2.5.1.31		7-(2,6-dimethyl-8-diphospho-2,6-octadienyloxy)-8-methyl-4-trifluoromethyl-chromen-2-one geranyl diphosphate	708864	109273	competitive inhibitor, substrate analogue prepared and utilized to study ligand interactions
UDCPDPS	2.5.1.31		BPH-629	676880	24312	potent inhibitor
UDCPDPS	2.5.1.31		BPH-629	721794	24312	bindiing structure in enzyme chain B, overview
UDCPDPS	2.5.1.31		farnesyl thiodiphosphate	659476, 721275	3950	
UDCPDPS	2.5.1.31		Mg2+	659476	25	inhibitory at high concentrations of e.g. 50 mM; inhibitory at high concentrations of e.g. 50 mM
UDCPDPS	2.5.1.31		N,N'-bis(6-chloro-1,3-benzothiazol-2-yl)methanedisulfonamide	699031	4255	; i.e. BTB06061
UDCPDPS	2.5.1.31		N,N'-bis(6-chloro-1,3-benzothiazol-2-yl)methanedisulfonamide	704720	4255	barely inhibits UPPS of Escherichia coli
UDCPDPS	2.5.1.31		S-farnesyl thiodiphosphate	637494	3950	
UDCPDPS	2.5.1.31		Triton X-100	721794	57	C55 is retained in the active site for further elongation, whereas the kcat is increased by 190fold under steady-state condition by 0.1% Triton X-100
UDCPDPS	2.5.1.31	Phospholipid		637485	528	
UDCPDPS	2.5.1.31	Triton		637485	57	0.01 microM of UPPs with 5 microM of (2E,6E)-farnesyl diphosphate and 50 microM of isopentenyl diphosphate, 0.5 mM MgCl2, and 50 mM KCl in Hepes buffer (pH 7.5) is 190fold less active (0.013 s-1) for the IPP consumption in the absence of Triton; the UPPs steady-state kcat value in the presence of 0.1% Triton is 190fold larger than in the absence of Triton
UDCPDPS	2.5.1.31	Triton X-100		637482	57	no activity in absence; no activity in the activation by Triton X-100 is almost saturated at a concentration of 0.02%
UDCPDPS	2.5.1.31	Triton X-100		659232	57	1.5% v/v, 2 molecules are bound in the active site tunnel of the beta-subunit, binding structure
UDCPDPS	2.5.1.31	Triton X-100		673055	57	
KDOPS	2.5.1.55		1,10-phenanthroline	637416	58	
KDOPS	2.5.1.55		2-Deoxy-2-fluoro-D-arabinoate-5-phosphate	637397	66955	
KDOPS	2.5.1.55		2,6-Anhydro-3-deoxy-2beta-phosphonylmethyl-8-phosphate-D-glycero-D-talo-octonate	637408	29902	most potent inhibitor
KDOPS	2.5.1.55		Bromopyruvate	637403	1425	phosphoenolpyruvate, but not arabinose-5-phosphate protects
KDOPS	2.5.1.55		Cd2+	637395	48	
KDOPS	2.5.1.55		Cd2+	637397	48	1 mM
KDOPS	2.5.1.55		Cu2+	637397	28	1 mM
KDOPS	2.5.1.55		Cu2+	637395, 637416	28	
KDOPS	2.5.1.55		D-ribose 5-phosphate	637395	165	weak, competitive
KDOPS	2.5.1.55		D-ribose 5-phosphate	637397	165	
KDOPS	2.5.1.55		EDTA	637416	223	
KDOPS	2.5.1.55		Hg2+	637395	31	reversed by dithiothreitol
KDOPS	2.5.1.55		Hg2+	637397	31	1 mM
KDOPS	2.5.1.55		phosphate	637397	12	
KDOPS	2.5.1.55		Zn2+	637397	19	1 mM
KDOPS	2.5.1.55		Zn2+	637395, 637416	19	
KDOPS	2.5.1.55	EDTA		637416	223	1 mM, 40% stimulation
KDOPS	2.5.1.55	EDTA		659404	223	
METAT	2.5.1.6		1-(3-(2-ethoxyphenyl)ureidoacetyl)-4-(2-methyl-5-nitrophenyl)semicarbazide	705048	53381	binding to adenosyl region of the active site
METAT	2.5.1.6		1-(4-chloro-2-nitrophenyl)-3-(4-sulfamoylphenyl)-urea	705048	53382	binding to adenosyl region of the active site
METAT	2.5.1.6		Adenyl-5'-ylimidodiphosphate	639045, 639056	2969	competitive with ATP
METAT	2.5.1.6		diimidotriphosphate	658062	37196	mechanism
METAT	2.5.1.6		diphosphate	639045, 639056	13	
METAT	2.5.1.6		GTP	639056	35	
METAT	2.5.1.6		phosphate	639045, 639056	12	
METAT	2.5.1.6		S-adenosylmethionine	639045, 639056	22	
METAT	2.5.1.6		S-carbamylcysteine	639045, 639056	32992	competitive with methionine
METAT	2.5.1.6		tripolyphosphate	639045	596	
METAT	2.5.1.6		tripolyphosphate	639056	596	competitive with ATP
METAT	2.5.1.6	S-adenosylmethionine		639056	22	enhances tripolyphosphatase activity
HMBS	2.5.1.61		NaBH4	489944	507	partially inactivates
HMBS	2.5.1.61		pyridoxal 5'-phosphate	489944	30	partially inactivates
UAGCVT	2.5.1.7		(E)-3-fluorophosphoenolpyruvate	637596	11148	pseudosubstrate, formation of a tetrahedral intermediate in the reaction pathway, investigation of chirality of the intermediate stereospecifically formed at the active site in D2O
UAGCVT	2.5.1.7		(E)-3-fluorophosphoenolpyruvate	637597	11148	formation of 2 reaction intermediates: a covalent phosphofluorolactyl-enzyme adduct and a free phosphofluorolactyl-UDP-GlcNAc tetrahedral adduct; inactivation; kinetics
UAGCVT	2.5.1.7		(Z)-3-fluorophosphoenolpyruvate	637596	2350	pseudosubstrate, formation of a tetrahedral intermediate in the reaction pathway, investigation of chirality of the intermediate stereospecifically formed at the active site in D2O
UAGCVT	2.5.1.7		(Z)-3-fluorophosphoenolpyruvate	637597	2350	formation of 2 reaction intermediates: a covalent phosphofluorolactyl-enzyme adduct and a free phosphofluorolactyl-UDP-GlcNAc tetrahedral adduct; inactivation; kinetics
UAGCVT	2.5.1.7		(Z)-3-fluorophosphoenolpyruvate	637598	2350	kinetics, mutant C115D; wild-type and mutant C115D, competitive against phosphoenolpyruvate
UAGCVT	2.5.1.7		1-tuliposide A	721372	111808	potent inhibitor
UAGCVT	2.5.1.7		1-tuliposide B	721372	111809	potent inhibitor
UAGCVT	2.5.1.7		2-(4-methylpiperazin-1-yl)-3,4-dihydronaphthalen-1(2H)-one	685595	16867	
UAGCVT	2.5.1.7		2-[4-(2-hydroxyethyl)piperazin-1-yl]-3,4-dihydronaphthalen-1(2H)-one	685595	16839	
UAGCVT	2.5.1.7		2-[4-(2-hydroxyethyl)piperazin-1-yl]-6,7-dimethoxy-3,4-dihydronaphthalen-1(2H)-one	685595	16834	
UAGCVT	2.5.1.7		2-oxo-1,3-benzoxathiol-5-yl (3-chlorophenyl)carbamate	721372, 722469	5350	
UAGCVT	2.5.1.7		2-oxo-1,3-benzoxathiol-5-yl methylcarbamate	722469	19635	
UAGCVT	2.5.1.7		2-oxo-1,3-benzoxathiol-5-yl pyridine-4-carboxylate	722469	19636	
UAGCVT	2.5.1.7		2-oxo-1,3-benzoxathiol-6-yl 4-nitrobenzenesulfonate	722469	19638	
UAGCVT	2.5.1.7		2-oxo-1,3-benzoxathiol-6-yl benzenesulfonate	721372, 722469	5353	
UAGCVT	2.5.1.7		2-oxo-1,3-benzoxathiol-6-yl methanesulfonate	721372, 722469	5352	
UAGCVT	2.5.1.7		2-oxo-1,3-benzoxathiol-6-yl sulfamate	722469	10287	
UAGCVT	2.5.1.7		4,7-dichloro-5-hydroxy-1,3-benzoxathiol-2-one	721372, 722469	5351	
UAGCVT	2.5.1.7		5-(prop-2-en-1-yloxy)-1,3-benzoxathiol-2-one	721372, 722469	5349	
UAGCVT	2.5.1.7		5-bromo-2-oxo-1,3-benzoxathiol-6-yl phenyl carbonate	721372	10289	
UAGCVT	2.5.1.7		5-hydroxy-1,3-benzoxathiol-2-one	721372	10288	
UAGCVT	2.5.1.7		5-hydroxy-7-(3-methylphenyl)-1,3-benzoxathiol-2-one	722469	28327	
UAGCVT	2.5.1.7		5-hydroxy-7-(4-methoxyphenyl)-1,3-benzoxathiol-2-one	721372, 722469	6020	
UAGCVT	2.5.1.7		5-hydroxybenzo[d][1,3]oxathiol-2-one	722469		
UAGCVT	2.5.1.7		5-hydroxynaphtho[1,2-d][1,3]oxathiol-2-one	721372, 722469	5354	
UAGCVT	2.5.1.7		5-hydroxynaphtho[2,1-d][1,3]oxathiol-2-one	722469	19637	
UAGCVT	2.5.1.7		5-methoxy-1,3-benzoxathiole	722469	28328	
UAGCVT	2.5.1.7		5-methoxybenzo[d][1,3]oxathiol-2-one	722469		
UAGCVT	2.5.1.7		5,7-dibromo-6-hydroxy-1,3-benzoxathiol-2-one	722469	19639	
UAGCVT	2.5.1.7		6,7-dimethoxy-2-[4-(2-phenylethyl)piperazin-1-yl]-3,4-dihydronaphthalen-1(2H)-one	685595	16912	
UAGCVT	2.5.1.7		7-(4-fluorophenyl)-5-hydroxy-1,3-benzoxathiol-2-one	722469	28326	
UAGCVT	2.5.1.7		cnicin	688290	46837	sesquiterpene lactone. The enzyme catalyzes the formation of a covalent adduct between cnicin and substrate UDP-N-acetylglucosamine via an anti-Michael 1,3-addition of UDP-N-acetylglucosamine to an alpha,beta-unsaturated carbonyl function in cnicin thus forming a noncovalent suicide inhibitor
UAGCVT	2.5.1.7		cnicine	721372	111805	
UAGCVT	2.5.1.7		Co2+	706916	21	metal ions do not enhance the activity of enzymes, activity is inhibited by 10 mM
UAGCVT	2.5.1.7		Cu2+	706916	28	metal ions do not enhance the activity of enzymes, activity is inhibited by 10 mM
UAGCVT	2.5.1.7		cynaropicrin	721372	111806	
UAGCVT	2.5.1.7		diarylmethane	721372		
UAGCVT	2.5.1.7		ebselen	721372	1837	
UAGCVT	2.5.1.7		Fe2+	706916	23	metal ions do not enhance the activity of enzymes, activity is inhibited by 10 mM
UAGCVT	2.5.1.7		fosfomycin	637598	872	alkylates Cys115; competitive against phosphoenolpyruvate; inhibits the wild-type, mutant C155D is completely resistant; t1/2 for inactivation of the wild-type enzyme: 6 s
UAGCVT	2.5.1.7		fosfomycin	637599	872	binds covalently to Cys115
UAGCVT	2.5.1.7		fosfomycin	637606	872	binding study by isothermal titration calorimetry; binds covalently to Cys115
UAGCVT	2.5.1.7		fosfomycin	675082	872	selectively inhibited by fosfomycin, which forms a covalent bond to the sulfhydryl group of the catalytically relevant Cys115 residue
UAGCVT	2.5.1.7		fosfomycin	702267	872	enolpyruvyl UDP-GlcNAc synthase is an antimicrobial target that is inhibited by the antibiotic fosfomycin
UAGCVT	2.5.1.7		fosfomycin	721372	872	irreversible inhibitor
UAGCVT	2.5.1.7		fosfomycin	685595, 706916, 722469	872	
UAGCVT	2.5.1.7		HESFWYLPHHQSY	721372	111804	competitive inhibition
UAGCVT	2.5.1.7		imidazole	721372	390	
UAGCVT	2.5.1.7		MnCl2	706916	262	metal ions do not enhance the activity of enzymes, activity is inhibited by 10 mM
UAGCVT	2.5.1.7		PGE-553828	637606		competitive against UDP-GlcNAc; inhibition mechanism, kinetics
UAGCVT	2.5.1.7		phosphonomycin	637590		i.e. L-cis-2-epoxypropylphosphonic acid; inhibitor binding site is distinct from active site; irreversible inactivation, requires the presence of UDP-GlcNAc
UAGCVT	2.5.1.7		phosphonomycin	637593		irreversible inactivation, requires the presence of UDP-GlcNAc
UAGCVT	2.5.1.7		pyrazolopyrimidine	721372	111802	reversible inhibitor
UAGCVT	2.5.1.7		RWJ-110192	721372	111763	reversible inhibitor
UAGCVT	2.5.1.7		RWJ-140998	721372	111764	irreversible inhibitor
UAGCVT	2.5.1.7		RWJ-3981	721372	14279	irreversible inhibitor
UAGCVT	2.5.1.7		T6361	721372	111765	competitive inhibition
UAGCVT	2.5.1.7		T6362	721372	5763	competitive inhibition
UAGCVT	2.5.1.7		terreic acid	721372	111803	irreversible inhibitor
UAGCVT	2.5.1.7		thimerosal	721372	1997	
UAGCVT	2.5.1.7		thiram	721372	4706	
UAGCVT	2.5.1.7		tulipaline A	721372	61531	
UAGCVT	2.5.1.7		tulipaline B	721372	111807	
UAGCVT	2.5.1.7		UDP-N-acetylmuramic acid	637590	1441	weak
UAGCVT	2.5.1.7		UDP-N-acetylmuramic acid	658113	1441	competitive with phosphate
UAGCVT	2.5.1.7		UDP-N-acetylmuramic acid	702267	1441	
UAGCVT	2.5.1.7		UDP-N-acetylmuramic acid-L-Ala	637590	3004	weak
UAGCVT	2.5.1.7		UDP-N-acetylmuramic acid-L-Ala-D-Glu	637590	2727	weak
UAGCVT	2.5.1.7		UDP-N-acetylmuramyl-L-Ala-D-Glu-meso-alpha,epsilon-diaminopimelic acid	637590	13548	above 1 mM
UAGCVT	2.5.1.7		uridine diphospho-N-acetylmuramyl-L-Ala-D-gamma-Glu-meso-alpha,epsilon-diaminopimelic-acid-D-Ala-D-Ala	637590	8627	above 1 mM
UAGCVT	2.5.1.7		Zn2+	706916	19	metal ions do not enhance the activity of enzymes, activity is inhibited by 10 mM
UAGCVT	2.5.1.7	dithiothreitol		637606	42	included in the assay reaction mixture
QULNS	2.5.1.72		1,10-phenanthroline	684659	58	inhibits reactivation of O2-inactivated enzyme
QULNS	2.5.1.72		2,2'-dipyridyl	684659	317	inhibits reactivation of O2-inactivated enzyme
QULNS	2.5.1.72		4,5-dithiohydroxyphthalic acid	721290		structural analogue of the 5-hydroxy-4,5-dihydropyridine-2,3-dicarboxylic acid intermediate. Compound coordinates to the enzyme [4Fe-4S] cluster through a differentiated iron site, thus leading to the inhibition of quinolate formation. Compound is inhibitory in vitro and in vivo
QULNS	2.5.1.72		H2O2	684659	20	1 mM, inactivation
QULNS	2.5.1.72		O2	684659	11	the activity of the enzyme within Escherichia coli is diminished by exposure of the cells to 4.2 atm O2, while the activity in extracts is rapidly decreased by 0.2 atm O2. Inactivation in extracts can be gradually reversed during anaerobic incubation, but is blocked by alpha, alpha'-dipyridyl or by 1,10-phenanthroline
QULNS	2.5.1.72		paraquat	684659	302	inactivation
RBFSb	2.5.1.9		[3-(4-chlorophenyl)-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](m-tolyl)methanone	705302	9991	covalent hydrate of trifluoromethylated pyrazole
RBFSb	2.5.1.9		[3-(4-chlorophenyl)-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](o-tolyl)methanone	705302	12767	covalent hydrate of trifluoromethylated pyrazole
RBFSb	2.5.1.9		[3-(4-chlorophenyl)-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](p-tolyl)methanone	705302	12768	covalent hydrate of trifluoromethylated pyrazole
RBFSb	2.5.1.9		[5-(4-chlorophenyl)-5-hydroxy-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](m-tolyl)methanone	705302	9990	covalent hydrate of trifluoromethylated pyrazole
RBFSb	2.5.1.9		[5-(4-chlorophenyl)-5-hydroxy-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](o-tolyl)methanone	705302	9992	covalent hydrate of trifluoromethylated pyrazole
RBFSb	2.5.1.9		[5-(4-chlorophenyl)-5-hydroxy-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl](p-tolyl)methanone	705302	9993	covalent hydrate of trifluoromethylated pyrazole
RBFSb	2.5.1.9		1-deoxy-1-[2,6,8-trioxo-7-[4-(phosphonooxy)butyl]-1,2,3,6,7,8-hexahydro-9H-purin-9-yl]-D-ribitol	723033	8055	competitive inhibition
RBFSb	2.5.1.9		2-chloro-N-(2,4-dioxo-6-((2S,3S,4R)-2,3,4,5-tetrahydroxypentylamino)-1,2,3,4-tetrahydropyrimidin-5-yl)acetamide	723033		
RBFSb	2.5.1.9		2-chloro-N-(2,4-dioxo-6-((2S,3S,4R)-2,3,4,5-tetrahydroxypentylamino)-1,2,3,4-tetrahydropyrimidin-5-yl)propanamide	723033		
RBFSb	2.5.1.9		2,4-dioxo-6-[(3S,4S,5R)-3,4,5,6-tetrahydroxyhexyl]-1,2,3,4-tetrahydropyrimidin-5-aminium chloride	723033	61732	uncompetitive inhibition
RBFSb	2.5.1.9		2,4-dioxo-6-[[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]sulfanyl]-1,2,3,4-tetrahydropyrimidin-5-aminium chloride	688575	5180	
RBFSb	2.5.1.9		4-[2,4,7-trioxo-8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,4,7,8-hexahydropteridin-6-yl]butanoic acid	637585	16844	comparison with inhibition of Bacillus subtilis lumazine synthase
RBFSb	2.5.1.9		4-[2,4,7-trioxo-8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,4,7,8-hexahydropteridin-6-yl]butyl dihydrogen phosphate	637585	16845	comparison with inhibition of Bacillus subtilis lumazine synthase
RBFSb	2.5.1.9		4-[2,4,7-trioxo-8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,4,7,8-hexahydropteridin-6-yl]propyl dihydrogen phosphate	637585	16846	competitive, comparison with inhibition of Bacillus subtilis lumazine synthase
RBFSb	2.5.1.9		5-(4-phosphonobutyryl)amino-6-D-ribitylaminouracil	637586	16866	comparison with inhibition of Bacillus subtilis luminazine synthase/riboflavin synthase
RBFSb	2.5.1.9		5-(4-phosphonopentyryl)amino-6-D-ribitylaminouracil	637586	46826	comparison with inhibition of Bacillus subtilis luminazine synthase/riboflavin synthase
RBFSb	2.5.1.9		5-(5-phosphonoxyvaleryl)amino-6-D-ribitylaminouracil	637586	16905	mixed inhibition, comparison with inhibition of Bacillus subtilis luminazine synthase/riboflavin synthase
RBFSb	2.5.1.9		5-(hexyl 6-dihydrogen phosphate)-6-([(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino)pyrimidine-2,4(1H,3H)-dione	637585	6778	comparison with inhibition of Bacillus subtilis lumazine synthase
RBFSb	2.5.1.9		5-(hexyl 6-dihydrogen phosphate)-6-([(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino)pyrimidine-2,4(1H,3H)-dione	637586	6778	mixed inhibition, comparison with inhibition of Bacillus subtilis luminazine synthase/riboflavin synthase
RBFSb	2.5.1.9		5-(pentyl 6-dihydrogen phosphate)-6-([(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino)pyrimidine-2,4(1H,3H)-dione	637585	16906	comparison with inhibition of Bacillus subtilis lumazine synthase
RBFSb	2.5.1.9		5-amino-6-((2R,3R,4S)-2,3,4,5-tetrahydroxypentyloxy)-pyrimidine-2,4(1H,3H)-dione	723033		uncompetitive inhibition
RBFSb	2.5.1.9		5-amino-6-[[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]sulfanyl]pyrimidine-2,4(1H,3H)-dione	723033	19641	partial inhibition
RBFSb	2.5.1.9		5-nitro-6-[(3S,4S,5R)-3,4,5,6-tetrahydroxyhexyl]pyrimidine-2,4(1H,3H)-dione	723033	19642	partial inhibition
RBFSb	2.5.1.9		5-nitro-6-[[(2R,3R,4R)-2,3,4,5 tetrahydroxypentyl]sulfanyl]pyrimidine-2,4(1H,3H)-dione	688575	5183	
RBFSb	2.5.1.9		5-nitro-6-[[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]sulfanyl]pyrimidine-2,4(1H,3H)-dione	723033	5183	partial inhibition
RBFSb	2.5.1.9		5-nitro-6-[[(2S,3R,4R)-2,3,4,5-tetrahydroxypentyl]oxy]pyrimidine-2,4(1H,3H)-dione	723033	19640	competitive inhibition
RBFSb	2.5.1.9		5-nitro-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]pyrimidine-2,4(1H,3H)-dione	723033	6439	mixed-type inhibition
RBFSb	2.5.1.9		6-methyl-7-methylidene-8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-7,8-dihydropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione	637585	16903	competitive, comparison with inhibition of Bacillus subtilis lumazine synthase
RBFSb	2.5.1.9		7-hydroxy-7-methyl-8-((2S,3S,4R)-2,3,4,5-tetrahydroxypentyl)-7,8-dihydropteridin-2,4,6(1H,3H,5H)-trione	723033		
RBFSb	2.5.1.9		8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-5,8-dihydropteridine-2,4,6,7(1H,3H)-tetrone	723033	17497	competitive inhibition
RBFSb	2.5.1.9		9-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-7,9-dihydro-1H-purine-2,6,8(3H)-trione	637585	7991	competitive, comparison with inhibition of Bacillus subtilis lumazine synthase
RBFSb	2.5.1.9		9-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-7,9-dihydro-1H-purine-2,6,8(3H)-trione	723033	7991	competitive inhibition
RBFSb	2.5.1.9		ethyl [(2,4-dioxo-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]-1,2,3,4-tetrahydropyrimidin-5-yl)amino](oxo)acetate	723033	6019	mixed-type inhibition
RBFSb	2.5.1.9		ethyl [(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)amino](oxo)acetate	723033	61733	
RBFSb	2.5.1.9		ethyl 2-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-ylamino)-2-oxoacetate	723033		uncompetitive inhibition
RBFSb	2.5.1.9		methyl 2-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-ylamino)-2-oxoacetate	723033		uncompetitive inhibition
RBFSb	2.5.1.9		N-(2,4-dioxo-6-((2R,3R,4R)-2,3,4,5-tetrahydroxypentylthio)-1,2,3,4-tetrahydropyrimidin-5-yl)methacrylamide	723033		
RBFSb	2.5.1.9		N-(2,4-dioxo-6-((2R,3R,4R)-2,3,4,5-tetrahydroxypentylthio)-1,2,3,4-tetrahydropyrimidin-5-yl)propionamide	723033		
RBFSb	2.5.1.9		N-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-yl)isobutyramide	723033		
RBFSb	2.5.1.9		N-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-yl)methacrylamide	723033		
RBFSb	2.5.1.9		N-(2,4-dioxo-6-((2S,3R,4R)-2,3,4,5-tetrahydroxypentyloxy)-1,2,3,4-tetrahydropyrimidin-5-yl)propionamide	723033		
RBFSb	2.5.1.9		N-(2,4-dioxo-6-((2S,3S,4R)-2,3,4,5-tetrahydroxypentylamino)-1,2,3,4-tetrahydropyrimidin-5-yl)-3,3,3-trifluoropropanamide	723033		
RBFSb	2.5.1.9		N-(2,4-dioxo-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methylpropanamide	723033	7986	uncompetitive inhibition
RBFSb	2.5.1.9		N-(2,4-dioxo-6-[[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino]-1,2,3,4-tetrahydropyrimidin-5-yl)propanamide	723033	7985	uncompetitive inhibition
RBFSb	2.5.1.9		N-(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-methacrylamide	723033		
RBFSb	2.5.1.9		N-(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)propanamide	723033	61734	
RBFSb	2.5.1.9		N-[2,4-dioxo-6-((2S,3S,4R)-2,3,4,5-tetrahydroxypentylamino]-1,2,3,4-tetrahydropyrimidin-5-yl)methacrylamide	723033		
RBFSb	2.5.1.9		N-[2,4-dioxo-6-(ribitylamino)-1,2,3,4-tetrahydropyrimidin-5-yl]oxalamic acid ethyl ester	688578	6019	mixed type inhibition
RBFSb	2.5.1.9		N-6-(ribitylamino)pyrimidine-2,4(1H,3H)-dion-5-ylpropionamide	688578	7985	uncompetitive
RBFSb	2.5.1.9		N-6-(ribitylamino)pyrimidine-2,4(1H,3H)-dione-5-ylisobutyramide	688578	7986	uncompetitive
OCTDPS	2.5.1.90	Triton X-100		707541	57	presence can accelerate the steady-state rate by 3fold
HSK	2.6.1.16		1,1'-dithiodiformamidine	639911	11149	irreversible inhibition
HSK	2.6.1.16		1,2-anhydrohexitol 6-phosphate	639929	73421	mixture of the four diastereoisomers. Irreversible inactivation. D-fructose 6-phosphate and 2-amino-2-deoxyglucitol protect, L-glutamine does not
HSK	2.6.1.16		2-amino-2-deoxy-D-glucitol 6-phosphate	684404	3035	
HSK	2.6.1.16		2-amino-2-deoxy-D-glucitol-6-phosphate	672619	3035	IC50: 0.056 mM
HSK	2.6.1.16		2-amino-2-deoxy-D-mannitol 6-phosphate	684404	16666	
HSK	2.6.1.16		2-Amino-2-deoxyglucitol 6-phosphate	639926, 639927	3035	competitive with respect to D-fructose 6-phosphate
HSK	2.6.1.16		4-(furan-2-ylcarbonyl)-3-hydroxy-5-(4-phenoxyphenyl)-1-(pyridin-3-ylmethyl)-1,5-dihydro-2H-pyrrol-2-one	672619	85830	20% inhibition at 0.1 mM
HSK	2.6.1.16		5,5'-dithionitrobenzoic acid	639911		irreversible inhibition
HSK	2.6.1.16		6-diazo-5-oxo-L-norleucine	674745	666	2 mM
HSK	2.6.1.16		6-diazo-5-oxo-L-norleucine	639904, 639917, 639922, 677033	666	
HSK	2.6.1.16		6,6'-Dithiodinicotinic acid	639911	6260	irreversible inhibition
HSK	2.6.1.16		6,7-bis(2-methoxyphenyl)-10-methyl-1,4,7,12-tetrahydro-6H-chromeno[4,3-d][1,2,4]triazolo[1,5-a]pyrimidine	672619	85831	70% inhibition at 0.1 mM
HSK	2.6.1.16		Aaptamine	672619	24148	IC50: 0.12 mM
HSK	2.6.1.16		amitrole	672619	1350	IC50: 0.1 mM
HSK	2.6.1.16		anticapsin	639911	3785	L-glutamine protects, irreversible inhibition
HSK	2.6.1.16		azaserine	639904	1381	weak
HSK	2.6.1.16		D-glucitol 6-phosphate	639929	4838	competitive with respect to D-fructose 6-phosphate
HSK	2.6.1.16		D-Glucosamine 6-phosphate	689045	417	negative feedback-regulation at post-transcriptional level. The biological function of small RNA GlmZ is to positively control the enzyme's mRNA in response to D-glucosamine 6-phosphate concentrations. YhbJ, a gene of the rpoN operon, negatively regulates GlmZ
HSK	2.6.1.16		D-Glucosamine-6-phosphate	672444	417	1 mM, about 50% loss of activity
HSK	2.6.1.16		DL-delta-1-pyrroline-5-carboxylate	639926	1456	competitive with respect to L-glutamine
HSK	2.6.1.16		ethyl 2-[2-(3-bromophenyl)-3-[(4-fluorophenyl)carbonyl]-4-hydroxy-5-oxo-2,5-dihydro-1H-pyrrol 1-yl]-4-methyl-1,3-thiazole-5-carboxylate	672619	86374	70% inhibition at 0.1 mM
HSK	2.6.1.16		ethyl 2-[3-[(4-fluorophenyl)carbonyl]-4-hydroxy-2-(4-methoxyphenyl)-5-oxo-2,5-dihydro-1H pyrrol-1-yl]-4-methyl-1,3-thiazole-5-carboxylate	672619	86375	70% inhibition at 0.1 mM
HSK	2.6.1.16		iodoacetamide	639911	63	irreversible inhibition
HSK	2.6.1.16		iodoacetamide	639922	63	
HSK	2.6.1.16		L-2,3-diaminopropanoic acid	639916	6178	
HSK	2.6.1.16		N-ethylmaleimide	639911	46	irreversible inhibition
HSK	2.6.1.16		N-iodoacetylglucosamine 6-phosphate	639927	74529	D-fructose 6-phosphate protects
HSK	2.6.1.16		N3-(4-Methoxyfumaroyl)-L-2,3-diaminopropanoic acid	639917	5493	
HSK	2.6.1.16		N3-bromoacetyl-L-2,3-diaminopropanoic acid	639916	11183	competitive with respect to L-glutamine
HSK	2.6.1.16		N3-chloroacetyl-L-2,3-diaminopropanoic acid	639916	14382	competitive with respect to L-glutamine
HSK	2.6.1.16		N3-fumaramoyl-L-2,3-diaminopropanoic acid	639917	22124	
HSK	2.6.1.16		N3-Fumaroyl-L-2,3-diaminopropanoic acid	639917	6017	
HSK	2.6.1.16		N3-iodoacetyl-L-2,3-diaminopropanoic acid	639916	14383	competitive with respect to L-glutamine
AMAOTr	2.6.1.62		7-amino-8-oxononanoate	637092	10459	2 mM
AMAOTr	2.6.1.62		7-amino-8-oxononanoate	637094	10459	
AMAOTr	2.6.1.62		7-Keto-8-aminopelargonic acid	637092, 637094	1131	competitive with adenosyl-L-methionine
AMAOTr	2.6.1.62		7-Keto-8-aminopelargonic acid	637090, 637095	1131	
AMAOTr	2.6.1.62		8-Amino-7-oxononanoate	661047	1131	
AMAOTr	2.6.1.62		adenine	637092	136	8 mM
AMAOTr	2.6.1.62		adenosine	637092	116	5 mM
AMAOTr	2.6.1.62		adenosine	637094	116	
AMAOTr	2.6.1.62		amiclenomycin	663002	11717	
AMAOTr	2.6.1.62		cis-amiclenomycin	661047	11717	and analogues, overview, irreversible inactivation, kinact. 0.4 min-1, little or no inhibition by the trans-compound, overview
AMAOTr	2.6.1.62		S-Adenosyl-L-(2-hydroxy-4-methylthio)butyric acid	637092	29725	2.5 mM
AMAOTr	2.6.1.62		S-Adenosyl-L-(2-hydroxy-4-methylthio)butyric acid	637094	29725	
AMAOTr	2.6.1.62		S-adenosyl-L-ethionine	637092	2861	2 mM
AMAOTr	2.6.1.62		S-adenosyl-L-ethionine	637094	2861	
AMAOTr	2.6.1.62		S-adenosyl-L-homocysteine	637092	34	5 mM
AMAOTr	2.6.1.62		S-Inosyl-L-(2-hydroxy-4-methylthio)butyric acid	637092	30440	2 mM
PFK	2.7.1.11		ATP	640421	7	
PFK	2.7.1.11		ATP	640490	7	at alkaline pH; mechanism
PFK	2.7.1.11		ATP	640526	7	inhibition of fructose 1-phosphate phosphorylation above 0.08 mM ATP
PFK	2.7.1.11		citrate	640421	125	strong inhibition
PFK	2.7.1.11		citrate	640463	125	isoenzyme PFK2
PFK	2.7.1.11		citrate	640486	125	cAMP, ADP or fructose 1,6-bisphosphate restore activity
PFK	2.7.1.11		D-Fructose 1-phosphate	640421	544	
PFK	2.7.1.11		D-fructose 6-phosphate	722736	82	inhibition occurs at low concentrations of fructose 6-phosphate
PFK	2.7.1.11		MgATP2-	722736	102	inhibition occurs at high concentrations of MgATP2-
PFK	2.7.1.11		phosphoenolpyruvate	640486	47	feedback inhibition
PFK	2.7.1.11		phosphoenolpyruvate	640421, 640463, 722736	47	
PFK	2.7.1.11	ADP		722736	8	
PFK	2.7.1.11	GDP		640489	49	activation
PFK	2.7.1.11	GDP		640490, 722736	49	
PFK	2.7.1.11	MgATP2-		722736	102	the apparent Km for MgATP2- is 0.022 mM
PFK	2.7.1.11	NH4+		640421	50	
PFK	2.7.1.11	NH4+		640486	50	can replace K+
ADSL2r	2.7.1.23		HgCl2	641189	104	0.25 mM, 65% inhibition
ADSL2r	2.7.1.23		NADH	641189	3	0.01 mM, 61% inhibition
ADSL2r	2.7.1.23		NADH	691390	3	
ADSL2r	2.7.1.23		NADP+	641189	6	0.1 mM, 21% inhibition
ADSL2r	2.7.1.23		NADPH	641189	5	0.01 mM, 76% inhibition
ADSL2r	2.7.1.23		NADPH	691390	5	
ADSL2r	2.7.1.23		PCMB	641189	40	0.25 mM, 67% inhibition
ADSK	2.7.1.25		2,4,6-Trinitrobenzene sulfonate	641217	2353	0.05 mM, complete inhibition
ADSK	2.7.1.25		2,6-dichlorophenol indophenol	641217	152	0.05 mM, complete inhibition
ADSK	2.7.1.25		adenosine 5'-phosphosulfate	641215	354	
ADSK	2.7.1.25		ADP	641215	8	free form, reverse reaction, weak
ADSK	2.7.1.25		ATP	641215	7	free form, weak inhibition; MgATP2-: product inhibition, reverse reaction
ADSK	2.7.1.25		Bromosuccinimide	641217	6131	0.05 mM, complete inhibition
ADSK	2.7.1.25		Cd2+	641215	48	in excess
ADSK	2.7.1.25		Co2+	641215	21	in excess, activating below
ADSK	2.7.1.25		dehydroascorbate	641217	362	
ADSK	2.7.1.25		EDTA	641215	223	
ADSK	2.7.1.25		FAD	641217	14	
ADSK	2.7.1.25		ferricyanide	641217	126	0.05 mM, complete inhibition
ADSK	2.7.1.25		Mercuriphenylacetate	641217	1830	0.05 mM, complete inhibition
ADSK	2.7.1.25		Mn2+	641215	26	in excess, activating below
ADSK	2.7.1.25		oxidized glutathione	641217	283	thioredoxin reverses inactivation
ADSK	2.7.1.25		reduced glutathion	641217		
ADSK	2.7.1.25	ascorbate		641217	88	activation
ADSK	2.7.1.25	dithiothreitol		641217	42	activation
ADSK	2.7.1.25	glutathione		641217	41	reduced glutathione increases the activity significantly
ADSK	2.7.1.25	L-cysteine		641217	70	activation
ADSK	2.7.1.25	thioredoxin		641217	115	activation in the presence of dithiothreitol
GLYK	2.7.1.30		ADP	641287, 641294	8	
GLYK	2.7.1.30		ATP	722712	7	substrate inhibition
GLYK	2.7.1.30		cytosolic subunit of the glucose-specific phosphotransferase system	722712		allosteric inhibition
GLYK	2.7.1.30		D-fructose 1,6-bisphosphate	701931	100	
GLYK	2.7.1.30		D-fructose-1,6-bisphosphate	722712	100	allosteric inhibition
GLYK	2.7.1.30		DTNB	641298	196	inactivation reversed by dithiothreitol
GLYK	2.7.1.30		fructose 1,6-bisphosphate	661122	100	
GLYK	2.7.1.30		fructose 1,6-diphosphate	641287, 641294, 641295, 641309	100	
GLYK	2.7.1.30		fructose 1,6-diphosphate	641311	100	normal enzyme is inhibited, genetically altered enzyme not, inhibition is reduced by high pH, high ionic strength or 0.2 M guanidine HCl
GLYK	2.7.1.30		fructose 1,6-diphosphate	641326	100	mechanism
GLYK	2.7.1.30		glucose-specific phosphocarrier protein of the phosphoenolpyruvate:glucose phosphotransferase system	701931		
GLYK	2.7.1.30		glucose-specific phosphocarrier protein of the phosphoenolpyruvate:glucose phosphotransferase system (IIA(Glc))	701908		allosteric inhibitor
GLYK	2.7.1.30		glycerol 3-phosphate	641287	352	
GLYK	2.7.1.30		iodoacetate	641287	87	
GLYK	2.7.1.30		L-alpha-glycerophosphate	641295	2845	no inhibition up to 3 mM in presence of 0.1 M glycerol
GLYK	2.7.1.30		N-ethylmaleimide	641287, 641297	46	
GLYK	2.7.1.30		N-ethylmaleimide	641298	46	protection by: glycerol propane-1,2-diol, ATP, ADP, AMP, cAMP, no protection by: Mg2+, fructose 1,6-bisphosphate, propane-1,3-diol
GLYK	2.7.1.30		p-Hydroxymercuriphenylsulfonate	641287, 641294	3353	
PNTK	2.7.1.30		phosphocarrier protein IIAGlc	685101		the unphosphorylated form of the phosphocarrier protein IIAGlc is an allosteric inhibitor of Escherichia coli glycerol kinase
PNTK	2.7.1.33		(R)-3-azido-4,4-dimethyl-dihydro-furan-2-one	661331	37661	
PNTK	2.7.1.33		(R)-4-(2-amino-4-hydroxy-3,3-dimethyl-butyrylamino)-butyric acid	661331	37663	11% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		(R)-4-(2-azido-4-hydroxy-3,3-dimethyl-butyrylamino)-butyric acid	661331	37662	
PNTK	2.7.1.33		(R)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid	661331	15358	29.4% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		(S)-4-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-butyric acid	661331	24323	12.5% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		(S)-trifluoro-methanesulfonic acid 4,4-dimethyl-2-oxo-tetrahydro-furan-3-yl-ester	661331	37660	
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-(2-[1-methyl-3-phenyl-propylcarbamoyl]-ethyl)-butyramide	661331	15181	71.7% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-(2-[2-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-ethyl)-butyramide	661331	15180	44.2% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-(2-[3,4,5-trimethoxy-benzylcarbamoyl]-ethyl)-butyramide	661331	15182	33.4% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-(2-heptylcarbamoyl-ethyl)-butyramide	661331	6579	76.4% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-(2-isobutylcarbamoyl-ethyl)-butyramide	661331	15187	71.2% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-(2-pentylcarbamoyl-ethyl)-butyramide	661331	6578	72.2% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-(2-phenethylcarbamoyl-ethyl)-butyramide	661331	15359	57.8% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-(2-propylcarbamoylethyl)-butyramide	661331	9078	82.5% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethoxy-ethylcarbamoyl)-ethyl]-butyramide	661331	15192	28.6% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-[2-(2-ethylsulfanylethylcarbamoyl)-ethyl]-butyramide	661331	15191	53.7% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-[2-(2-methylsulfanylethylcarbamoyl)-ethyl]-butyramide	661331	15189	61.9% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-[2-(2-morpholin-4-yl-ethylcarbamoyl)-ethyl]-butyramide	661331	15184	10.7% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-[2-(2,6,6-trimethylbicyclo[3.1.1]hept-3-ylcarbamoyl)-ethyl]-butyramide	661331	15186	3.0% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-[2-(3-ethoxy-propylcarbamoyl)-ethyl]-butyramide	661331	9076	32.3% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-[2-(3-methylsulfanylpropylcarbamoyl)-ethyl]-butyramide	661331	9077	54.3% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-[2-(3,7-dimethylocta-2,6-dienylcarbamoyl)-ethyl]-butyramide	661331	15188	90.6% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-[2-(4-methoxy-benzylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15185	55.7% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-3,3-dimethyl N-[3-(4-benzyl-piperazin-1-yl)-3-oxo-propyl]-butyramide	661331	15183	7.3% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-N-[2-(2-hydroxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15360	3.4% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-N-[2-(2-methoxy-ethylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15190	28.7% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-N-[2-(3-hydroxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	15361	i.e. pantothenol, 11.5% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		2,4-dihydroxy-N-[2-(3-methoxy-propylcarbamoyl)-ethyl]-3,3-dimethyl-butyramide	661331	9075	38.6% inhibition at 0.1 mM, purified enzyme
PNTK	2.7.1.33		acetoacetyl-CoA	641393	167	
PNTK	2.7.1.33		acetyl-CoA	641393	27	
PNTK	2.7.1.33		ADP	641393	8	
PNTK	2.7.1.33		AMP	641393	9	
PNTK	2.7.1.33		CoA	641393	10	in vitro; in vivo; kinetics
PNTK	2.7.1.33		CoA	671053	10	feedback inhibitor
PNTK	2.7.1.33		CoA	686816	10	competitive
PNTK	2.7.1.33		coenzyme A	662251	10	allosteric regulator, feedback inhibition
PNTK	2.7.1.33		dephospho-CoA	641393	1349	not
PNTK	2.7.1.33		malonyl-CoA	641393	72	
PNTK	2.7.1.33		N-heptylpantothenamide	662251	6579	competitive to pantothenate
PNTK	2.7.1.33		N-pentylpantothenamide	662251	6578	competitive to pantothenate
PNTK	2.7.1.33		palmitoyl-CoA	641393	122	
PNTK	2.7.1.33		pantetheine 4'-phosphate	641393	966	not
PNTK	2.7.1.33		succinyl-CoA	641393	198	
PNTK	2.7.1.33	dithiothreitol		641393	42	activation
DHORD2	2.7.1.39		(4R)-4-hydroxypentan-2-one	641471	91688	
DHORD2	2.7.1.39		(p-hydroxyphenyl)-glyoxal	641471	20867	
DHORD2	2.7.1.39		1,2-amino-5-hydroxyvalerate	641471		substrate inhibition
DHORD2	2.7.1.39		2-amino-3-(phosphonoethyl)thiopropionate	641471	33093	
DHORD2	2.7.1.39		2-Amino-5-phosphonovalerate	641471	28699	
DHORD2	2.7.1.39		2-amino-5-phosphovalerate	641471	33095	
DHORD2	2.7.1.39		2-chloro-L-alanine	641470	28728	
DHORD2	2.7.1.39		5'-adenylylimidodiphosphate	641463	2969	
DHORD2	2.7.1.39		alpha-amino-beta-hydroxy valeric acid	641465	31826	
DHORD2	2.7.1.39		diethyl dicarbonate	641473	265	
DHORD2	2.7.1.39		L-2-aminobutyrate	641470	1112	
DHORD2	2.7.1.39		L-2-aminobutyric acid	641465	1302	40 mM, 50% inhibition
DHORD2	2.7.1.39		L-alpha-aminobutyric acid	641463	1302	
DHORD2	2.7.1.39		L-aspartate semialdehyde	641463	472	mixed inhibition versus L-homoserine and ATP
DHORD2	2.7.1.39		L-Cys	641470, 641471	70	
DHORD2	2.7.1.39		L-Glutamic acid	641471	38	
DHORD2	2.7.1.39		L-homocysteine	641470	260	
DHORD2	2.7.1.39		L-homoserine	641463	294	above 0.75 mM
DHORD2	2.7.1.39		L-homoserine	641471	294	
DHORD2	2.7.1.39		L-homoserine	641473	294	substrate inhibition
DHORD2	2.7.1.39		L-homoserine alpha-methyl ester	641471	11179	substrate inhibition
DHORD2	2.7.1.39		L-homoserine ethyl ester	641471	8849	unlike the wild-type enzyme the mutant enzyme H202L is inhibited
DHORD2	2.7.1.39		L-homoserine isopropyl ester	641471	14375	unlike the wild-type enzyme the mutant enzyme H202L is inhibited
DHORD2	2.7.1.39		L-homoserine n-propyl ester	641471	14376	unlike the wild-type enzyme the mutant enzyme H202L is inhibited
DHORD2	2.7.1.39		L-Ile	641470	266	
DHORD2	2.7.1.39		L-Met	641470	83	
DHORD2	2.7.1.39		L-norvaline	641471	559	
DHORD2	2.7.1.39		L-Ser	641470	89	
DHORD2	2.7.1.39		L-Thr	641465	220	
DHORD2	2.7.1.39		L-Thr	641470	220	competitive to the substrate L-homoserine
DHORD2	2.7.1.39		L-Thr	641471	220	substrate inhibition
DHORD2	2.7.1.39		L-Val	641470	217	
DHORD2	2.7.1.39		O-phospho-L-serine	641471	899	
DHORD2	2.7.1.39		pyridoxal 5'-phosphate	641473	30	
DHORD2	2.7.1.39	NH4+		641465	50	30% of the activity obtained with 0.5 M K+
GLU5K	2.7.2.11		5-oxoproline	681421	784	AAK domain has a crater on the beta sheet C-edge that hosts the active centre and binds 5-oxoproline
GLU5K	2.7.2.11		ADP	642200	8	
GLU5K	2.7.2.11		L-proline	681421	215	AAK domain is responsible for inhibition
GLU5K	2.7.2.11		L-proline	679845, 722974	215	
PPKr_reverse	2.7.4.1		(NH4)2SO4	645115	334	activation up to 100 mM; inhibition at higher concentrations; strong inhibition
PPKr_reverse	2.7.4.1		ADP	645111	8	0.08 mM, complete inhibition
PPKr_reverse	2.7.4.1		ADP	645114	8	0.2 mM, complete inhibition
PPKr_reverse	2.7.4.1		ADP	645115	8	50%, 70% and 93% inhibition at 0.08 mM, 0.15 mM and 0.2 mM ADP, respectively
PPKr_reverse	2.7.4.1		Ca2+	645116	18	1 mM, 10% inhibition
PPKr_reverse	2.7.4.1		Co2+	645116	21	1 mM, 40% inhibition
PPKr_reverse	2.7.4.1		Cu2+	645116	28	0.1 mM, 92% inhibition, 1 mM, complete inhibition
PPKr_reverse	2.7.4.1		diphosphate	645111	13	weak inhibition
PPKr_reverse	2.7.4.1		diphosphate	645114	13	1 mM, complete inhibition
PPKr_reverse	2.7.4.1		diphosphate	645129	13	10 mM, 66% inhibition of polyphosphate synthesis, 75% inhibition of GTP synthesis
PPKr_reverse	2.7.4.1		F-	645111	158	5 mM, complete inhibition
PPKr_reverse	2.7.4.1		F-	645114	158	20 mM, complete inhibition
PPKr_reverse	2.7.4.1		GMP	645129	150	competitive inhibition of polyphosphate 750 and GDP in guanosine 5'-tetraphosphate synthesis
PPKr_reverse	2.7.4.1		Guanidine HCl	645129	804	5 mM, 50% inhibition of polyphosphate synthesis
PPKr_reverse	2.7.4.1		histone	645114	780	reverse reaction, strong, activates forward reaction in the presence of phosphate
PPKr_reverse	2.7.4.1		KCl	645114	74	
PPKr_reverse	2.7.4.1		KCl	645115	74	50 mM, 50% inhibition
PPKr_reverse	2.7.4.1		Mn2+	645116	26	weak inhibition at 10 mM Mg2+
PPKr_reverse	2.7.4.1		NaCl	645114	39	
PPKr_reverse	2.7.4.1		phosphate	645114	12	above 20 mM; activates in the presence of histone
PPKr_reverse	2.7.4.1		Polyphosphate	645129	723	65 residues, competitive inhibition of polyphosphate 750 and GDP in guanosine 5'-tetraphosphate synthesis
PPKr_reverse	2.7.4.1		Zn2+	645116	19	0.1 mM, 67% inhibition, 1 mM, complete inhibition
PPKr_reverse	2.7.4.1	(NH4)2SO4		645111	334	
PPKr_reverse	2.7.4.1	(NH4)2SO4		645115	334	activation, up to 100 mM, inhibition at higher concentrations
PPKr_reverse	2.7.4.1	(NH4)2SO4		645125	334	40 mM, approx. 14fold activation of ATP synthesis
PPKr_reverse	2.7.4.1	basic protein		645113, 645114		activation
PPKr_reverse	2.7.4.1	Bovine serum albumin		645114		activation, can substitute for histone only in the absence of phosphate
PPKr_reverse	2.7.4.1	casein		645114	595	activation, can substitute for histone only in the absence of phosphate
PPKr_reverse	2.7.4.1	diphosphate		645129	13	10 mM, 100% activation of guanosine 5'-tetraphosphate synthesis
PPKr_reverse	2.7.4.1	Guanidine HCl		645129	804	5 mM, 20% activation of guanosine 5'-tetraphosphate synthesis
PPKr_reverse	2.7.4.1	histone		645114	780	maximum activation in the presence of 20 mM phosphate; strong inhibition of reverse reaction
PPKr_reverse	2.7.4.1	phosphate		645114	12	inhibiton above 20 mM; required for activity, only in the presence of histone
PPKr_reverse	2.7.4.1	protamine		645113	978	
PPKr_reverse	2.7.4.1	protamine		645114	978	required for maximal activity
PPKr_reverse	2.7.4.1	Tetrapolyphosphate		645115	2402	activation, removes lag-phase in synthesis at low ATP-levels, not phosphate, diphosphate or tripolyphosphate
TMPK	2.7.4.16		ADP	642545	8	product inhibition
TMPK	2.7.4.16		AMP	642545	9	
TMPK	2.7.4.16		Cs+	642545	478	antagonizes stimulation by K+
TMPK	2.7.4.16		diphosphate	642545	13	
TMPK	2.7.4.16		EDTA	642545	223	
TMPK	2.7.4.16		Li+	642545	142	antagonizes stimulation by K+
TMPK	2.7.4.16		N-ethylmaleimide	642545	46	
TMPK	2.7.4.16		Na+	642545	55	antagonizes stimulation by K+
TMPK	2.7.4.16		NaF	642545	209	weak
TMPK	2.7.4.16		Oxythiamine	642545	3831	
TMPK	2.7.4.16		PCMB	642545	40	2-mercaptoethanol reverses
TMPK	2.7.4.16		pyrithiamine	642545	3841	
TMPK	2.7.4.16		Pyrithiamine phosphate	642545	65398	
TMPK	2.7.4.16		thiamine	642545	522	
GK1	2.7.4.8		Ap5G	672440	24119	Ap5G locks an incompletely closed conformation of the enzyme, in which the adenine moiety is located outside its expected binding site. Instead, it binds at a subunit interface that is unique to the bacterial enzyme, which is in equilibrium between a dimeric and an hexameric form in solution.
DTMPK	2.7.4.9		5-iodo-2'-dUMP	645198	13238	
DTMPK	2.7.4.9		dCTP	645198	161	
DTMPK	2.7.4.9		dTTP	645198	137	
DTMPK	2.7.4.9		dUMP	645198	496	
DTMPK	2.7.4.9		NaCl	645198	39	0.1 M, 25% inhibition
DTMPK	2.7.4.9		NH4Cl	645198	282	0.4 M, 75% inhibition
HPPK2	2.7.6.3		2-amino-6-[(2-[4-[5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-ylmethylsulfanyl]-piperidin-1-yl]-ethylamino)-methyl]-3H-pteridin-4-one	721840		
HPPK2	2.7.6.3		2-amino-6-[(2-[4-[5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-ylmethylsulfanyl]-piperidin-1-yl]-ethylamino)-methyl]-7,7-dimethyl-7,8-dihydro-3H-pteridin-4-one	721840		
HPPK2	2.7.6.3		2-amino-7,7-dimethyl-4-oxo-3,4,7,8-tetrahydro-pteridine-6-carboxylic acid (2-[4-[5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethylsulfanyl]-piperidin-1-yl]-ethyl)-amide	721840		
HPPK2	2.7.6.3		2-amino-7,7-dimethyl-4-oxo-3,4,7,8-tetrahydropteridine-6-carboxylic acid (2-[2-[5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethanesulfonyl]-ethylcarbamoyl]-ethyl)-amide	721839		about 45% residual activity at 0.01 mM, about 30% residual activity at 0.02 mM, about 15% residual activity at 0.05 mM, almost complete inhibition at 0.1 mM
HPPK2	2.7.6.3		5'-S-[1-(2-{[(2-amino-7,7-dimethyl-4-oxo-3,4,7,8-tetrahydropteridin-6-yl)carbonyl]amino}ethyl)piperidin-4-yl]-5'-thioadenosine	721839		
HPPK2	2.7.6.3		6-hydroxymethyl-7-methyl-7-phenethyl-7,8-dihydropterin	721840		
HPPK2	2.7.6.3		6-hydroxymethyl-7,7-dimethyl-7,8-dihydropterin	721840		
HPPK2	2.7.6.3		alpha,beta-methyleneadenosine triphosphate	642759	4820	competitive with respect to ATP
HPPK2	2.7.6.3		P1-(6-hydroxymethylpterin)-P2-(5'-adenosyl)diphosphate	721840		
HPPK2	2.7.6.3		P1-(6-hydroxymethylpterin)-P3-(5'-adenosyl)triphosphate	721840		
HPPK2	2.7.6.3		P1-(6-hydroxymethylpterin)-P4-(5'-adenosyl)tetraphosphate	721839, 721840		
UAGDP	2.7.7.23		UDP-N-acetyl-D-glucosamine	288685	120	slight product inhibition in reverse reaction
GARFT	2.7.7.3		CoA	674344	10	
GARFT	2.7.7.3		dephospho-CoA	674344	1349	
GARFT	2.7.7.3		diphosphate	674344	13	
GARFT	2.7.7.3		phosphopantetheine	674344	966	
GARFT	2.7.7.3		PTX040334	643184	21987	IC50: 0.03 mM
GARFT	2.7.7.3		PTX042695	643184	21986	IC50: 0.000006 mM
HSST	2.7.7.38		(1R,4S,5R)-3-[2-[(S)-1-((S)-1-carboxy-ethylcarbamoyl)-ethylamino]-ethyl]-4,5-dihydroxy-cyclohexanecarboxylic acid	661340	80704	
HSST	2.7.7.38		2,6-Anhydro-3-deoxy-D-glycero-D-talo-octanoate	645229	8504	2-deoxy KDO analog
HSST	2.7.7.38		2,6-Anhydro-3-deoxy-D-glycero-D-talo-octanoate	645238	8504	
HSST	2.7.7.38		diphosphate	645227	13	weak inhibition
HSST	2.7.7.38		Hg2+	645227	31	strong inhibition
HSST	2.7.7.38	GSH		645226	41	
MEPCT	2.7.7.60		CTP	661089	56	substrate inhibition
PSSA160	2.7.8.8		Triton X-100	643782	57	inhibits activity as the molar ratio of Triton X-100 to CDP-diacylglycerol raises beyond the point of maximal activity
PSSA160	2.7.8.8	cardiolipin		643784	652	activates. The enzyme is completely desensitized by treatment for 5 min at 40&deg;C against the effect of cadiolipin without loss of activity
PSSA160	2.7.8.8	diphosphatidylglycerol		661745	652	membrane association and activity of PtdSer synthase is increased, studied with mixed micelles containing phosphatidylglycerol (one charge) or diphosphatidylglycerol (two charges), the two main anionic membrane lipids in Escherichia coli
PSSA160	2.7.8.8	phosphatidylethanolamine		643784	427	slightly activates. The enzyme is completely desensitized by treatment for 5 min at 40&deg;C against the effect of phosphatidylethanolamine without loss of activity
PSSA160	2.7.8.8	phosphatidylglycerol		661745	550	membrane association and activity of PtdSer synthase is increased, studied with mixed micelles containing phosphatidylglycerol (one charge) or diphosphatidylglycerol (two charges), the two main anionic membrane lipids in Escherichia coli
PSSA160	2.7.8.8	Triton X-100		643778	57	enzyme is dependent on a nonionic detergent such as Triton X-100
PSSA160	2.7.8.8	Triton X-100		643779	57	dependent on nonionic detergent, at 0.1 mM CDP-diacylglycerol optimal activity occurs at a Triton to substrate molar ratio of 8:1
PSSA160	2.7.8.8	Triton X-100		643782	57	increasing levels of Triton X-100 at low molecular ratios of Triton X-100 to CDP-diacylglycerol stimulate
PPS	2.7.9.2		2-oxoglutarate	645472, 645473	32	
PPS	2.7.9.2		3-phosphoglyceraldehyde	645472	473	
PPS	2.7.9.2		3-phosphoglyceraldehyde	645473	473	weak
PPS	2.7.9.2		5'-adenylylmethylene diphosphonate	645469	3780	competitive to ATP
PPS	2.7.9.2		ADP	645472, 645473	8	
PPS	2.7.9.2		ADP-glucose	645473	493	weak
PPS	2.7.9.2		AMP	645473	9	
PPS	2.7.9.2		ATP	645468	7	excess of ATP inhibits at high concentrations of MgCl2 or MnCl2
PPS	2.7.9.2		Ca2+	645468	18	inhibits Mn2+-activated enzyme
PPS	2.7.9.2		F-	645470	158	
PPS	2.7.9.2		iodoacetate	645468	87	
PPS	2.7.9.2		malate	645473	246	
PPS	2.7.9.2		Mg2+	645468	25	divalent metal ion Mg2+ or Mn2+ required for forward reaction, inhibition at high concentrations of Mg2+ or Mn2+
PPS	2.7.9.2		Mn2+	645468	26	divalent metal ion Mg2+ or Mn2+ required for forward reaction, inhibition at high concentrations of Mg2+ or Mn2+
PPS	2.7.9.2		oxalacetate	645472, 645473	53	
PPS	2.7.9.2		PCMB	645468	40	
PPS	2.7.9.2		phosphoenolpyruvate	645473	47	competitive to ATP
PPS	2.7.9.2		sulfhydryl reagents	645468	752	
BTS5	2.8.1.6		5'-deoxyadenosine	645608	734	strong inhibitor, reversible, 90% inhibition upon addition of 1 equivalent of 5'-deoxyadenosine with regard to the enzyme
BTS5	2.8.1.6		methionine and 5'-deoxyadenosine	724296		modest inhibitor
BTS5	2.8.1.6		NaBH4	645609	507	decreases cysteine desulfurase and biotin synthase activity
BTS5	2.8.1.6		S-adenosyl-L-homocysteine	724296	34	potent inhibitor
BTS5	2.8.1.6		sinefungin	724296	535	
BTS5	2.8.1.6	amino acid		645585	3318	one of the amino acids: Asn, Asp, Gln or Ser
BTS5	2.8.1.6	asparagine		645594	231	required
BTS5	2.8.1.6	dithiothreitol		645593	42	potential sulfur donor
BTS5	2.8.1.6	dithiothreitol		645595	42	
BTS5	2.8.1.6	dithiothreitol		645609	42	10fold stimulation of cysteine desulfurase activity of the enzyme at 20 mM
BTS5	2.8.1.6	dithiothreitol		645613	42	required for formation of mixed [Fe-S] cluster state
BTS5	2.8.1.6	Flavodoxin		645599		
BTS5	2.8.1.6	flavodoxin reductase		645595		omission results in a 100fold decrease in activity
BTS5	2.8.1.6	flavodoxin reductase		645599		
BTS5	2.8.1.6	fructose 1,6-diphosphate		645593	100	
BTS5	2.8.1.6	L-cysteine		645585	70	required as sulfur donor
BTS5	2.8.1.6	L-cysteine		645593, 645594	70	required
BTS5	2.8.1.6	L-cysteine		645609	70	increases biotin production
BTS5	2.8.1.6	MioC		645599		essential, may function as an electron transport protein
BTS5	2.8.1.6	NifS		645614		a member of the Nif protein family stimulates biotin production
BTS5	2.8.1.6	NifU		645614		a member of the Nif protein family stimulates biotin production
BTS5	2.8.1.6	Pyridine nucleotide		645585		required, NADPH being most effective
BTS5	2.8.1.6	pyridoxal 5'-phosphate		645609	30	required for cysteine desulfurase activity of the enzyme
BTS5	2.8.1.6	S-adenosyl-L-methionine		645594	22	two molecules of S-adenosyl-L-methionine are used to synthesize one molecule of biotin, one from dethiobiotin to the intermediate, and a second from the intermediate to biotin
BTS5	2.8.1.6	S-adenosyl-L-methionine		645583, 645585, 645593, 645595, 645605	22	required
BTS5	2.8.1.6	S-adenosyl-L-methionine		645608	22	one molecule S-adenosyl-L-methionine is required to form one molecule of biotin
BTS5	2.8.1.6	S-adenosyl-L-methionine		645597, 645598, 645612	22	
BTS5	2.8.1.6	thiamine diphosphate-dependent protein		645585		required
FACOAE120	3.1.2.20		2,2-dinitrofluorobenzene	646120		inhibits very slowly
FACOAE120	3.1.2.20		4-hydroxyphenacyl-CoA	690932	3675	
FACOAE120	3.1.2.20		CoA	690932	10	strong feedback inhibitor, product inhibition
FACOAE120	3.1.2.20		diethyldicarbonate	646178	265	hydroxylamine reverses
FACOAE120	3.1.2.20		diisopropylfluorophosphate	646119	216	at 0.01 mM inhibition of 95% after 40 min.
FACOAE120	3.1.2.20		diisopropylfluorophosphate	646123	216	1 mM DFP at 40 min at 25&deg;C produces a 95% inhibition at palmityl thioesterase I
FACOAE120	3.1.2.20		hexyl-CoA	690932	17315	
FACOAE120	3.1.2.20		IAA	646178	2122	
FACOAE120	3.1.2.20		iodoacetamide	646120	63	
FACOAE120	3.1.2.20		methylene blue	646120	426	photooxidation
FACOAE120	3.1.2.20		PMSF	646123	218	less effective than DFP, produces a 27% loss of activity under similar conditions
KDOPP	3.1.3.45		Ca2+	646344, 652389	18	
KDOPP	3.1.3.45		Cd2+	646344, 652389	48	
KDOPP	3.1.3.45		Cl-	646344	134	
KDOPP	3.1.3.45		Cu2+	646344, 652389	28	
KDOPP	3.1.3.45		EDTA	646344	223	
KDOPP	3.1.3.45		Hg2+	646344, 652389	31	
BPNT	3.1.3.7		LiCl	677696	654	
BPNT	3.1.3.7		Mg2+	677696	25	activity is decreased to approximately 70% in the presence of 10 mM MgCl2
AHCYSNS	3.2.2.9		(+/-)-cis-1-[(9-deazaadenin-9-yl)methyl]-4-ethyl-3-hydroxypyrrolidine	715849	111972	
AHCYSNS	3.2.2.9		(+/-)-trans-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(1H-1,2,3-triazol-4-yl)pyrrolidine	715849	111968	
AHCYSNS	3.2.2.9		(+/-)-trans-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(penta-3-yl)pyrrolidine	715849	111963	
AHCYSNS	3.2.2.9		(+/-)-trans-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-isobutylpyrrolidine	715849	111962	
AHCYSNS	3.2.2.9		(+/-)-trans-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-phenylpyrrolidine	715849	112559	
AHCYSNS	3.2.2.9		(+/-)-trans-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-vinylpyrrolidine	715849	112560	
AHCYSNS	3.2.2.9		(+/-)-trans-1-[(9-deazaadenin-9-yl)methyl]-4-ethynyl-3-hydroxypyrrolidine	715849	111967	
AHCYSNS	3.2.2.9		(+/-)-trans-4-(1-benzyl-1H-1,2,3-triazol-4-yl)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	715849	111969	
AHCYSNS	3.2.2.9		(+/-)-trans-4-(cyclohexylmethyl)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxypyrrolidine	715849	111965	
AHCYSNS	3.2.2.9		(+/-)-trans-4-[3-(benzylthio)propyl]-1-[(9-deazaadenin-9-yl)-methyl]-3-hydroxypyrrolidine	715849	111970	
AHCYSNS	3.2.2.9		(+/-)-trans-4-allyl-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	715849	111966	
AHCYSNS	3.2.2.9		(+/-)-trans-4-butyl-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	715849	111961	
AHCYSNS	3.2.2.9		(+/-)-trans-4-cyclopentyl-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	715849	112558	
AHCYSNS	3.2.2.9		(+/-)-trans-4-cyclopropyl-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	715849	111964	
AHCYSNS	3.2.2.9		(+/-)trans-1-[(9-deazaadenin-9-yl)methyl]-4-ethyl-3-hydroxypyrrolidine	715849	111971	
AHCYSNS	3.2.2.9		(1S)-1-(9-deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-(3-methylphenylthio)-D-ribitol	669334	23873	
AHCYSNS	3.2.2.9		(1S)-1-(9-deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-(4-methylphenylthio)-D-ribitol	669334	23872	
AHCYSNS	3.2.2.9		(1S)-1-(9-deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-methylthio-D-ribitol	727159	37178	
AHCYSNS	3.2.2.9		(1S)-5-(4-chlorophenylthio)-1-(9-deaza-adenin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol	669334	23871	
AHCYSNS	3.2.2.9		(2R,3R)-2-([[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl](methyl)amino]methyl)-4-(methylsulfanyl)butane-1,3-diol	727159	111299	
AHCYSNS	3.2.2.9		(2R,3R)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-4-(methylsulfanyl)butane-1,3-diol	727159	111293	
AHCYSNS	3.2.2.9		(2R,3S)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-4-(methylsulfanyl)butane-1,3-diol	727159	111291	
AHCYSNS	3.2.2.9		(2R,3S)-4-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl](methyl)amino]-3-[(methylsulfanyl)methyl]butane-1,2-diol	727159	111298	
AHCYSNS	3.2.2.9		(2R)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-3-(methylsulfanyl)propan-1-ol	727159	111510	
AHCYSNS	3.2.2.9		(2R)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-3-[(hydroxymethyl)sulfanyl]propan-1-ol	727159	111288	
AHCYSNS	3.2.2.9		(2S,3R)-1-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl](methyl)amino]-4-(methylsulfanyl)butane-2,3-diol	727159	111312	
AHCYSNS	3.2.2.9		(2S,3R)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-4-(methylsulfanyl)butane-1,3-diol	727159	111292	
AHCYSNS	3.2.2.9		(2S,3R)-N-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-3,4-dihydroxy-2-[(methylsulfanyl)methyl]butan-1-aminium trifluoroacetate	727159	111297	
AHCYSNS	3.2.2.9		(2S,3S)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-4-(methylsulfanyl)butane-1,3-diol	727159	111294	
AHCYSNS	3.2.2.9		(2S)-1-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-3-(methylsulfanyl)propan-2-ol	727159	111296	
AHCYSNS	3.2.2.9		(2S)-2-[[(1S)-1-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-2-hydroxyethyl]amino]-3-(methylsulfanyl)propan-1-ol	727159	111301	
AHCYSNS	3.2.2.9		(2S)-2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-3-[(hydroxymethyl)sulfanyl]propan-1-ol	727159	111289	
AHCYSNS	3.2.2.9		(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine	669334	2436	
AHCYSNS	3.2.2.9		(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-4-ethyl-3-hydroxypyrrolidine	715849	111971	
AHCYSNS	3.2.2.9		(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]3-hydroxy-4-methylthiomethylpyrrolidine	727159	113052	
AHCYSNS	3.2.2.9		(3R,4S)-4-(1-butylthiomethyl)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxypyrrolidine	727674	41502	
AHCYSNS	3.2.2.9		(3R,4S)-4-(4-chlorophenyl-thiomethyl)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	669334	3968	potential antibiotic to interfere with the metabolic pathways involved in methylation, polyamine biosynthesis, methionine recycling, and quorum sensing pathways
AHCYSNS	3.2.2.9		(3R,4S)-4-(benzylthiomethyl)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	669334		
AHCYSNS	3.2.2.9		(3R,4S)-4-butyl-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxypyrrolidine	715849	111961	
AHCYSNS	3.2.2.9		(3R,4S)-butylthio-5'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin	715849	6906	
AHCYSNS	3.2.2.9		(3R,4S)-ethylthio-5'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin	715849	111769	
AHCYSNS	3.2.2.9		(3R,4S)-methylthio-5'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin	715849	2436	
AHCYSNS	3.2.2.9		(5'R)-cycloMethylthioadenosine	171858		competitive inhibition
AHCYSNS	3.2.2.9		(p-bromophenyl)thioadenosine	171857	68395	
AHCYSNS	3.2.2.9		(p-fluorophenyl)thioadenosine	171857	68396	
AHCYSNS	3.2.2.9		2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-2-[(methylsulfanyl)methyl]propane-1,3-diol	727159	111295	
AHCYSNS	3.2.2.9		2-[[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]amino]-3-(methylsulfanyl)propan-1-ol	727159	111290	
AHCYSNS	3.2.2.9		2',3'-didehydromethylthioadenosine	171858	68461	competitive inhibition
AHCYSNS	3.2.2.9		3'-deoxy-methylthioadenosine	171858	68511	competitive inhibition
AHCYSNS	3.2.2.9		4-chlorophenylthio-4'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin-A	678158	3968	
AHCYSNS	3.2.2.9		5'-(4-aminophenyl)thioadenosine	171857		
AHCYSNS	3.2.2.9		5'-(4-bromophenyl)thioadenosine	171857		moderate inhibitor
AHCYSNS	3.2.2.9		5'-(4-chlorophenyl)thioadenosine	171857		
AHCYSNS	3.2.2.9		5'-(4-fluorophenyl)thioadenosine	171857		moderate inhibitor
AHCYSNS	3.2.2.9		5'-(4-iodophenyl)thioadenosine	171857		
AHCYSNS	3.2.2.9		5'-(4-nitrophenyl)thioadenosine	171857		most potent inhibitor
AHCYSNS	3.2.2.9		5'-(p-nitrophenyl)thioadenosine	171857	9868	most potent inhibitor
AHCYSNS	3.2.2.9		5'-butylthioadenosine	171857	23242	
AHCYSNS	3.2.2.9		5'-Chloroadenosine	171857	10438	
AHCYSNS	3.2.2.9		5'-Chloroformycin	171854	7097	; powerful inhibitor
AHCYSNS	3.2.2.9		5'-Chloroformycin	171857	7097	competitive inhibition
AHCYSNS	3.2.2.9		5'-dimethylthioadenosine	171857	12784	
AHCYSNS	3.2.2.9		5'-Ethylthioadenosine	171851	3126	competitive inhibition
AHCYSNS	3.2.2.9		5'-Ethylthioadenosine	171857	3126	
AHCYSNS	3.2.2.9		5'-isobutylthio-3-deaza-adenosine	171854	68570	poor inhibitor
AHCYSNS	3.2.2.9		5'-isobutylthioadenosine	171857	7098	
AHCYSNS	3.2.2.9		5'-Isobutylthioinosine	171854	28963	
AHCYSNS	3.2.2.9		5'-Isopropylthioadenosine	171857	28964	
AHCYSNS	3.2.2.9		5'-Methylselenoadenosine	171857	63548	
AHCYSNS	3.2.2.9		5'-methylthio-3-deaza-adenosine	171854	113051	poor inhibitor
AHCYSNS	3.2.2.9		5'-methylthioadenosine	171857	335	
AHCYSNS	3.2.2.9		5'-Methylthioformycin	171854	28965	; powerful inhibitor
AHCYSNS	3.2.2.9		5'-Methylthioformycin	171857	28965	competitive inhibition
AHCYSNS	3.2.2.9		5'-methylthioinosine	171857	6097	
AHCYSNS	3.2.2.9		5'-methylthiotubercidin	171854	3249	; powerful inhibitor
AHCYSNS	3.2.2.9		5'-methylthiotubercidin	171857, 656196	3249	
AHCYSNS	3.2.2.9		5'-n-butylthioinosine	171854	68572	
AHCYSNS	3.2.2.9		5'-n-Propylthioadenosine	171851	13228	competitive inhibition
AHCYSNS	3.2.2.9		5'-phenylthioadenosine	171857	13893	; moderate inhibitor
AHCYSNS	3.2.2.9		5'-propylthioadenosine	171857	13228	
AHCYSNS	3.2.2.9		5'-purinothioadenosine	171857		
AHCYSNS	3.2.2.9		adenine	171854	136	poor inhibitor
AHCYSNS	3.2.2.9		adenine	171851, 171857	136	
AHCYSNS	3.2.2.9		adenine	171859	136	recombinant MTA/SAH'ase (rMTAN)
AHCYSNS	3.2.2.9		adenosine	171857	116	
AHCYSNS	3.2.2.9		carbocyclic 5'-methylthioadenosine	171857		
AHCYSNS	3.2.2.9		ethylthio-immucillin-A	678158	6752	
AHCYSNS	3.2.2.9		Formycin A	171857, 656196	1462	
AHCYSNS	3.2.2.9		methylthio-4'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin-A	678158	2436	
AHCYSNS	3.2.2.9		methylthio-immucillin-A	678158	6749	weak
AHCYSNS	3.2.2.9		p-tolylthio-immucillin-A	678158	6751	
AHCYSNS	3.2.2.9		phenylthio-immucillin-A	678158	6750	
AHCYSNS	3.2.2.9		S-8-aza-adenosyl-L-homocysteine	171854	8469	powerful inhibitor
AHCYSNS	3.2.2.9		S-8-aza-adenosylhomocysteine	171854	8469	
AHCYSNS	3.2.2.9		S-adenosyl-L-homocysteine	171857	34	; moderate inhibitor
AHCYSNS	3.2.2.9		S-adenosyl-L-homocysteine sulfoxide	171854	6228	poor inhibitor
AHCYSNS	3.2.2.9		S-adenosylhomocysteine	171851	34	competitive inhibition
AHCYSNS	3.2.2.9		S-Formycinylhomocysteine	171854		; powerful inhibitor
AHCYSNS	3.2.2.9		S-Formycinylhomocysteine	171857		competitive inhibition
AHCYSNS	3.2.2.9		S-N6-dimethyl-3-deaza-adenosyl-L-homocysteine	171854	29717	poor inhibitor
AHCYSNS	3.2.2.9		S-Tubercidinylhomocysteine	171854	10675	; powerful inhibitor
AHCYSNS	3.2.2.9		sinefungin	171854	535	poor inhibitor
UHGADA	3.5.1.108		(3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl)methanethiol	699421	51516	
UHGADA	3.5.1.108		(3R,5R)-3-hydroxy-5-(2-(hydroxyamino)-2-oxoethyl)-2-(hydroxymethyl)tetrahydro-2H-pyran-4-yl tetradecanoate	696206	17688	substrate-analog LpxC inhibitor, possesses little or no antibacterial activity, because it probably cannot penetrate the Gram-negative cell envelope
UHGADA	3.5.1.108		(4R)-2-(3,4-dimethoxy-5-propylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide	695538	17656	i.e L-161,240
UHGADA	3.5.1.108		(4R)-2-(3,4-dimethoxy-5-propylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide	695629	17656	the inhibitor is active against a Pseudomonas aeruginosa construct in which the endogenous lpxC gene is inactivated and in which LpxC activity is supplied by the lpxC gene from Escherichia coli. An Escherichia coli construct in which growth is dependent on the Pseudomonas aeruginosa lpxC gene is resistant to the compound
UHGADA	3.5.1.108		(4R)-N-hydroxy-2-(4-methoxyphenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide	695538	26024	i.e. L-159,692
UHGADA	3.5.1.108		(4R)-N-hydroxy-2-tricyclo[3.3.1.1-3,7]dec-1-yl-4,5-dihydro-1,3-oxazole-4-carboxamide	698451	94239	1 microg/ml, high inhibitory activity
UHGADA	3.5.1.108		(R,E)-2-(2-chlorostyryl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94237	1 microg/ml, moderate activity
UHGADA	3.5.1.108		(R,E)-N-hydroxy-2-(3-(trifluoromethyl)styryl)-4,5-dihydrooxazole-4-carboxamide	698451	94236	1 microg/ml, moderate activity
UHGADA	3.5.1.108		(R,E)-N-hydroxy-2-(4-nitrostyryl)-4,5-dihydrooxazole-4-carboxamide	698451	94235	1 microg/ml, moderate activity
UHGADA	3.5.1.108		(R,E)-N-hydroxy-2-styryl-4,5-dihydrooxazole-4-carboxamide	698451	94234	1 microg/ml, moderate activity
UHGADA	3.5.1.108		(R)-2-(2-bromophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94217	1 microg/ml, nearly complete loss of activity
UHGADA	3.5.1.108		(R)-2-(3-(dichloromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94224	1 microg/ml
UHGADA	3.5.1.108		(R)-2-(3-bromo-4-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94231	1 microg/ml, exellet biological activity
UHGADA	3.5.1.108		(R)-2-(3-chloro-4-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94229	1 microg/ml, exellet biological activity
UHGADA	3.5.1.108		(R)-2-(3-cyanophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94223	1 microg/ml
UHGADA	3.5.1.108		(R)-2-(3-fluoro-4-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94226	1 microg/ml, slight lower inhibitory activity than (R)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide
UHGADA	3.5.1.108		(R)-2-(3-fluoro-5-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94232	1 microg/ml, good activity
UHGADA	3.5.1.108		(R)-2-(3,4-dichlorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94230	1 microg/ml, exellet biological activity
UHGADA	3.5.1.108		(R)-2-(3,4-difluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94228	1 microg/ml, exellet biological activity
UHGADA	3.5.1.108		(R)-2-(3,4-dimethoxy-5-propylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	17656	1 microg/ml
UHGADA	3.5.1.108		(R)-2-(3,5-dichlorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94227	1 microg/ml, moderate activity
UHGADA	3.5.1.108		(R)-2-(3,5-difluoro-4-methoxyphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	51530	1 microg/ml, good activity
UHGADA	3.5.1.108		(R)-2-(3,5-difluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	51532	1 microg/ml, moderate activity
UHGADA	3.5.1.108		(R)-2-(3,5-dimethoxyphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94211	1 microg/ml, 67% inhibition
UHGADA	3.5.1.108		(R)-2-(4-(hexyloxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	51531	1 microg/ml, 86% inhibition
UHGADA	3.5.1.108		(R)-2-(4-(hydroxycarbamoyl)-4,5-dihydrooxazol-2-yl)benzyl benzoate	698451	94216	1 microg/ml, nearly complete loss of activity
UHGADA	3.5.1.108		(R)-2-(4-bromophenylsulfonamido)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxypropanamide	695628	51495	
UHGADA	3.5.1.108		(R)-2-(4-chloro-3-nitrophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94221	1 microg/ml
UHGADA	3.5.1.108		(R)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	26073	1 microg/ml, most potent compound
UHGADA	3.5.1.108		(R)-2-(4-fluoro-3-nitrophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94219	1 microg/ml
UHGADA	3.5.1.108		(R)-2-(4-tert-butylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94214	1 microg/ml, 58% inhibition
UHGADA	3.5.1.108		(R)-2-(biphenyl-4-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94213	1 microg/ml, 69% inhibition
UHGADA	3.5.1.108		(R)-2-decyl-N-hydroxy-4,5-dihydrooxazole-4-carboxamide	698451	94238	1 microg/ml, high inhibitory activity
UHGADA	3.5.1.108		(R)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxy-2-(naphthalene-2-sulfonamido)propanamide	695628, 696206, 696322, 700934	4281	
UHGADA	3.5.1.108		(R)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine	699421	51509	
UHGADA	3.5.1.108		(R)-N-hydroxy-2-(2-methylprop-1-enyl)-4,5-dihydrooxazole-4-carboxamide	698451	94233	1 microg/ml, moderate activity
UHGADA	3.5.1.108		(R)-N-hydroxy-2-(2,3,5-trifluoro-4-methoxyphenyl)-4,5-dihydrooxazole-4-carboxamide	698451	52749	1 microg/ml, good activity
UHGADA	3.5.1.108		(R)-N-hydroxy-2-(3-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	698451	94225	1 microg/ml, exellet inhibitory activity
UHGADA	3.5.1.108		(R)-N-hydroxy-2-(3-methoxyphenyl)-4,5-dihydrooxazole-4-carboxamide	698451	94210	1 microg/ml, 44% inhibition
UHGADA	3.5.1.108		(R)-N-hydroxy-2-(3,4,5-triethoxyphenyl)-4,5-dihydrooxazole-4-carboxamide	698451	94212	1 microg/ml, 72% inhibition
UHGADA	3.5.1.108		(R)-N-hydroxy-2-(4-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide	698451	9760	1 microg/ml
UHGADA	3.5.1.108		(R)-N-hydroxy-2-(4-methoxy-3-nitrophenyl)-4,5-dihydrooxazole-4-carboxamide	698451	94220	1 microg/ml
UHGADA	3.5.1.108		(R)-N-hydroxy-2-(4-methoxy-3,5-dimethylphenyl)-4,5-dihydrooxazole-4-carboxamide	698451	94215	1 microg/ml, 71% inhibition
UHGADA	3.5.1.108		(R)-N-hydroxy-2-(4-methoxyphenyl)-4,5-dihydrooxazole-4-carboxamide	698451	26024	1 microg/ml
UHGADA	3.5.1.108		(R)-N-hydroxy-2-(4-methyl-3-nitrophenyl)-4,5-dihydrooxazole-4-carboxamide	698451	94222	1 microg/ml
UHGADA	3.5.1.108		(R)-N-hydroxy-2-(4-nitrophenyl)-4,5-dihydrooxazole-4-carboxamide	698451	94218	1 microg/ml
UHGADA	3.5.1.108		(S)-3-(4-methoxyphenyl)-4,5-dihydro-isoxazole-5-carboxylic acid hydroxyamide	699421	51510	
UHGADA	3.5.1.108		(S)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine	696206	3986	phenyloxazoline hydroxamic acid, competitive inhibitor in Escherichia coli, not active as an antibiotic against Aquifex aeolicus, Pseudomonas aeruginosa and other clinically important pathogens
UHGADA	3.5.1.108		(S)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine	695628, 696322, 700934	3986	
UHGADA	3.5.1.108		[3-(4-methoxyphenyl)-4,5-dihydro-isoxazol-5-yl]phosphonic acid	699421	51514	
UHGADA	3.5.1.108		2-[[4-(diethylamino)-2-hydroxyphenyl]carbonyl]benzoic acid	719053	19209	compound shows good activity against Escherichia coli and Pseudomonas aeruginosa
UHGADA	3.5.1.108		2-mercapto-1-[3-(4-methoxyphenyl)-4,5-dihydro-isoxazol-5-yl]ethanone	699421	51512	racemate
UHGADA	3.5.1.108		2-thioacetyl-1-[3-(4-methoxyphenyl)-4,5-dihydro-isoxazol-5-yl]ethanone	699421	51511	racemate
UHGADA	3.5.1.108		2,3-dihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime	696322	51552	weak inhibitor
UHGADA	3.5.1.108		2,4-dihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime	696322	51551	
UHGADA	3.5.1.108		3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl(methyl)phosphinic acid	699421	51515	
UHGADA	3.5.1.108		3,4,5-trihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime	696322	51553	weak inhibitor, contains a 5 position hydroxyl and exhibits greatly reduced inhibitory potency
UHGADA	3.5.1.108		5'-O-[(E)-(2,3,4-trihydroxybenzylidene)amino]uridine	696322	18016	50 microM, 80% inhibition, pH-dependent, two-step, covalent inhibitor. 2,3,4-trihydroxybenzaldehyde O-((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime represents a new class of LpxC inhibitors that exploit the uridine binding site to form a covalent complex. While not antibiotic, it may provide a new scaffold for extension of existing LpxC-inhibiting antibiotics to target the UDP binding pocket
UHGADA	3.5.1.108		5'-O-[(E)-(3,4-dihydroxybenzylidene)amino]uridine	696322	51550	50 microM, 60% inhibition, inhibitor as potent as (E)-2,3,4-trihydroxybenzaldehyde O-((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime
UHGADA	3.5.1.108		Ciprofloxacin	696206	932	
UHGADA	3.5.1.108		dipicolinic acid	696193	1090	0.02 mM, complete inhibition
UHGADA	3.5.1.108		EDTA	695538	223	5 mM, complete loss of activity
UHGADA	3.5.1.108		EDTA	696193	223	t1/2: 4 min at 0.005 mM EDTA at 1 &deg;C
UHGADA	3.5.1.108		N-(((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)-2-((Z)-2,3,4-trihydroxybenzylideneaminooxy)acetamide	696322	51554	
UHGADA	3.5.1.108		N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide	696206	3987	N-aroyl-L-threonine hydroxamic acid, antibiotic activity comparable to ciprofloxacin, slow, tight-binding LpxC inhibitor
UHGADA	3.5.1.108		N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide	696322	3987	
UHGADA	3.5.1.108		N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide	700934	3987	as effectively as ciprofloxacin or tobramycin
UHGADA	3.5.1.108		N-[3-amino-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-(phenylethynyl)phenyl]piperazine-1-carboxamide	719053	60753	compound shows good activity against Escherichia coli and Pseudomonas aeruginosa
UHGADA	3.5.1.108		N-[3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(phenylethynyl)benzamide	719053	60750	compound shows good activity against Escherichia coli and Pseudomonas aeruginosa
UHGADA	3.5.1.108		N-[3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-(phenylethynyl)phenyl]piperidine-1-carboxamide	719053	60751	compound shows good activity against Escherichia coli and Pseudomonas aeruginosa
UHGADA	3.5.1.108		N-[3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-4-[4-(phenylethynyl)phenyl]piperazine-1-carboxamide	719053	60752	compound shows good activity against Escherichia coli and Pseudomonas aeruginosa
UHGADA	3.5.1.108		N-ethylmaleimide	696180	46	1 mM, complete inhibition
UHGADA	3.5.1.108		N'-formyl-3-(4-methoxyphenyl)-4,5-dihydroisoxazole-5-carbohydrazide	699421	51513	
UHGADA	3.5.1.108		tobramycin	696206	731	
UHGADA	3.5.1.108		Zn2+	695538	19	0.1 mM, about 65% loss of activity
UHGADA	3.5.1.108		Zn2+	696193	19	
UHGADA	3.5.1.108	Bovine serum albumin		695538		addition of bovine serum albumin slightly increases activity
MDH	3.5.1.16		[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]leucine	687815	16724	bestatin, competitive inhibitor
MDH	3.5.1.16		1,10-phenanthroline	171964	58	zinc-specific chelator
MDH	3.5.1.16		acetate	171964	44	product inhibition
MDH	3.5.1.16		Cu2+	171960	28	
MDH	3.5.1.16		EDTA	171960, 171964	223	
MDH	3.5.1.16		NaF	171964	209	linear uncompetitive inhibition
MDH	3.5.1.16		Ni2+	171960	36	
MDH	3.5.1.16		ornithine	171964	172	product inhibition
MDH	3.5.1.16		p-chloromercuribenzoate	171960	40	
MDH	3.5.1.16		Zn2+	171960	19	
MDH	3.5.1.16	glutathione		171960	41	
MDH	3.5.1.16	phosphate		171964	12	
DHORTS_reverse	3.5.2.3		(S)-1,2,3,6-tetrahydro-6-oxopyridine-2-carboxylic acid	667912	40253	competitive inhibitor versus dihydroorotate and thio-dihydroorotate
DHORTS_reverse	3.5.2.3		2-oxo-1,2,3,6-tetrahydropyrimidine-4,6-dicarboxylate	688362	7826	
DHORTS_reverse	3.5.2.3		4,6-dioxo-piperidine-2-(S)-carboxylic acid	667912	7825	most active competitive inhibitor versus dihydroorotate and thio-dihydroorotate
DHORTS_reverse	3.5.2.3		4(R)-hydroxy-6-oxo-piperidine-2(S)-carboxylic acid	667912	40252	competitive inhibitor versus dihydroorotate and thio-dihydroorotate
DHORTS_reverse	3.5.2.3		4(S)-hydroxy-6-oxo-piperidine-2(S)-carboxylic acid	667912	40251	competitive inhibitor versus dihydroorotate and thio-dihydroorotate
DHORTS_reverse	3.5.2.3		5-Fluoroorotate	684208, 688362	2276	
GTPCI	3.5.4.16		8-Azaguanine	670924	1540	43% inhibition at 2.9 mM
GTPCI	3.5.4.16		8-ethoxycarbonyl-7-deazaguanine	670924	84910	78% inhibition at 2.9 mM
GTPCI	3.5.4.16		8-methyl-7-deazaguanine	670924	84908	94% inhibition at 2.9 mM
GTPCI	3.5.4.16		8-trifluoromethyl-7-deazaguanine	670924	84909	17% inhibition at 2.9 mM
GTPCI	3.5.4.16		ADP	209546	8	competitive inhibitor
GTPCI	3.5.4.16		ascorbate	209553	88	
GTPCI	3.5.4.16		ATP	209546	7	competitive inhibitor
GTPCI	3.5.4.16		ATP	209541, 209549	7	
GTPCI	3.5.4.16		Cu2+	209545, 209546, 209553	28	
GTPCI	3.5.4.16		dGTP	209546	194	competitive inhibitor
GTPCI	3.5.4.16		dGTP	209549	194	
GTPCI	3.5.4.16		Fe2+	209553	23	
GTPCI	3.5.4.16		guanosine 5'-tetraphosphate	209546, 209549	1332	
GTPCI	3.5.4.16		Hg2+	209545, 209546, 209553	31	
GTPCI	3.5.4.16		L-erythro-5,6,7,8-tetrahydrobiopterin	209566	221	UTP reduces inhibition
GTPCI	3.5.4.16		Mn2+	209553	26	
GTPCI	3.5.4.16		PO43-	209546	684	uncompetitive inhibitor
GTPCI	3.5.4.16		PO43-	209545, 209549	684	
GTPCI	3.5.4.16		tetrahydrobiopterin	654607	221	feedback inhibition
GTPCI	3.5.4.16		TTP	209546	137	competitive inhibitor
GTPCI	3.5.4.16		UTP	209541	61	
GTPCI	3.5.4.16		UTP	209546	61	competitive inhibitor
GTPCII2	3.5.4.25		diphosphate	246729	13	0.1 mM
GTPCII2	3.5.4.25		diphosphate	209545, 246730	13	
GTPCII2	3.5.4.25		diphosphate	246732	13	competitive inhibitor
GTPCII2	3.5.4.25		diphosphate	656006	13	competitive
GTPCII2	3.5.4.25		phosphate	656006	12	partial uncompetitive at low concentration, competitive at concentrations above 6 mM
DHPPDA2	3.5.4.26	EDTA		246736	223	
ACODA	3.5.99.6		2-deoxy-2-amino-D-glucitol 6-phosphate	648221, 648239, 648244, 667624, 667638	3035	
ACODA	3.5.99.6		2,5-anhydro mannitol 6-phosphate	648239	33680	
ACODA	3.5.99.6		5,5'-dithiobis(2-nitrobenzoate)	648227	196	
ACODA	3.5.99.6		D-fructose 6-phosphate	648239	82	
ACODA	3.5.99.6		D-fructose oxime 6-phosphate	648239	33902	
ACODA	3.5.99.6		diethyl dicarbonate	648239	265	complete inactivation, 2-deoxy-2-amino-D-glucitol 6-phosphate protects
ACODA	3.5.99.6		Zn2+	648233	19	tightly bound and slow partial inhibitor
ACODA	3.5.99.6	N-acetylglucosamine 6-phosphate		648215	830	activates; increases reaction velocity when D-glucosamine 6-phosphate is present at levels below that required for saturation
ACODA	3.5.99.6	N-acetylglucosamine 6-phosphate		648220	830	activates
ACODA	3.5.99.6	N-acetylglucosamine 6-phosphate		648226, 648237, 648238, 648240, 648243	830	
ACODA	3.5.99.6	N-acetylglucosamine-6-phosphate		712289	830	allosteric activator of NagB
ASP1DC	4.1.1.11		2-(difluoromethyl)-L-aspartic acid	714741	112563	
ASP1DC	4.1.1.11		beta-hydroxy-DL-Asp	3947, 3948	30090	
ASP1DC	4.1.1.11		CuCl	3947, 3948	4403	10 mM, 88% inhibition
ASP1DC	4.1.1.11		D-Ser	3947, 3948	401	
ASP1DC	4.1.1.11		hydroxylamine	3947, 3948	80	
ASP1DC	4.1.1.11		KCl	3947, 3948	74	200 mM, 63% inhibition
ASP1DC	4.1.1.11		L-cysteic acid	3947, 3948	2703	
ASP1DC	4.1.1.11		L-Glu	3947, 3948	38	
ASP1DC	4.1.1.11		L-Ser	3947, 3948	89	
ASP1DC	4.1.1.11		NaBH4	3947, 3948	507	
ASP1DC	4.1.1.11		oxaloacetate	3947, 3948	53	
ASP1DC	4.1.1.11		phenylhydrazine	3947, 3948	333	
ASP1DC	4.1.1.11		succinate	3947, 3948	54	
ASP1DC	4.1.1.11	acetyl-CoA		726873	27	acetyl-CoA is required for activation
ASP1DC	4.1.1.11	PanZ		726873		analysis of the protein complex between Escherichia coli PanD and PanZ in vitro using isothermal titration calorimetry and mass spectrometry and thereby determine the stoichiometry and affinity of the components of this protein complex, high affinity 4:4 heterooctameric complex, overview. Non-covalent interaction between the acetyl group of acetyl-CoA and the PanD zymogen may be required to induce activation
ASP1DC	4.1.1.11	PanZ		728266		PanD is activated by the putative acetyltransferase YhhK, termed PanZ. Activation of PanD both in vivo and in vitro is PanZ-dependent. PanZ binds to PanD. Gene panZ is conserved only in Escherichia coli-related enterobacterial species including Shigella, Salmonella, Klebsiella and Yersinia
ASP1DC	4.1.1.11	Pyruvoyl group		3947, 3948	6287	1 mol of pyruvate is covalently bound per mol of enzyme
ASP1DC	4.1.1.11	Pyruvoyl group		3949	6287	catalytic pyruvoyl groups at three active sites and an ester at the fourth. The ester is an intermediate in the autocatalytic self-processing leading to formation of the pyruvoyl group
ASP1DC	4.1.1.11	Pyruvoyl group		3950	6287	contains 3 pyruvoyl groups per tetrameric enzyme
ASP1DC	4.1.1.11	Pyruvoyl group		714741	6287	
DAPDC	4.1.1.20		2,3-Diaminopropionic acid	4110	8502	
DAPDC	4.1.1.20		D-Lysine	4127	1155	not
DAPDC	4.1.1.20		glutamic acid	4110	38	
DAPDC	4.1.1.20		L-cystine	4110	923	
DAPDC	4.1.1.20		L-lysine	4110	128	
DAPDC	4.1.1.20		L-lysine	4127	128	reversed by diaminoheptanedioate addition
DAPDC	4.1.1.20		Penicillamine	4110	1829	no effect at 10fold pyridoxal phosphate concentration
DAPDC	4.1.1.20	2,3-Dimercaptopropan-1-ol		4110	1854	activates
DAPDC	4.1.1.20	D-Lysine		4127	1155	activates
OMPDC	4.1.1.23		1-(5'-phospho-beta-D-ribofuranosyl)barbituric acid	649973	8036	mode of binding
OMPDC	4.1.1.23		1-(5'-phospho-beta-D-ribofuranosyl)barbituric acid	652881	8036	
OMPDC	4.1.1.23		6-aminouridine 5'-monophosphate	694055	4276	
OMPDC	4.1.1.23		6-azauridine 5'-monophosphate	694055	2252	
OMPDC	4.1.1.23		6-cyanouridine 5'-monophosphate	694055	4275	
OMPDC	4.1.1.23		6-iodouridine 5'-monophosphate	694055	3081	
OMPDC	4.1.1.23		6-thiocarboxamidouridine 5'-monophosphate	694055	8037	
OMPDC	4.1.1.23		barbituric acid ribonucleoside 5'-monophosphate	694055	8036	
OMPDC	4.1.1.23		pyrazofurin 5'-monophosphate	694055	5345	
OMPDC	4.1.1.23		UMP	649973	127	weak inhibitor
OMPDC	4.1.1.23		xanthosine 5'-monophosphate	694055	772	
TPI	4.1.1.31		3-Mercaptopropionate	4311	2359	
TPI	4.1.1.31		Asp	4308, 4311, 657356	91	
TPI	4.1.1.31		citrate	4311	125	
TPI	4.1.1.31		Cys	4311	70	
TPI	4.1.1.31		fumarate	4311	156	
TPI	4.1.1.31		malate	4308, 4311	246	
TPI	4.1.1.31		Maleate	4311	474	
TPI	4.1.1.31		NEM	4286	46	
TPI	4.1.1.31		succinate	4311	54	
TPI	4.1.1.31		Tartrate	4311	614	
TPI	4.1.1.31	2-mercaptoethanol		4286	59	activates
TPI	4.1.1.31	fructose diphosphate		4286	100	activates
TPI	4.1.1.31	GTP		4286	35	activates
PPCDC	4.1.1.36		hydroxylamine	4415	80	
PPCDC	4.1.1.36		KCN	4415	149	
PPCDC	4.1.1.36		phenylhydrazine	4415	333	
PPCDC	4.1.1.36		pyridoxal	4415	501	
PPCDC	4.1.1.36		pyridoxal 5'-phosphate	4415	30	
IGPS	4.1.1.48		Reduced 1-[2-carboxyphenyl)amino]-1-deoxyribulose 5-phosphate	4611		
PSD160	4.1.1.65		4-Bromo-3-hydroxybenzyloxyamine	4769, 4775	20703	
PSD160	4.1.1.65		Bile salt detergents	4773	6266	inactivation by dissociating the oligomeric enzyme
PSD160	4.1.1.65		Cyanoborohydride	4769	13327	inactivation in presence of phosphatidylserine, no inactivation in absence of phosphatidylserine
PSD160	4.1.1.65		Cyanoborohydride	4775	13327	
PSD160	4.1.1.65		Hydrazines	4769	20408	phenylhydrazine
PSD160	4.1.1.65		Hydrazines	4786	20408	in presence of an amine
PSD160	4.1.1.65		hydroxylamine	4769, 4775	80	
PSD160	4.1.1.65		hydroxylamine	4786	80	in presence of an amine
PSD160	4.1.1.65		Ionic detergents	4764		e.g., Barlox-12, SDS
PSD160	4.1.1.65		N-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate	4773	7335	
PSD160	4.1.1.65		NaBH4	4786	507	in presence of an amine
PSD160	4.1.1.65		NaCNBH3	4786		in presence of an amine
PSD160	4.1.1.65		O-Benzylhydroxylamine	4769	4499	
PSD160	4.1.1.65		Zwitterionic detergents	4773		inactivation by dissociating the oligomeric enzyme
PSD160	4.1.1.65	Nonionic detergents		4764		e.g. Triton X-100, absolute requirement
PSD160	4.1.1.65	pyruvate		4780	29	dependent on
PSD160	4.1.1.65	pyruvate		4783	29	the small subunit contains a pyruvoyl prosthetic group
PSD160	4.1.1.65	pyruvate		4785	29	the pyruvoyl residue is covalently bound to the amino terminus of one of the two nonidentical subunits
PSD160	4.1.1.65	pyruvate		4790	29	dependent on; the pyruvate prosthetic group is in amide linkage to the amino terminus of the alpha-subunit. The prosthetic group is derived from Ser through a post-tranlational cleavage of a proenzyme
PSD160	4.1.1.65	Triton X-100		4767	57	
CHRPL	4.1.3.40		3-carboxymethylaminomethyl-4-hydroxybenzoate	650373	14679	
CHRPL	4.1.3.40		4-hydroxybenzaldehyde	650373	571	
CHRPL	4.1.3.40		4-hydroxybenzoate	650373	311	product inhibition
CHRPL	4.1.3.40		vanillate	650373, 663775	1395	
DHQTi	4.2.1.10		acetate	5473, 5474	44	
DHQTi	4.2.1.10		Cl-	5473, 5474	134	
DHQTi	4.2.1.10		Cu2+	5463	28	partial
DHQTi	4.2.1.10		D-(+)-tartrate	5473	3375	
DHQTi	4.2.1.10		diethyl dicarbonate	5483	265	
DHQTi	4.2.1.10		Fe2+	5463	23	partial
DHQTi	4.2.1.10		hydroxylamine	5463	80	partial
DHQTi	4.2.1.10		iodoacetamide	5463	63	partial
DHQTi	4.2.1.10		NaBH4	5473	507	irreversible inactivation in presence of 3-dehydroquinate
DHQTi	4.2.1.10		succinate	5473, 5474	54	
DHQTi	4.2.1.10		Zn2+	5463	19	partial
ENO	4.2.1.11		F-	33600, 33605	158	
PPBNGS	4.2.1.24		1,10-phenanthroline	210734	58	
PPBNGS	4.2.1.24		4-oxosebaic acid	652256	49509	active site-directed irreversible inhibitor, less potent than 4,7-dioxosebaic acid
PPBNGS	4.2.1.24		4,7-dioxosebaic acid	652256	77308	
PPBNGS	4.2.1.24		5-chlorolevulinic acid	649816	30770	inactivation results fromthe initial formation of a Schiff base with lysine-247, followed by alkylation of lysine-195 by the resulting reactive chloroimide
PPBNGS	4.2.1.24		D-glucose	691351	33	
PPBNGS	4.2.1.24		D-xylose	691351	109	
PPBNGS	4.2.1.24		levulinic acid	210721	5555	
PPBNGS	4.2.1.24		methyl methanethiosulfonate	210734	1724	
PPNDH	4.2.1.51		3-phenylpropanoate	33886	2450	
PPNDH	4.2.1.51		5,5'-dithiobis(2-nitrobenzoate)	3574	196	
PPNDH	4.2.1.51		alpha-oxo-1-carboxy-4-tetrahydrothiopyranpropanoic acid S-oxide	33891	67058	
PPNDH	4.2.1.51		alpha-oxo-1-carboxy-5,6-dihydrothiopyranpropanoic acid S-oxide	33891	67059	
PPNDH	4.2.1.51		cis-aconitate	33877	933	
PPNDH	4.2.1.51		citrate	33877	125	
PPNDH	4.2.1.51		KCl	3543	74	
PPNDH	4.2.1.51		L-phenylalanine	33886, 3543	98	
PPNDH	4.2.1.51		L-phenylalanine	3574	98	one phenylalanine-binding site per subunit
PPNDH	4.2.1.51		L-phenylalanine	649980	98	feedback inhibition
PPNDH	4.2.1.51		L-phenylalanine	702720	98	feedback inhibition. PDT of Escherichia coli WSH-Z06 is almost completely inhibited by 10 mM L-phenylalanine (92.9% activity loss). PDT of Escherichia coli WSH-Z06 (pAP-B03) exhibits strong resistance to 200 mM L-phenylalanine, manifested by the high residual activities (10 mM L-phenylalanine with only 7.1% loss of activity)
PPNDH	4.2.1.51		m-Chlorophenylalanine	33886	22987	
PPNDH	4.2.1.51		m-Fluorophenylalanine	33886	13431	
PPNDH	4.2.1.51		m-hydroxyphenylalanine	33886	7315	
PPNDH	4.2.1.51		N-carbobenzoxyphenylalanine	33886		
PPNDH	4.2.1.51		N-ethylmaleimide	3574	46	
PPNDH	4.2.1.51		NaCl	3543	39	
PPNDH	4.2.1.51		o-Chlorophenylalanine	33886	22986	
PPNDH	4.2.1.51		o-Fluorophenylalanine	33886	20523	
PPNDH	4.2.1.51		o-Hydroxyphenylalanine	33886	30247	
PPNDH	4.2.1.51		p-Chlorophenylalanine	33886	6086	
PPNDH	4.2.1.51		p-Fluorophenylalanine	33886	7229	
PPNDH	4.2.1.51		tetrathionate	3574	1641	
PPNDH	4.2.1.51		trans-aconitate	33877	2067	
PPNDH	4.2.1.51	Bovine serum albumin		33886		activation
UPP3S	4.2.1.75		5,5'-dithiobis(2-nitrobenzoate)	5888	196	
UPP3S	4.2.1.75		diethyl dicarbonate	5888	265	
UPP3S	4.2.1.75		iodoacetamide	5888	63	
UPP3S	4.2.1.75		iodoacetic acid	5888	87	
UPP3S	4.2.1.75		N-ethylmaleimide	5888	46	
UPP3S	4.2.1.75		p-chloromercuribenzoate	5888	40	
DHAD2	4.2.1.9		3-(5-nitrofuran-2-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole hydrochloride	33978	67002	
DHAD2	4.2.1.9		4,7-dicyanobenzofurazan	33979	66053	bacteriostatic effect due to inactivation of 2,3-dihydroxyisovalerate dehydratase
DHAD2	4.2.1.9		benzoquinone	33978	270	
DHAD2	4.2.1.9		Cu2+	33959	28	CuSO4
DHAD2	4.2.1.9		duroquinone	33978	946	
DHAD2	4.2.1.9		EDTA	33959	223	
DHAD2	4.2.1.9		hydralazine	33978	2042	
DHAD2	4.2.1.9		juglone	33978	1018	
DHAD2	4.2.1.9		NaF	33959	209	
DHAD2	4.2.1.9		nitric oxide	682577	240	nitric oxide halts bacterial growth via inhibition of the branched-chain amino acid biosynthesis enzyme dihydroxyacid dehydratase
DHAD2	4.2.1.9		Nitrofurantoin	33978	1827	
DHAD2	4.2.1.9		NO	700277	240	IlvD is completely inactivated in cells by NO with the concomitant formation of the IlvD-bound dinitrosyl iron complex, DNIC. While the IlvD-bound DNIC and other protein-bound DNICs are stable in cells under anaerobic growth conditions, they are efficiently repaired under aerobic growth conditions even without new protein synthesis, L-cysteine plays an important role, overview
DHAD2	4.2.1.9		paraquat	33978	302	
DHAD2	4.2.1.9		PCMB	33959	40	
DHAD2	4.2.1.9		Plumbagin	33978	1882	
MTHFD	4.2.3.4		[(1R)-(1alpha,3beta,4alpha ,5beta)]-5-(2-phosphonoethyl)-1,3,4-trihydroxycyclohexane-1-carboxylic acid	718819		
MTHFD	4.2.3.4		[(1R)-(1alpha,3beta,4alpha,5beta)]-1,4,5-trihydroxy-3-(phosphonooxy)-cyclohexane-1-carboxylate	718819		
MTHFD	4.2.3.4		[(1R)-(1alpha,3beta,4alpha,5beta)]-5-(E)-(2-phosphonoethenyl)-1,3,4-trihydroxycyclohexane-1-carboxylic acid	718819		
MTHFD	4.2.3.4		[(1R)-(1alpha,3beta,4alpha,5beta)]-5-(phosphonomethyl)-l,3,4-trihydroxycyclohexane-1-carboxylic acid	718819		slow binding inhibitor
MTHFD	4.2.3.4		[(1R)-(1alpha,3beta,4alpha,5beta)]-5-(Z)-(2-phosphonoethenyl)-1,3,4-trihydroxycyclohexane-1-carboxylic acid	718819		
MTHFD	4.2.3.4		[(2R)-(2alpha,4beta,5alpha,6beta)]-6-(2-phosphonoethyl)-2,4,5-trihydroxytetrahydropyran-2-carboxylate	718819		
MTHFD	4.2.3.4		[(2R)-(2alpha,4beta,5alpha,6beta)]-6-(phosphonomethyl)-2,4,5-trihydroxytetrahydropyran-2-carboxylate	718819		
MTHFD	4.2.3.4		3-deoxy-D-arabino-heoptulosonic acid	137635	63315	
MTHFD	4.2.3.4		3-deoxy-D-arabino-heptulosonic acid 7-homophosphate	137633		
MTHFD	4.2.3.4		3-deoxy-D-arabino-heptulosonic acid 7-phosphonate	137619	3060	
MTHFD	4.2.3.4		3-deoxy-D-arabino-heptulosonic acid-2-O-methylglycoside 7-phosphate	137635		
MTHFD	4.2.3.4		alpha-(2,6-anhydro-3-deoxy-D-arabino-heptulopyranosid)onate 7-phosphate	137619	30590	
MTHFD	4.2.3.4		alpha-(2,6-anhydro-3-deoxy-D-arabino-heptulopyranosid)onate 7-phosphonate	137619	67049	
MTHFD	4.2.3.4		beta-(2,6-anhydro-3-deoxy-D-arabino-heptulopyranosid)onate 7-phosphate	137619	67070	
MTHFD	4.2.3.4		D-2-cis-hydroquinic acid	137635	67102	
MTHFD	4.2.3.4		D-gluco-3-heptulosonate 7-phosphate	137633	67109	
MTHFD	4.2.3.4		D-gluco-heptulosonate 7-homophosphonate	137633	67110	
MTHFD	4.2.3.4		D-gluco-heptulosonate 7-phosphonate	137633	67111	
MTHFD	4.2.3.4		EDTA	718818	223	treatment of the Co2+-holoenzyme with EDTA in the absence of substrate results in the rapid loss of catalytic activity
MTHFD	4.2.3.4		EGTA	137623	157	
MTHFD	4.2.3.4		epoxyshikimic acid	137635	64477	
ORPT_reverse	4.2.3.5		(6R)-6-fluoro-5-enoylpyruvylshikimate 3-phosphate	652056	35540	IC50 is 0.0005 mM when the enzyme is preincubated with the inhibitor, the IC50 is 0.25 mM when the enzyme is not preincubated with the inhibitor, inhibition is not absolutely irreversible
ORPT_reverse	4.2.3.5		bathophenanthroline	137655	1972	
ORPT_reverse	4.2.3.5		Fe2+	137655	23	
DHDPS	4.3.3.7		(1SR,3R,5S)-1-hydroxy-3,5-bis(methoxycarbonyl)thiomorpholin-1-ium	664304	83388	30 mM, 18% inhibition
DHDPS	4.3.3.7		(1SS,3R,5S)-1-hydroxy-3,5-bis(methoxycarbonyl)thiomorpholin-1-ium	664304	83387	9 mM, 48% inhibition
DHDPS	4.3.3.7		(2E,5E)-4-oxohepta-2,5-dienedioic acid	691243	47680	
DHDPS	4.3.3.7		(2E)-4-oxohept-2-enedioic acid	691243	47679	
DHDPS	4.3.3.7		(2R,6S)-piperidine-2,6-dicarboxylic acid	664304	9183	IC50: 20 mM, 83% inhibition at 50 mM
DHDPS	4.3.3.7		(2R,6S)-piperidine-2,6-dicarboxylic acid	678711	9183	20 mM, 49% inhibition
DHDPS	4.3.3.7		(3R,5R)-thiomorpholine-3,5-dicarboxylic acid	664304	83386	50 mM, 32% inhibition
DHDPS	4.3.3.7		(3R,5R)-thiomorpholine-3,5-dicarboxylic acid 1,1-dioxide	664304	83390	50 mM, 11% inhibition
DHDPS	4.3.3.7		(3R,5S)-thiomorpholine-3,5-dicarboxylic acid 1,1-dioxide	664304	83389	50 mM, 14% inhibition
DHDPS	4.3.3.7		(S)-Lys	663499	128	partial mixed inhibition with respect to pyruvate and partial non-competitive inhibition with resoect to L-aspartate 4-semialdehyde
DHDPS	4.3.3.7		(S)-lysine	664072	128	mutant enzymes R138H and R138A show the same IC50 values as the wild-type enzyme, but different partial inhibition patterns
DHDPS	4.3.3.7		(S)-lysine	664244	128	partial mixed inhibition with respect to its first substrate, pyruvate
DHDPS	4.3.3.7		(S)-lysine	690914	128	partial mixed inhibition with respect to (S)-aspartate 4-semialdehyde, partial non-ncompetitive inhibition with respect to pyruvate in wild-type and in Y107W mutant, Y107W mutant still retains over 25% of uninhibited activity, even at high inhibitor concentrations compared to the wild-type enzyme retaining less than 10% of normal activity
DHDPS	4.3.3.7		(S)-lysine	695011	128	allosteric inhibitor
DHDPS	4.3.3.7		(S)-lysine	729062	128	feedback inhibition, feedback inhibition of the Escherichia coli enzyme by lysine is successfully alleviated after substitution of the residues around the inhibitor's binding sites with those of the Corynabacterium glutamicum enzyme
DHDPS	4.3.3.7		2-fluoropyruvate	33920		
DHDPS	4.3.3.7		2-oxobutyrate	712704	313	competitive inhibitor of DHDPS
DHDPS	4.3.3.7		2-oxoglutarate	712704	32	competitive inhibitor of DHDPS
DHDPS	4.3.3.7		2-oxopimelic acid	718827	21889	
DHDPS	4.3.3.7		2,2'-(2-hydroxy-1,3-phenylene)bis(2-oxoacetic acid)	729385		slow-tight inhibition
DHDPS	4.3.3.7		2,2'-benzene-1,3-diylbis(oxoacetic acid)	691294	47891	
DHDPS	4.3.3.7		2,2'-benzene-1,3-diylbis(oxoacetic acid)	729385	47891	slow inhibition
DHDPS	4.3.3.7		3-Bromopyruvate	33912	1425	
DHDPS	4.3.3.7		3-Fluoropyruvate	712704	2448	competitive inhibitor of DHDPS, and a competitive substrates
DHDPS	4.3.3.7		3-hydroxy-2-oxopropanoate	695011	326	time-dependent inhibition, qualitatively followed by mass spectrometry, initial noncovalent adduct formation, followed by the slow formation of the covalent adduct
DHDPS	4.3.3.7		3-hydroxypyruvate	712704	326	competitive inhibitor of DHDPS and a competitive substrate
DHDPS	4.3.3.7		4-oxo-1,4-dihydropyridine-2,6-dicarboxylic acid	664304	7800	i.e. chelidamic acid, IC50: 22 mM, 99% inhibition at 50 mM, uncompetitive inhibitor with respect to both substrates
DHDPS	4.3.3.7		4-oxo-1,4-dihydropyridine-2,6-dicarboxylic acid	678711	7800	
DHDPS	4.3.3.7		Bromopyruvate	712704	1425	is an irreversible inhibitor of DHDPS
DHDPS	4.3.3.7		cis-(1SS,3R5S)-3,5-thiomorpholinedicarboxylic acid, dimethyl ester, 1-oxide	678711	24804	20 mM, 8% inhibition
DHDPS	4.3.3.7		cis-piperidine-2,6-dicarboxylic acid	33918	9183	and derivatives
DHDPS	4.3.3.7		diethyl (2E,5E)-4-oxohepta-2,5-dienedioate	691243	48096	
DHDPS	4.3.3.7		diethyl (2E)-4-oxohept-2-enedioate	691243	48095	
DHDPS	4.3.3.7		dimethyl (2R,6S)-piperidine-2,6-dicarboxylate	678711	16210	20 mM, 92% inhibition
DHDPS	4.3.3.7		dimethyl (3R,5R)-thiomorpholine-3,5-dicarboxylate	678711	42213	20 mM, 12% inhibition
DHDPS	4.3.3.7		dimethyl (3R,5R)-thiomorpholine-3,5-dicarboxylate 1,1-dioxide	664304	15572	50 mM, 12% inhibition
DHDPS	4.3.3.7		dimethyl (3R,5R)-thiomorpholine-3,5-dicarboxylate 1,1-dioxide	678711	15572	20 mM, 14% inhibition
DHDPS	4.3.3.7		dimethyl (3R,5S)-thiomorpholine-3,5-dicarboxylate	664304	23659	50 mM, 36% inhibition
DHDPS	4.3.3.7		dimethyl (3R,5S)-thiomorpholine-3,5-dicarboxylate	678711	23659	20 mM, 35% inhibition
DHDPS	4.3.3.7		dimethyl 2,2'-benzene-1,3-diylbis[(hydroxyimino)ethanoate]	691294	48097	
DHDPS	4.3.3.7		dimethyl 4-oxo-1,4-dihydropyridine-2,6-dicarboxylate	678711	15571	
DHDPS	4.3.3.7		dimethyl chelidamate	664304	15571	IC50: 14 mM. 99% inhibition at 50 mM, noncompetitive with respect to both substrates
DHDPS	4.3.3.7		dimethyl piperidine-2,6-dicarboxylate	664304	83385	
DHDPS	4.3.3.7		dimethyl pyridine-2,6-dicarboxylate	678711	42212	20 mM, 5% inhibition
DHDPS	4.3.3.7		dimethyl-(2E,2'E)-2,2'-benzene-1,3-diylbis[(hydroxyimino)ethanoate]	729385		slow inhibition
DHDPS	4.3.3.7		dimethyl-2,2'-(2-hydroxy-1,3-phenylene)bis(2-oxoacetate)	729385		slow-tight inhibition
DHDPS	4.3.3.7		dipicolinic acid	33912	1090	1.2 mM, 50% inhibition
DHDPS	4.3.3.7		dipicolinic acid	33918	1090	1 mM, 50% inhibition
DHDPS	4.3.3.7		dipicolinic acid	664304	1090	IC50: 20 mM, competitive inhibitor
DHDPS	4.3.3.7		dipicolinic acid	33920, 718827	1090	
DHDPS	4.3.3.7		dipicolinic acid di-imidate	33918	67121	
DHDPS	4.3.3.7		dipicolinic acid N-oxide	33918	30162	0.8 mM 50% inhibition
DHDPS	4.3.3.7		L-aspartate 4-semialdehyde	702484	472	competitive inhibition at high substrate concentrations
DHDPS	4.3.3.7		L-lysine	33907	128	Ki: 0.21 mM
DHDPS	4.3.3.7		L-lysine	33912	128	1 mM, 50% inhibition
DHDPS	4.3.3.7		L-lysine	33920, 701934, 702036, 702445	128	
DHDPS	4.3.3.7		L-lysine	702448	128	at 1 mM 23% residual activity, at 100 mM 13% residual activity
DHDPS	4.3.3.7		L-lysine	702479	128	no difference in its sensitivity or behaviour with respect to L-lysine when compared to the wild-type
DHDPS	4.3.3.7		L-lysine	702484	128	binding interaction of L-lysine is characterised as a cooperative event in which an entropic pre-organisation step precedes a secondary enthalpic association. This allosteric association is of a mixed competitive nature in which heterotropic ligand cooperativity is observed to subtly influence the binding events
DHDPS	4.3.3.7		L-lysine	713953	128	inhibition of the tetrameric wild-type enzyme, but not of the disrupted minimeric mutant enzyme. Allosteric binding by two molecules of (S)-lysine at the DHDPS tight-dimer interface cleft has been observed to operate via a cooperative mechanism and to result in incomplete partial mixed inhibition, inhibition kinetics, overview
DHDPS	4.3.3.7		L-lysine	718827	128	natural feedback inhibitor
DHDPS	4.3.3.7		L-threonine	702448	220	at 100 mM 23% residual activity, at 100 mM 33% residual activity
DHDPS	4.3.3.7		lysine	702489	128	inhibition of wild-type DHDPS by lysine with respect to pyruvate is partial and uncompetitive, and partial non-competitive with respect to L-aspartate 4-semialdehyde. Ethanolamine, n-butylamine, 1-amino-2-propanol, 3-amino-1-propanol, iso-butylamine and Tris-HCl cannot rescue activity
DHDPS	4.3.3.7		NaBH4	702484	507	NaBH4 reduction of the pyruvyl-Schiff-base intermediate results in enzyme inactivation
DHDPS	4.3.3.7		pyridine-2,6-dicarboxylic acid	678711	1090	
DHDPS	4.3.3.7		S-(2-aminoethyl)-L-cysteine	33912	1512	4.6 mM, 50% inhibition
DHDPS	4.3.3.7		Sodium borohydride	702489	507	wild-type DHDPS is inactivated when incubated with pyruvate, whereas incubation with L-aspartate 4-semialdehyde has no effect
DHDPS	4.3.3.7		Succinate-semialdehyde	718827	440	reversible inhibitor which is competitive with respect to L-aspartate-4-semialdehyde and uncompetitive with respect to pyruvate
DHDPS	4.3.3.7		Succinic semialdehyde	33920	440	
DHDPS	4.3.3.7		trans-(1SS,3R5S)-3,5-thiomorpholinedicarboxylic acid, dimethyl ester, 1-oxide	678711	16211	20 mM, 20% inhibition
DHDPS	4.3.3.7	L-methionine		702448	83	at 10 mM 112% activity, at 100 mM 111% activity
DHDPS	4.3.3.7	meso-diaminopimelate		702448	1057	at 1 mM 108% activity, at 10 mM 122% activity
RHCCE	4.4.1.21		(2S)-2-amino-4-[(2R,3R)-2,3-dihydroxy-3-N-hydroxycarbamoylpropylmercapto] butyric acid	681282	6760	
RHCCE	4.4.1.21		(2S)-2-amino-4-[(2R,3S)-2,3-dihydroxy-3-N-hydroxycarbamoylpropylmercapto] butyric acid	681282	6759	
RHCCE	4.4.1.21		D-erythronohydroxamic acid	681282	6761	
RHCCE	4.4.1.21		S-[3-bromo-3,5-dideoxy-D-ribofuranos-5-yl]-L-homocysteine	692775	9634	
RHCCE	4.4.1.21		S-[3-fluoro-3,5-dideoxy-D-ribofuranos-5-yl]-L-homocysteine	692775	17374	
MECDPS	4.6.1.12		(-)-(R)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6923	
MECDPS	4.6.1.12		(+)-(S)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6922	
MECDPS	4.6.1.12		(+/-)-(2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-5,7-dimethyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylic acid	708124	5969	
MECDPS	4.6.1.12		(+/-)-(2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylic acid	708124	5965	
MECDPS	4.6.1.12		(+/-)-benzyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5964	
MECDPS	4.6.1.12		(+/-)-ethyl (2Z)-2-(3-bromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5962	
MECDPS	4.6.1.12		(+/-)-ethyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-5-(4-methoxyphenyl)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5968	
MECDPS	4.6.1.12		(+/-)-ethyl (2Z)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5961	
MECDPS	4.6.1.12		(+/-)-ethyl (2Z)-2-(3,5-difluoro-4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	6921	
MECDPS	4.6.1.12		(+/-)-ethyl (2Z)-2-(4-hydroxybenzylidene)-7-methyl-3-oxo-5-(2-thienyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5963	
MECDPS	4.6.1.12		(+/-)-ethyl (2Z)-2-[4-(acetyloxy)-3,5-dibromobenzylidene]-5-(1-benzofuran-2-yl)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo-[3,2-a]pyrimidine-6-carboxylate	708124	6924	
MECDPS	4.6.1.12		(+/-)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dibromo-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5966	
MECDPS	4.6.1.12		(+/-)-ethyl (2Z)-5-(1-benzofuran-2-yl)-2-(3,5-dichloro-4-hydroxybenzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate	708124	5967	
MECDPS	4.6.1.12		2-amino-N-hydroxy-3-(1-H-indol-3-yl)-propionimidic acid	709435	16199	highest affinity of all the ligands examined, due to Zn2+-hydroxamate coordination, KD value of 0.0019 mM
MECDPS	4.6.1.12		4-amino-1-(3-O-phosphono-a-D-lyxofuranosyl)pyrimidin-2(1H)-one	709435	99382	
MECDPS	4.6.1.12		4-amino-1-[(2S,3aS,4S,6R,6aR)-2-hydroxy-6-(hydroxymethyl)-2-oxidotetrahydrofuro[3,4-d][1,3,2]dioxaphosphol-4-yl]pyrimidin-2(1H)-one	709435	99381	KD value of 20.5 mM
MECDPS	4.6.1.12		4-amino-1-[(4aR,6R,7R,7aS)-2,7-dihydroxy-2-oxidotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]pyrimidin-2(1H)-one	709435	7305	KD value of 0.925 mM
MECDPS	4.6.1.12		5-fluorocytidine	709435	8302	KD value of 2.02 mM
MECDPS	4.6.1.12		Cidofovir	709435	24404	KD value of ca. 40 mM
MECDPS	4.6.1.12		Cytosine arabinoside monophosphate	709435	3219	KD value of 18.91 mM
MECDPS	4.6.1.12		N-([4-[(4-amino-2-oxopyrimidin-1(2H)-yl)methyl]-1-naphthyl]methyl)-4-chlorobenzamide	680059	42231	1 mM, 52% inhibition
MECDPS	4.6.1.12		N-([4-[(4-amino-2-oxopyrimidin-1(2H)-yl)methyl]-1-naphthyl]methyl)benzamide	680059	42230	1 mM, 59% inhibition
MECDPS	4.6.1.12		N-[4-[(6-aminopyridin-3-yl)amino]-3-methylbenzyl]-4-(trifluoromethyl)benzamide	680059	42229	1 mM, 60% inhibition
GLUR_reverse	5.1.1.3	UDP-MurNAc-Ala		676152	86554	strong activation by UDP-MurNAc-Ala, the product of the preceding enzyme in the peptidoglycan biosynthetic pathway
GLUR_reverse	5.1.1.3	UDP-N-acetylmuramyl-L-Ala		2102, 2113	3004	absolutely required
GLUR_reverse	5.1.1.3	UDP-N-acetylmuramyl-L-Ala		2111, 2115	3004	activator
DAPE	5.1.1.7		2-(4-amino-4-carboxybutyl)aziridine-2-carboxylic acid	2146, 2155	28688	irreversible
DAPE	5.1.1.7		3-Chlorodiaminopimelate	2144	63304	the inhibitor is converted to a tight-binding transition state analog at the active site of this enzyme
DAPE	5.1.1.7		3-Fluoro analogs of diaminopimelate	2148		potent competitive inhibitors
DAPE	5.1.1.7		4-Oxo-1,2,3,4-tetrahydro-pyridine-2,6-dicarboxylic acid	653403	76424	very poor inhibitor
DAPE	5.1.1.7		dilithium (2Z,6S)-2,6-diamino-4-oxohept-2-enedioate	653403	34285	competitive, IC50: 0.5 mM
DAPE	5.1.1.7		hydroxylamine	2054	80	no inhibition
DAPE	5.1.1.7		hydroxylamine	2140	80	; no inhibition
DAPE	5.1.1.7		iodoacetamide	2140	63	half-life for inactivation with 0.25 mM iodoacetamide is 9.6 min
DAPE	5.1.1.7		iodoacetamide	2155	63	
DAPE	5.1.1.7		Isoniazid	2054	674	
DAPE	5.1.1.7		Lanthionine isomers	2145		
DAPE	5.1.1.7		Lanthionine sulfone	2145	64767	
DAPE	5.1.1.7		Lanthionine sulfoxide	2145	64768	
DAPE	5.1.1.7		Mercurials	2054		
DAPE	5.1.1.7		N-Aminodiaminopimelate	2145	67196	
DAPE	5.1.1.7		N-Hydroxydiaminopimelate	2145	21349	
DAPE	5.1.1.7		Phosphonate analogs of diaminopimelate	2150		
DAPE	5.1.1.7		Semicarbazide	2054	322	
DAPE	5.1.1.7	thiol compound		2155	752	required for activity
PGL	5.3.1.1		2-Phosphoglycolate	2586	997	
PGL	5.3.1.1		2-Phosphoglycolate	2586	997	
PGL	5.3.1.1		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
PGL	5.3.1.1		bromohydroxyacetone phosphate	714686	66011	suicide inhibitor
PGL	5.3.1.1		cyclo(Gly-Pro-Phe-Val-Phe-PSI[CS-NH]Phe)	2576	13626	no inhibition
PGL	5.3.1.1		cyclo(Gly-Pro-Phe-Val-Phe-PSI[CS-NH]Phe)	2576	13626	no inhibition
PGL	5.3.1.1		cyclo[Trp-Phe-D-Pro-Phe-Phe-Lys(benzyloxycarbonyl)-]	2582	13627	no inhibition
PGL	5.3.1.1		cyclo[Trp-Phe-D-Pro-Phe-Phe-Lys(benzyloxycarbonyl)-]	2582	13627	no inhibition
PGL	5.3.1.1		DL-glycidol phosphate	714686	109182	suicide inhibitor
PGL	5.3.1.1		DL-glycidol phosphate	714686	109182	suicide inhibitor
PGL	5.3.1.1		S-Phenyl-p-toluenethiosulfonate	2584	10773	no inhibition
PGL	5.3.1.1		S-Phenyl-p-toluenethiosulfonate	2584	10773	no inhibition
PRAIi	5.3.1.24		1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate	4611	747	product inhibition
PRAIi	5.3.1.24		Reduced 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate	4611, 648873		competitive inhibitor
PRAIi	5.3.1.24		Reduced 1-(2-carboxyphenylamino)-1-deoxy-D-ribulose 5-phosphate	648872, 648876		
G6PDA	5.3.1.6		5-phospho-D-ribonamide	703070	8142	
G6PDA	5.3.1.6		5-phospho-D-ribonate	703070	4616	competitive inhibitor of a Rpi, displays specific inhibition of Mycobacterium tuberculosis RpiB versus Escherichia coli RpiB, inhibition kinetics, overview
G6PDA	5.3.1.6		5-phospho-D-ribonohydroxamic acid	703070	5838	
G6PDA	5.3.1.6		6-phosphogluconate	2787	327	
G6PDA	5.3.1.6		AMP	2787	9	
G6PDA	5.3.1.6		arabinose 5-phosphate	653911	447	
G6PDA	5.3.1.6		fructose 6-phosphate	2787	82	
G6PDA	5.3.1.6		iodoacetate	2779	87	1.25 mM, 100% loss of ribosephosphate isomerase B, no effect on ribosephosphate isomerase A
G6PDA	5.3.1.6		N-(5-phospho-D-ribonoyl)-gamma-aminobutanoate	703070	12799	
G6PDA	5.3.1.6		N-(5-phospho-D-ribonoyl)-glycine	703070	12798	poor inhibition with substrate D-ribose 5-phosphate, no inhibition with substrate D-allose 5-phosphate
G6PDA	5.3.1.6		N-(5-phospho-D-ribonoyl)-hydrazine	703070	18365	
G6PDA	5.3.1.6		N-(5-phospho-D-ribonoyl)-methylamine	703070	8143	
G6PDA	5.3.1.6		phosphate	653911	12	
PGI	5.3.1.9		6-phosphogluconate	2624, 2841	327	
PGI	5.3.1.9		6-phosphogluconate	2624, 2841	327	
PGAMT_reverse	5.4.2.10		Ca2+	210870	18	80% reduced activity
PGAMT_reverse	5.4.2.10		EDTA	210870	223	abolishes autophosphorylation and catalytic activity
PGAMT_reverse	5.4.2.10		Mn2+	210870	26	80% reduced activity
PGAMT_reverse	5.4.2.10		Zn2+	210870	19	efficient autophosphorylation, but absence of catalytic activity
PGAMT_reverse	5.4.2.10	D-glucosamine 1,6-diphosphate		210870, 210871	14064	retains the enzyme in an active and phosphorylated form
PGAMT_reverse	5.4.2.10	D-glucose 1,6-diphosphate		210871	1231	retains the enzyme in an active and phosphorylated form
PGAMT_reverse	5.4.2.10	D-glucose 1,6-diphosphate		210874	1231	20fold activation at 0.7 mM
GLUTRS	6.1.1.17		1,10-phenanthroline	210	58	ATP protects the enzyme against zinc removal
GLUTRS	6.1.1.17		5'-O-(N-(L-glutamyl)-sulfamoyl)adenosine	659591	15237	potent competitive with respect to glutamic acid
GLUTRS	6.1.1.17		5'-O-(N'-(L-pyroglutamyl)-sulfamoyl)adenosine	659591	37224	weak
GLUTRS	6.1.1.17		Glu-AMS	672564	15237	
GLUTRS	6.1.1.17		glutaminyl-beta-ketophosphonate-adenosine	672564	16129	i.e. Gln-KPA, competitive inhibition, non-cognate, binds at one site on the monomeric enzyme
GLUTRS	6.1.1.17		glutamyl adenylate	650511	35644	
GLUTRS	6.1.1.17		glutamyl cytidylate	650511	35647	weak inhibition
GLUTRS	6.1.1.17		glutamyl dihydrocytidylate	650511	35648	very weak inhibition
GLUTRS	6.1.1.17		glutamyl N6-benzoyladenylate	650511	35645	
GLUTRS	6.1.1.17		glutamyl uridylate	650511	35646	very weak inhibition
GLUTRS	6.1.1.17		glutamyl-beta-ketophosphonate-adenosine	672564	16128	i.e. Glu-KPA, selective, competitive inhibition of GluRS, binds at one site on the monomeric enzyme
GLUTRS	6.1.1.17		N6-Benzoyl-L-glutamyl AMP	201	65141	specific for glutamyl-tRNA synthetase, does not inhibit glutaminyl-tRNA synthetase
GLUTRS	6.1.1.17		p-hydroxymercuribenzoate	216	92	
GLUTRS	6.1.1.17	Bovine serum albumin		215		optimal activity at 0.25 mg/ml
NADS1	6.3.1.5		adenosine	953	116	
NADS1	6.3.1.5		Decoyinine	951, 953	6147	
NADS1	6.3.1.5		Mg2+	653053	25	slightly inhibiting above 5 mM
NADS1	6.3.1.5		Mn2+	953	26	can satisfy the metal ion requirement at low concentrations, at high concentrations Mn2+ markedly inhibits
NADS1	6.3.1.5		Psicofuranine	951, 953	13502	i.e. 9-D-psicofuranosyl-6-aminopurine, each substrate provides some protection
PANTS	6.3.2.1		(2RS)-5'-O-(2-hydroxy-4-methoxybutyrylsulfamoyl)adenosine	676279	86509	
PANTS	6.3.2.1		(2RS)-5'-O-(3,3-dimethyl-2-aminobutyrylsulfamoyl)adenosine	676279	16135	
PANTS	6.3.2.1		(2RS)-5'-O-(3,3-dimethyl-2-hydroxy-4-methoxybutyrylsulfamoyl)adenosine	676279	16137	
PANTS	6.3.2.1		(2RS)-5'-O-(3,3-dimethyl-2-hydroxybutyrylsulfamoyl)adenosine	676279	16138	
PANTS	6.3.2.1		(2RS)-5'-O-(3,3-dimethyl-2-oxobutyrylsulfamoyl)adenosine	676279	16136	
PANTS	6.3.2.1		(2RS)-adenosyl-2-hydroxy-3,3-dimethylbuyrate	676279	41753	
PANTS	6.3.2.1		(2RS)-adenosyl-2-hydroxy-4-methoxybutyrate	676279	41751	
PANTS	6.3.2.1		(2RS)-adenosyl-3,3-dimethyl-2-hydroxy-4-methoxybutyrate	676279	41752	
PANTS	6.3.2.1		(2S)-adenosyl-2-L-amino-3,3-dimethylbutanoate	676279	41749	
PANTS	6.3.2.1		1,10-phenanthroline	977, 978, 979	58	
PANTS	6.3.2.1		2-hydroxybutanoate	978	2470	slight
PANTS	6.3.2.1		2-Hydroxypropanoate	978	924	slight
PANTS	6.3.2.1		2,3-Diaminopropanoate	978	8502	slight
PANTS	6.3.2.1		3-hydroxybutanoate	978	2001	slight
PANTS	6.3.2.1		3-hydroxypropanoate	978	1223	slight
PANTS	6.3.2.1		3,3-dimethyl-2-oxobutyric acid 5-(6-aminopurin-9-yl)-3,4-dihydroxytetrahydrofuran-2-ylmethyl ester	676279	41750	
PANTS	6.3.2.1		4-Amino-3-hydroxybutanoate	977	13210	32% inhibition at 1 mM
PANTS	6.3.2.1		4-Amino-3-hydroxybutanoate	978	13210	
PANTS	6.3.2.1		4-aminobutanoate	977	492	27% inhibition at 1 mM
PANTS	6.3.2.1		4-aminobutanoate	978, 979	492	
PANTS	6.3.2.1		5-Aminopentanoate	978	1967	slight
PANTS	6.3.2.1		5-Aminopentanoate	979	1967	
PANTS	6.3.2.1		6-Aminohexanoate	978	1969	slight
PANTS	6.3.2.1		Ag+	977, 978, 979	71	
PANTS	6.3.2.1		AMP	979	9	
PANTS	6.3.2.1		anserine	978	4388	slight
PANTS	6.3.2.1		Asp	979	91	uncompetitive
PANTS	6.3.2.1		aspartate	977	91	24% inhibition at 1 mM
PANTS	6.3.2.1		Ba2+	977, 978	105	
PANTS	6.3.2.1		Ca2+	977, 978, 979	18	
PANTS	6.3.2.1		carnosine	978	2458	slight
PANTS	6.3.2.1		Co2+	977, 978	21	
PANTS	6.3.2.1		Cu2+	977, 978, 979	28	
PANTS	6.3.2.1		cysteine	979	70	weak
PANTS	6.3.2.1		diphosphate	979	13	
PANTS	6.3.2.1		DTT	979	42	weak
PANTS	6.3.2.1		EDTA	977, 978	223	
PANTS	6.3.2.1		EGTA	977, 978	157	
PANTS	6.3.2.1		Fe2+	977	23	slight
PANTS	6.3.2.1		Fe2+	978, 979	23	
PANTS	6.3.2.1		gluconate	977, 978	562	32% inhibition at 1 mM
PANTS	6.3.2.1		glycolate	977, 978	399	30% inhibition at 1 mM
PANTS	6.3.2.1		Hg2+	977, 978, 979	31	
PANTS	6.3.2.1		iodoacetate	978	87	
PANTS	6.3.2.1		iodoacetate	979	87	weak
PANTS	6.3.2.1		L-Ala	978, 979	97	
PANTS	6.3.2.1		L-cysteate	978	2703	
PANTS	6.3.2.1		L-Val	978	217	
PANTS	6.3.2.1		L-Val	979	217	uncompetitive
PANTS	6.3.2.1		Lactate	978	924	
PANTS	6.3.2.1		Li+	979	142	
PANTS	6.3.2.1		mercaptoethanol	979	59	weak
PANTS	6.3.2.1		Mercaptoethanolamine	979	632	weak
PANTS	6.3.2.1		Mercaptopurine	979	1019	weak
PANTS	6.3.2.1		Methylmalonate	977	1628	38% inhibition at 1 mM
PANTS	6.3.2.1		Mg2+	977	25	inhibition above 10 mM
PANTS	6.3.2.1		Mn2+	977	26	inhibition above 5 mM
PANTS	6.3.2.1		Ni2+	977, 978	36	slight
PANTS	6.3.2.1		Ni2+	979	36	
PANTS	6.3.2.1		pantothenic acid	979	1139	
PANTS	6.3.2.1		Pb2+	977	132	slight
PANTS	6.3.2.1		Pb2+	979	132	
PANTS	6.3.2.1		PCMB	979	40	
PANTS	6.3.2.1		Sn2+	977, 978	346	slight
PANTS	6.3.2.1		Sr2+	977, 978	289	slight
PANTS	6.3.2.1		taurine	977	490	52% inhibition at 1 mM
PANTS	6.3.2.1		taurine	978, 979	490	
PANTS	6.3.2.1		Zn2+	977, 978, 979	19	
DHFS	6.3.2.12		7,8-dihydrofolate	1018	173	
DHFS	6.3.2.12		Dihydro-10-thiopteroic acid	1013, 1017	20318	
DHFS	6.3.2.12		dihydrofolic acid	1013, 1017	173	
DHFS	6.3.2.12		Dihydrohomopteroic acid	1013, 1017, 1018	13349	
DHFS	6.3.2.12		Dihydroisopteroic acid	1013, 1017	20319	
DHFS	6.3.2.12		Dihydropterin-sulfonamides	1014		
UAAGDS	6.3.2.13		Butylamine	651110	1044	500 mM, 88% inhibition
UAAGDS	6.3.2.13		Butyrate	651110	385	500 mM, 44% inhibition
UAAGDS	6.3.2.13		ethylamine	651110	565	500 mM, 73% inhibition
UAAGDS	6.3.2.13		methylamine	651110	279	500 mM, 80% inhibition
UAAGDS	6.3.2.13		MurNAc(alpha-methyl)-L-Ala-D-Glu	1027	66565	
UAAGDS	6.3.2.13		MurNAc(beta-methyl)-L-Ala-D-Glu	1027	66566	
UAAGDS	6.3.2.13		Nalpha-Propionyl-L-Ala-2-amino-6-phosphonohexanoate	1036	66650	
UAAGDS	6.3.2.13		Nalpha-Propionyl-L-Ala-3-phosphonoacetamido-Ala	1036	66651	
UAAGDS	6.3.2.13		Nalpha-Propionyl-L-Ala-buthionine sulfoximine	1036	66652	
UAAGDS	6.3.2.13		P1-MurNAc-L-Ala-D-Glu	1027	28612	
UAAGDS	6.3.2.13		Propionyl-L-Ala-D-Glu(CH2Cl)-OH	1037	66718	
UAAGDS	6.3.2.13		Propionyl-L-Ala-xi-2-amino-4-phosphonobutanoate	1037	66719	
UAAGDS	6.3.2.13		Propylamine	651110	1072	500 mM, 87% inhibition
PRASCSi	6.3.2.6		adenosine 5'-(beta,gamma-imido)triphosphate	661204	2889	
PRASCSi	6.3.2.6		IMP	661204	206	competitive with respect to 1-(5'-phosphoribosyl)-5-amino-4-carboxyimidazole
PRASCSi	6.3.2.6		Maleate	661204	474	competitive with respect to L-Asp
UAMAS	6.3.2.8		(5Z)-5-([2-[(4-chlorobenzyl)sulfanyl]-5-nitrophenyl]methylidene)-2-thioxo-1,3-thiazolidin-4-one	694288	47717	
UAMAS	6.3.2.8		(5Z)-5-([4-[(E)-2-phenylethenyl]phenyl]methylidene)-2-thioxo-1,3-thiazolidin-4-one	694288	47718	
UAMAS	6.3.2.8		1H-indazole-3-carbohydrazide	691815	49641	
UAMAS	6.3.2.8		2-((4-[(2S)-butan-2-ylamino]-6-(ethylamino)-1,3,5-triazin-2-yl)sulfanyl)-N-(2-chlorophenyl)acetamide	715974	59224	0.5 mM, 26% inhibition
UAMAS	6.3.2.8		2-([2-(2-naphthylsulfonyl)hydrazono)methyl]phenyl 2-nitrobenzenesulfonate	694288	49650	55% inhibition at 0.05 mM
UAMAS	6.3.2.8		2-([2-(2-naphthylsulfonyl)hydrazono)methyl]phenyl 3-nitrobenzenesulfonate	694288	49651	65% inhibition at 0.05 mM
UAMAS	6.3.2.8		2-([2-(2-naphthylsulfonyl)hydrazono)methyl]phenyl 4-nitrobenzenesulfonate	694288	25766	75% inhibition at 0.10 mM
UAMAS	6.3.2.8		2-([2-(naphthalen-2-ylsulfonyl)hydrazono]methyl)phenyl 2-(benzo[d][1,3]dioxol-5-yl)acetate	694288	49657	57% inhibition at 0.10 mM
UAMAS	6.3.2.8		2-(4-{[(E)-2-(1H-indazol-3-ylcarbonyl)hydrazono]methyl} phenoxy) acetic acid	691815	92895	complete inhibition at 0.5 mM
UAMAS	6.3.2.8		2-[4-({(E)-2-[(4-methyl-1,3-thiazol-5-yl)carbonyl]hydrazono} methyl)phenoxy]acetic acid	691815	92907	complete inhibition at 0.5 mM
UAMAS	6.3.2.8		2-bromo-N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	25767	41% inhibition at 0.10 mM
UAMAS	6.3.2.8		2-phenyl-1,3-thiazole-5-carbohydrazide	691815	92886	
UAMAS	6.3.2.8		2-phenyl-N'-[(E)-(2,3,4-trihydroxyphenyl)methylidene]-1,3-thiazole-5-carbohydrazide	691815	49642	18% inhibition at 0.25 mM
UAMAS	6.3.2.8		3-bromo-N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	17392	
UAMAS	6.3.2.8		3-chloro-L-Ala	1277, 1286, 1287, 1288, 1289	1230	
UAMAS	6.3.2.8		3-Cyano-L-Ala	1277, 1286, 1287, 1288, 1289	2822	
UAMAS	6.3.2.8		3-Fluoro-L-Ala	1286, 1287, 1288	20017	
UAMAS	6.3.2.8		3,3-Difluoro-L-Ala	1286, 1288	28796	
UAMAS	6.3.2.8		3,3,3-Trifluoro-DL-Ala	1286, 1288	8342	
UAMAS	6.3.2.8		4-([(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl)-6-(naphthalen-2-ylmethyl)-1,3,5-triazin-2-amine	715974	59226	0.5 mM, 30% inhibition
UAMAS	6.3.2.8		4-({(E)-2-[(4-methyl-1,3-thiazol-5-yl)carbonyl]hydrazono} methyl)benzoic acid	691815	92906	94% inhibition at 0.5 mM
UAMAS	6.3.2.8		4-{[(E)-2-(1H-indazol-3-ylcarbonyl)hydrazono]methyl}benzoic acid	691815	92894	complete inhibition at 0.5 mM
UAMAS	6.3.2.8		4-cyano-N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	49654	91% inhibition at 0.05 mM
UAMAS	6.3.2.8		4-methyl-1,3-thiazole-5-carbohydrazide	691815	92885	
UAMAS	6.3.2.8		4-methyl-N'-[(E)-(2-phenyl-1,3-thiazol-4-yl)methylidene]-1,3-thiazole-5-carbohydrazide	691815	92909	complete inhibition at 0.5 mM
UAMAS	6.3.2.8		4-methyl-N'-[(E)-(2,3,4-trihydroxyphenyl)methylidene]-1,3-thiazole-5-carbohydrazide	691815	92901	26% inhibition at 0.5 mM
UAMAS	6.3.2.8		5-methyl-N-([4-(5-phenyl-1-benzofuran-2-yl)phenyl]sulfonyl)thiophene-2-carboxamide	661276	15398	IC50 2.3 microM
UAMAS	6.3.2.8		6-([(1,1-dioxidotetrahydrothiophen-3-yl)sulfanyl]methyl)-N-(2-phenylethyl)-1,3,5-triazine-2,4-diamine	715974	59225	0.25 mM, 32% inhibition
UAMAS	6.3.2.8		6-[(1-methyl-1H-imidazol-2-yl)sulfanyl]-N,N'-diphenyl-1,3,5-triazine-2,4-diamine	715974	59227	0.5 mM, 36% inhibition
UAMAS	6.3.2.8		ADP	662701	8	
UAMAS	6.3.2.8		benzohydrazide	691815	16899	
UAMAS	6.3.2.8		benzylidene rhodanines	694288		possess MurC inhibitory activity in the low micromolar range
UAMAS	6.3.2.8		beta-gamma-methyleneadenosine 5'-triphosphate	662701	2691	
UAMAS	6.3.2.8		feglymycin	727302	108742	isolated from Streptomyces sp. DSM 11171, 13-mer peptide, noncompetitive inhibition, the inhibition is fully reversible after dilution
UAMAS	6.3.2.8		Gly	1286, 1289	68	
UAMAS	6.3.2.8		KCl	1289	74	inhibition above 100 mM
UAMAS	6.3.2.8		L-2-aminobutyrate	1286, 1288	1112	
UAMAS	6.3.2.8		L-Allylglycine	1288	14152	weak
UAMAS	6.3.2.8		L-Cys	1286, 1288	70	weak
UAMAS	6.3.2.8		L-lactate	1286	338	
UAMAS	6.3.2.8		L-Propargylglycine	1286, 1288	729	
UAMAS	6.3.2.8		L-Ser	1286, 1289	89	
UAMAS	6.3.2.8		L-Vinylglycine	1286, 1288	1625	
UAMAS	6.3.2.8		methyl4-({(E)-2-[(4-methyl-1,3-thiazol-5-yl)carbonyl]hydrazono}methyl)benzoate	691815	92905	95% inhibition at 0.5 mM
UAMAS	6.3.2.8		methyl4-{[(E)-2-(1H-indazol-3-ylcarbonyl)hydrazono]methyl} benzoate	691815	92893	complete inhibition at 0.5 mM
UAMAS	6.3.2.8		N-(2-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-3,5-dinitrobenzamide	694288	49656	51% inhibition at 0.10 mM
UAMAS	6.3.2.8		N-(2-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-4-nitrobenzamide	694288	25769	
UAMAS	6.3.2.8		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-2-naphthamide	694288	25768	
UAMAS	6.3.2.8		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-2-nitrobenzamide	694288	17391	
UAMAS	6.3.2.8		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-3,5-dinitrobenzamide	694288	49653	72% inhibition at 0.10 mM
UAMAS	6.3.2.8		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-4-nitrobenzamide	694288	49655	71% inhibition at 0.05 mM
UAMAS	6.3.2.8		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	49652	97% inhibition at 0.10 mM
UAMAS	6.3.2.8		N-[(E)-(2,4-dihydroxyphenyl)methylidene]benzohydrazide	691815	92911	complete inhibition at 0.5 mM
UAMAS	6.3.2.8		N-Methyl-L-Ala	1286	5492	weak
UAMAS	6.3.2.8		N'-((2-[(2-nitrobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	25765	30% inhibition at 0.10 mM
UAMAS	6.3.2.8		N'-((2-[(3-nitrobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	49643	36% inhibition at 0.05 mM
UAMAS	6.3.2.8		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	25764	36% inhibition at 0.10 mM
UAMAS	6.3.2.8		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)-2-nitrobenzenesulfonohydrazide	694288	49645	95% inhibition at 0.01 mM
UAMAS	6.3.2.8		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)-3-nitrobenzenesulfonohydrazide	694288	49646	
UAMAS	6.3.2.8		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)(2-fluorophenyl)methanesulfonohydrazide	694288	49648	59% inhibition at 0.10 mM
UAMAS	6.3.2.8		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)(phenyl)methanesulfonohydrazide	694288	49647	complete inhibition at 0.10 mM
UAMAS	6.3.2.8		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)[4-(trifluoromethyl)phenyl]methanesulfonohydrazide	694288	49649	
UAMAS	6.3.2.8		N'-((3-[(3-nitrobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	49644	58% inhibition at 0.05 mM
UAMAS	6.3.2.8		N'-[(E)-(2-hydroxyphenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92892	complete inhibition at 0.25 mM
UAMAS	6.3.2.8		N'-[(E)-(2-phenyl-1,3-thiazol-4-yl)methylidene]-1H-indazole-3-carbohydrazide	691815	92899	78% inhibition at 0.10 mM
UAMAS	6.3.2.8		N'-[(E)-(2-phenyl-1,3-thiazol-4-yl)methylidene]benzohydrazide	691815	92917	70% inhibition at 0.25 mM
UAMAS	6.3.2.8		N'-[(E)-(2,3,4-trihydroxyphenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92887	42% inhibition at 0.25 mM
UAMAS	6.3.2.8		N'-[(E)-(2,3,4-trihydroxyphenyl)methylidene]benzohydrazide	691815	92910	64% inhibition at 0.10 mM
UAMAS	6.3.2.8		N'-[(E)-(2,4-dihydroxyphenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92888	74% inhibition at 0.25 mM
UAMAS	6.3.2.8		N'-[(E)-(3-hydroxy-4-methoxyphenyl)methylidene] benzohydrazide	691815	92913	92% inhibition at 0.5 mM
UAMAS	6.3.2.8		N'-[(E)-(3-hydroxy-4-methoxyphenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92890	67% inhibition at 0.25 mM
UAMAS	6.3.2.8		N'-[(E)-(3,4-dihydroxyphenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92889	36% inhibition at 0.5 mM
UAMAS	6.3.2.8		N'-[(E)-(3,4-dihydroxyphenyl)methylidene]-4-methyl-1,3-thiazole-5-carbohydrazide	691815	92902	95% inhibition at 0.5 mM
UAMAS	6.3.2.8		N'-[(E)-(3,4-dihydroxyphenyl)methylidene]benzohydrazide	691815	92912	complete inhibition at 0.5 mM
UAMAS	6.3.2.8		N'-[(E)-(3,4-dimethoxyphenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92891	complete inhibition at 0.5 mM
UAMAS	6.3.2.8		N'-[(E)-(3,4-dimethoxyphenyl)methylidene]-4-methyl-1,3-thiazole-5-carbohydrazide	691815	92903	complete inhibition at 0.5 mM
UAMAS	6.3.2.8		N'-[(E)-(3,4-dimethoxyphenyl)methylidene]benzohydrazide	691815	92914	97% inhibition at 0.5 mM
UAMAS	6.3.2.8		N'-[(E)-(3,5-dichloro-2-hydroxyphenyl)methylidene]-4-methyl-1,3-thiazole-5-carbohydrazide	691815	92904	43% inhibition at 0.25 mM
UAMAS	6.3.2.8		N'-[(E)-(4-cyanophenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92898	complete inhibition at 0.25 mM
UAMAS	6.3.2.8		N'-[(E)-(4-cyanophenyl)methylidene]benzohydrazide	691815	92916	complete inhibition at 0.25 mM
UAMAS	6.3.2.8		N'-[(E)-(4-nitrophenyl)methylidene]-1H-indazole-3-carbohydrazide	691815	92897	91% inhibition at 0.5 mM
UAMAS	6.3.2.8		N'-[(E)-1H-indol-3-ylmethylidene]-1H-indazole-3-carbohydrazide	691815	92900	complete inhibition at 010 mM
UAMAS	6.3.2.8		N'-[(E)-1H-indol-3-ylmethylidene]benzohydrazide	691815	92918	93% inhibition at 0.5 mM
UAMAS	6.3.2.8		N'-{(E)-[4-(dimethylamino)phenyl]methylidene}-1H-indazole-3-carbohydrazide	691815	92896	95% inhibition at 0.25 mM
UAMAS	6.3.2.8		N'-{(E)-[4-(dimethylamino)phenyl]methylidene}-4-methyl-1,3-thiazole-5-carbohydrazide	691815	92908	97% inhibition at 0.25 mM
UAMAS	6.3.2.8		N'-{(E)-[4-(dimethylamino)phenyl]methylidene}benzohydrazide	691815	92915	complete inhibition at 0.25 mM
UAMAS	6.3.2.8		NaCl	1289	39	inhibition above 100 mM
UAMAS	6.3.2.8		NEM	1287	46	partial protection by ATP
UAMAS	6.3.2.8		p-hydroxymercuribenzoate	1287	92	partial protection by ATP
UAMAS	6.3.2.8		potassium phosphate	1288	1140	no effect up to 20 mM, significant decrease of activity at higher concentrations
UAMAS	6.3.2.8		UDP-2-(acetylamino)-4-O-[[(2-carboxypropyl)(hydroxy)phosphoryl]methyl]-2-deoxy-alpha-D-glucopyranose	662701	82348	
UAMAS	6.3.2.8		UDP-N-acetylmuramoyl-L-Ala	1289	3004	
UAMAGS	6.3.2.9		(2R)-2-[((3-[(Z)-(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl)carbonyl)amino]pentanedioic acid	714905	59230	
UAMAGS	6.3.2.9		(2R)-2-[((4-[(Z)-(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl)carbonyl)amino]pentanedioic acid	714905	59228	
UAMAGS	6.3.2.9		(2R)-2-[[(7-(2-ethoxy-2-oxoethoxy)naphthalen-2-yl)sulfonyl]amino]pentanedioic acid	705031	54913	NMR and molecular dynamics analysis
UAMAGS	6.3.2.9		(2R)-2-[[(7-(3-phenylpropoxy)naphthalen-2-yl)sulfonyl]amino]pentanedioic acid	705031	54912	NMR and molecular dynamics analysis
UAMAGS	6.3.2.9		(2R)-2-[[(7-(4-cyanobenzyloxy)naphthalen-2-yl)sulfonyl]amino]pentanedioic acid	705031	18427	NMR and molecular dynamics analysis
UAMAGS	6.3.2.9		(2R)-2-[[(7-(4-cyanobenzyloxy)naphthalen-2-yl)sulfonyl]amino]pentanedioic acid	705227	18427	calculation of binding free energies. Main driving force for binding are non-polar van der Waals-interactions
UAMAGS	6.3.2.9		(2R)-2-[[(7-benzyloxynaphthalen-2-yl)sulfonyl]amino]pentanedioic acid	705227	54915	calculation of binding free energies. Main driving force for binding are non-polar van der Waals-interactions
UAMAGS	6.3.2.9		(2R)-2-[[(7-butoxynaphthalen-2-yl)sulfonyl]amino]pentanedioic acid	705031	54911	NMR and molecular dynamics analysis
UAMAGS	6.3.2.9		(2R)-2-[[(7-pentoxynaphthalen-2-yl)sulfonyl]amino]pentanedioic acid	705227	54914	calculation of binding free energies. Main driving force for binding are non-polar van der Waals-interactions
UAMAGS	6.3.2.9		(2S)-2-[((4-[(Z)-(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl)carbonyl)amino]pentanedioic acid	714905	59229	
UAMAGS	6.3.2.9		(R,Z)-2-(3-((1-carboxy-N-(4-((4-oxo-2-thioxothiazolidin-5-ylidene)-methyl)phenyl)formamido)methyl)benzamido)pentanedioic acid	715866	59233	
UAMAGS	6.3.2.9		(R,Z)-2-(3-((2-carboxy-N-(4-((4-oxo-2-thioxothiazolidin-5-ylidene)-methyl)phenyl)acetamido)methyl)benzamido)pentanedioic acid	715866	59234	in addition, weak activity against Gram-positive Staphylococcus aureus and Enterococcus faecalis
UAMAGS	6.3.2.9		(R,Z)-2-(3-((3-carboxy-N-(4-((4-oxo-2-thioxothiazolidin-5-ylidene)-methyl)phenyl)propanamido)methyl)benzamido)pentanedioic acid	715866	59235	in addition, weak activity against Gram-positive Staphylococcus aureus and Enterococcus faecalis
UAMAGS	6.3.2.9		(R,Z)-2-(3-((4-((2,4-dioxothiazolidin-5-ylidene)methyl)phenylamino)methyl)benzamido)pentanedioic acid	715847	59236	
UAMAGS	6.3.2.9		(R,Z)-2-(3-((4-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)phenylamino)methyl)benzamido)pentanedioic acid	715847	112424	
UAMAGS	6.3.2.9		[1-[(6-Uridinediphospho)hexanamido]ethyl](2,4-dicarboxybutyl)phosphinate pentasodium salt	1303	62596	good inhibitor, closely resembles the tetrahedral intermediate that is presumed to form the ligation reaction
UAMAGS	6.3.2.9		1-Phospho-N-acetylmuramoyl-L-Ala-D-Glu	1293	28612	
UAMAGS	6.3.2.9		2-((4-[(2S)-butan-2-ylamino]-6-(ethylamino)-1,3,5-triazin-2-yl)sulfanyl)-N-(2-chlorophenyl)acetamide	715974	59224	0.5 mM, 50% inhibition. Inhibitory to both MurC and MurD, ECs 6.3.2.8 and 6.3.2.9, respectively
UAMAGS	6.3.2.9		2-([2-(2-naphthylsulfonyl)hydrazono)methyl]phenyl 2-nitrobenzenesulfonate	694288	49650	71% inhibition at 0.05 mM
UAMAGS	6.3.2.9		2-([2-(2-naphthylsulfonyl)hydrazono)methyl]phenyl 3-nitrobenzenesulfonate	694288	49651	70% inhibition at 0.05 mM
UAMAGS	6.3.2.9		2-([2-(2-naphthylsulfonyl)hydrazono)methyl]phenyl 4-nitrobenzenesulfonate	694288	25766	
UAMAGS	6.3.2.9		2-([2-(naphthalen-2-ylsulfonyl)hydrazono]methyl)phenyl 2-(benzo[d][1,3]dioxol-5-yl)acetate	694288	49657	49% inhibition at 0.10 mM
UAMAGS	6.3.2.9		2-[([6-[(4-cyano-2-fluorobenzyl)oxy]naphthalen-2-yl]sulfonyl)amino]-5-hydroxybenzoic acid	714902	27999	
UAMAGS	6.3.2.9		2-[([6-[(4-cyano-2-fluorobenzyl)oxy]naphthalen-2-yl]sulfonyl)amino]benzene-1,4-dicarboxylic acid	714902	28000	
UAMAGS	6.3.2.9		2-bromo-N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	25767	
UAMAGS	6.3.2.9		2,3,4,5-tetrabromo-6-(3,6-dihydroxy-9H-xanthen-9-yl)benzoic acid	702636	54909	inhibitor identified by structure-based virtual screening
UAMAGS	6.3.2.9		2,4,6-Trinitrobenzenesulfonic acid	1302	2353	
UAMAGS	6.3.2.9		3-([[(5-amino-1,3,4-thiadiazol-2-yl)sulfanyl]acetyl]amino)-4-methylbenzoic acid	704728	54910	
UAMAGS	6.3.2.9		3-bromo-N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	17392	
UAMAGS	6.3.2.9		4-([(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl)-6-(naphthalen-2-ylmethyl)-1,3,5-triazin-2-amine	715974	59226	0.5 mM, 33% inhibition. Inhibitory to both MurC and MurD, ECs 6.3.2.8 and 6.3.2.9, respectively
UAMAGS	6.3.2.9		4-[([6-[(4-cyano-2-fluorobenzyl)oxy]naphthalen-2-yl]sulfonyl)amino]benzene-1,3-dicarboxylic acid	714902	28001	
UAMAGS	6.3.2.9		4-[([6-[(4-cyano-2-fluorobenzyl)oxy]naphthalen-2-yl]sulfonyl)amino]cyclohexane-1,3-dicarboxylic acid	714902	27998	
UAMAGS	6.3.2.9		4-cyano-N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	49654	78% inhibition at 0.05 mM
UAMAGS	6.3.2.9		6-([(1,1-dioxidotetrahydrothiophen-3-yl)sulfanyl]methyl)-N-(2-phenylethyl)-1,3,5-triazine-2,4-diamine	715974	59225	0.25 mM, 11% inhibition. Inhibitory to both MurC and MurD, ECs 6.3.2.8 and 6.3.2.9, respectively
UAMAGS	6.3.2.9		6-[(1-methyl-1H-imidazol-2-yl)sulfanyl]-N,N'-diphenyl-1,3,5-triazine-2,4-diamine	715974	59227	0.5 mM, 30% inhibition. Inhibitory to both MurC and MurD, ECs 6.3.2.8 and 6.3.2.9, respectively
UAMAGS	6.3.2.9		benzylidene rhodanines	694288		possess MurC inhibitory activity in the low micromolar range
UAMAGS	6.3.2.9		beta,gamma-methyleneadenosine 5'-triphosphate	704728	2691	nonhydrolyzable ATP analogue
UAMAGS	6.3.2.9		CPAHWPHPC	692904	49658	i.e. peptide MD-C7C_1, inhibits MurD
UAMAGS	6.3.2.9		CSAWSNKFC	692904	49659	i.e. peptide MD-C7C_2, inhibits MurD
UAMAGS	6.3.2.9		D-2-Aminoadipic acid	1293	29249	
UAMAGS	6.3.2.9		D-Asp	1293	517	weak
UAMAGS	6.3.2.9		D-erythro-3-Methylglutamic acid	1300	29262	
UAMAGS	6.3.2.9		D-erythro-4-Methylglutamic acid	1300	29263	
UAMAGS	6.3.2.9		D-Gln	1293	1586	weak
UAMAGS	6.3.2.9		D-Pyroglutamic acid	1293	20102	
UAMAGS	6.3.2.9		dihydrouridine 5'-diphosphate-N-acetylmuramoyl-L-Ala-D-Glu	1293	30158	
UAMAGS	6.3.2.9		DL-2-Amino-4-phosphonobutyric acid	1293	13355	
UAMAGS	6.3.2.9		DL-2-aminopimelic acid	1293	20331	
UAMAGS	6.3.2.9		DL-homocysteic acid	1300	5454	
UAMAGS	6.3.2.9		HSSWYIQHFPPL	692904	49660	i.e. peptide MD-12, inhibits MurD
UAMAGS	6.3.2.9		L-Glu	1293	38	
UAMAGS	6.3.2.9		N-([(2S)-2-[([1,1'-biphenyl]-4-yl-sulfonyl)amino]-propyl]sulfonyl)-D-glutamic acid	677175	41755	1 mM, 70% residual activity
UAMAGS	6.3.2.9		N-([(2S)-2-[(2-naphthylsulfonyl)amino]propyl]-sulfonyl)-D-glutamic acid	677175	41746	1 mM, 75% residual activity
UAMAGS	6.3.2.9		N-(2-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-3,5-dinitrobenzamide	694288	49656	
UAMAGS	6.3.2.9		N-(2-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-4-nitrobenzamide	694288	25769	
UAMAGS	6.3.2.9		N-(3-[[(carboxyacetyl)[4-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl]amino]methyl]benzoyl)-D-glutamic acid	715866	59232	
UAMAGS	6.3.2.9		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-2-naphthamide	694288	25768	19% inhibition at 0.01 mM
UAMAGS	6.3.2.9		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-2-nitrobenzamide	694288	17391	
UAMAGS	6.3.2.9		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-3,5-dinitrobenzamide	694288	49653	78% inhibition at 0.10 mM
UAMAGS	6.3.2.9		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)-4-nitrobenzamide	694288	49655	81% inhibition at 0.05 mM
UAMAGS	6.3.2.9		N-(4-([2-(2-naphthylsulfonyl)hydrazono]methyl)phenyl)benzamide	694288	49652	56% inhibition at 0.10 mM
UAMAGS	6.3.2.9		N-(6-butoxy-naphthalene-2-sulfonyl)-D-glutamic acid	675446	12117	competitive versus D-Glu, non-competitive versus ATP and UDP-N-acetylmuramoyl-L-Ala
UAMAGS	6.3.2.9		N-(6-butoxy-naphthalene-2-sulfonyl)-L-glutamic acid	675446	16139	competitive versus D-Glu, non-competitive versus UDP-N-acetylmuramoyl-L-Ala
UAMAGS	6.3.2.9		N-[((2S)-2-[[(E)-3-(1,3-benzodioxol-5-yl)-2-propenoyl]amino]propyl)sulfonyl]-D-glutamic acid	677175	41748	1 mM, 80% residual activity
UAMAGS	6.3.2.9		N-[[(2S)-2-([2-[2-(acetylamino)phenoxy]acetyl]-amino)propyl]sulfonyl]-D-glutamic acid	677175	41747	1 mM, 93% residual activity
UAMAGS	6.3.2.9		N-[[(2S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]sulfonyl]-D-glutamic acid	677175	41744	1 mM, 74% residual activity
UAMAGS	6.3.2.9		N-[[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-ethyl]sulfonyl]-D-glutamic acid	677175	41745	1 mM, 77% residual activity
UAMAGS	6.3.2.9		N-[2-fluoro-5-[([4-[(Z)-(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]phenyl]amino)methyl]benzoyl]-D-glutamic acid	715866	59231	
UAMAGS	6.3.2.9		N'-((2-[(2-nitrobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	25765	
UAMAGS	6.3.2.9		N'-((2-[(3-nitrobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	49643	70% inhibition at 0.05 mM
UAMAGS	6.3.2.9		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	25764	
UAMAGS	6.3.2.9		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)-2-nitrobenzenesulfonohydrazide	694288	49645	86% inhibition at 0.10 mM
UAMAGS	6.3.2.9		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)-3-nitrobenzenesulfonohydrazide	694288	49646	74% inhibition at 0.10 mM
UAMAGS	6.3.2.9		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)(2-fluorophenyl)methanesulfonohydrazide	694288	49648	39% inhibition at 0.10 mM
UAMAGS	6.3.2.9		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)(phenyl)methanesulfonohydrazide	694288	49647	58% inhibition at 0.10 mM
UAMAGS	6.3.2.9		N'-((2-[(4-cyanobenzyl)oxy]phenyl)methylidene)[4-(trifluoromethyl)phenyl]methanesulfonohydrazide	694288	49649	57% inhibition at 0.10 mM
UAMAGS	6.3.2.9		N'-((3-[(3-nitrobenzyl)oxy]phenyl)methylidene)-2-naphthalenesulfonohydrazide	694288	49644	61% inhibition at 0.05 mM
UAMAGS	6.3.2.9		Phosphinate	1302	13488	an analogue of UDP-N-acetylmuramoyl-dipeptide, the N-acetylmuramoyl moiety being replaced by a hexanoyl chain and the peptide bond between L-Ala and D-Glu by a tetrahedral phosphinate bond
UAMAGS	6.3.2.9		potassium phosphate	1305	1140	highly dependent on, optimal concentration: 11-16 mM, inhibition above 20 mM, phosphate ion is responsible for inhibition
UAMAGS	6.3.2.9		UDP-N-acetylmuramoyl-L-Ala-D-Glu	1276, 1293	2727	
PRAIS	6.3.3.1		1-(5-phosphoribosyl)-5-aminoimidazole	1308	3629	
PRAIS	6.3.3.1		ADP	1308	8	
PRAIS	6.3.3.1		fluorosulfonylbenzoyl adenosine	649909	5401	FSBA, time-dependent inactivation by covalent binding to Lys27
PRAIS	6.3.3.1		phosphate	1308	12	
DBTS	6.3.3.3		6-hydroxypyrimidin-4(3H)-one	653958	35671	competitive inhibition
DBTS	6.3.3.3		adenine	653958	136	
DBTS	6.3.3.3		ADP	1334	8	competitive to ATP
DBTS	6.3.3.3		ADP	1338	8	
DBTS	6.3.3.3		AMP	1338	9	
DBTS	6.3.3.3		AMP-PNP	653958	2889	
DBTS	6.3.3.3		dethiobiotin	1334	1865	10 mM, 30% inhibition
NADK	6.3.4.18		1-[(4-methylpiperazin-1-yl)methyl]-1H-indole-2,3-dione	702643	26694	; class II inhibitor
NADK	6.3.4.18		1-deoxy-1-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)pentitol	702643	18430	; noncompetitive, class III inhibitor
NADK	6.3.4.18		1,1'-(imidazolidine-1,3-diyldimethanediyl)bis(1H-indole-2,3-dione)	702643	27029	; class II inhibitor
NADK	6.3.4.18		2-(2,3-dioxo-2,3-dihydro-1H-indol-1-yl)-N,N-diethylacetamide	702643	18429	; noncompetitive, class II inhibitor
NADK	6.3.4.18		2-hydroxy-2-[(4-methyl-1,2,5-oxadiazol-3-yl)amino]-1H-indene-1,3(2H)-dione	702643	27025	; class I inhibitor
NADK	6.3.4.18		5-(trifluoromethoxy)-1H-indole-2,3-dione	702643	26706	; class II inhibitor
NADK	6.3.4.18		5-[(2-hydroxy-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)carbamoyl]-4-(trifluoromethyl)pyridin-2-olate	702643	96965	class I inhibitor
NADK	6.3.4.18		5-bromo-1-([3-[(2,3-dioxo-2,3-dihydro-1H-indol-1-yl)methyl]imidazolidin-1-yl]methyl)-1H-indole-2,3-dione	702643		
NADK	6.3.4.18		5-bromo-1-(morpholin-4-ylmethyl)-1H-indole-2,3-dione	702643	26707	; class II inhibitor
NADK	6.3.4.18		ethyl 1-[(2,3-dioxo-2,3-dihydro-1H-indol-1-yl)methyl]piperidine-4-carboxylate	702643	26712	; class II inhibitor
NADK	6.3.4.18		ethyl 4-(2-[[(4-chlorophenyl)sulfonyl]methyl]-1,3-thiazol-4-yl)-1,2-oxazole-3-carboxylate	702643	27030	
NADK	6.3.4.18		ethyl 4-(2-[[(4-chlorophenyl)sulfonyl]methyl]-1,3-thiazol-4-yl)-5-methyl-1,2-oxazole-3-carboxylate	702643	53610	; class III inhibitor
NADK	6.3.4.18		N-(2-hydroxy-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-1-methyl-1H-pyrazole-5-carboxamide	702643	96964	class I inhibitor
NADK	6.3.4.18		N-(2-hydroxy-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-1,3-dimethyl-1H-pyrazole-5-carboxamide	702643	54916	
NADK	6.3.4.18		N-(2-hydroxy-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-2-methyl-1,3-thiazole-4-carboxamide	702643	27026	; class I inhibitor
NADK	6.3.4.18		N-(2-hydroxy-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-4-methoxythiophene-3-carboxamide	702643	27028	; class I inhibitor
NADK	6.3.4.18		N-(2-hydroxy-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-6-methoxy-4-(trifluoromethyl)pyridine-3-carboxamide	702643	54917	
NADK	6.3.4.18		N-(2-hydroxy-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-9-oxo-9H-fluorene-4-carboxamide	702643	27027	; class I inhibitor
NADK	6.3.4.18		riboflavin	702643	298	
CTPS2	6.3.4.2		1-methyluric acid	702613	13135	
CTPS2	6.3.4.2		1,3-dimethyluric acid	702613	27031	pH-dependent inhibition, overview
CTPS2	6.3.4.2		1,3,7-trimethyluric acid	702613	27033	
CTPS2	6.3.4.2		1,3,7,9-tetramethyluric	702613	27034	
CTPS2	6.3.4.2		1,7-dimethyluric acid	702613	27032	pH-dependent inhibition, overview
CTPS2	6.3.4.2		2-aminopurine riboside	674909	5824	
CTPS2	6.3.4.2		2-Thiocytidine 5'-triphosphate	648986	19973	
CTPS2	6.3.4.2		2-thiouridine 5'-triphosphate	648986, 648993	8633	
CTPS2	6.3.4.2		2,6-diaminopurine riboside	674909	8830	
CTPS2	6.3.4.2		2'-deoxy-GTP	674909	194	no guanosine, kact: 1.5/sec, KA: 0.21 mM, Ki: 0.36 mM; the GTP analogue is capable of inhibiting Gln-dependent CTP formation at over 0.15 mM
CTPS2	6.3.4.2		2'-deoxy-guanosine	674909	419	
CTPS2	6.3.4.2		2',3'-dialdehyde adenosine 5'-triphosphate	672395	9333	irreversible inhibitor of CTPS
CTPS2	6.3.4.2		3,7-dimethyluric acid	702613	15230	
CTPS2	6.3.4.2		3'-deoxy-guanosine	674909	24354	
CTPS2	6.3.4.2		4-thiouridine 5'-triphosphate	648986, 648993	33741	
CTPS2	6.3.4.2		5-bromoUTP	648986, 648993	8299	
CTPS2	6.3.4.2		6-diazo-5-oxo-L-norleucine	648981	666	
CTPS2	6.3.4.2		6-thio-GTP	674909	12548	the GTP analogue is capable of inhibiting Gln-dependent CTP formation at over 0.15 mM
CTPS2	6.3.4.2		6-Thioguanine	674909	951	
CTPS2	6.3.4.2		6-thioguanosine	674909	6378	
CTPS2	6.3.4.2		6-thioguanosine 5'-triphosphate	674909	12118	no guanosine, kact: 8.5/sec, KA: 0.035 mM, Ki: 0.27 mM
CTPS2	6.3.4.2		7-deazaguanosine	674909	86514	
CTPS2	6.3.4.2		8-oxoguanosine	674909	16141	
CTPS2	6.3.4.2		8-oxoguanosine 5'-triphosphate	674909	24352	
CTPS2	6.3.4.2		acycloguanosine	674909	2196	
CTPS2	6.3.4.2		acycloguanosine monophosphate	674909	8513	
CTPS2	6.3.4.2		adenine	702613	136	
CTPS2	6.3.4.2		adenosine	674909	116	
CTPS2	6.3.4.2		Caffeine	702613	695	
CTPS2	6.3.4.2		Co2+	649002	21	above 2 mM
CTPS2	6.3.4.2		CTP	648986	56	
CTPS2	6.3.4.2		CTP	649000	56	IC50: 0.15 mM
CTPS2	6.3.4.2		Cu2+	649002	28	inhibition is not reversed by EDTA, in presence of dithiothreitol inhibition at concentrations below 0.2 mM
CTPS2	6.3.4.2		D,L-2-amino-4-phosphonobutyrate	648963	13355	
CTPS2	6.3.4.2		DELTA1-Pyrroline-5-carboxylate	648963	1456	weak
CTPS2	6.3.4.2		dideoxy-GTP	674909	11817	
CTPS2	6.3.4.2		GDP	674909	49	
CTPS2	6.3.4.2		glutamate gamma-semialdehyde	648963	6182	potent linear mixed-type inhibitor, competitive with respect to ammonia, no inhibition of the mutant enzyme C379A
CTPS2	6.3.4.2		GMP	674909	150	
CTPS2	6.3.4.2		GTP	661241	35	inhibition of glutamine-dependent CTP formation above 0.15 mM, inhibition of glutamine-dependent CTP formation in a concentration-dependent manner
CTPS2	6.3.4.2		GTP	674909	35	0.1 mM guanosine, kact: 10.3/sec, KA: 0.088 mM, Ki: 0.22 mM; 0.2 mM guanosine, kact: 8.2/sec, KA: 0.078 mM, Ki: 0.12 mM; allosteric effector, structural requirements for activation are stringent, but requirements for inhibition are lax. GTP promotes Gln hydrolysis but inhibits Gln-dependent CTP formation at concentrations of over 0.15 mM; no guanosine, kact: 10.6/sec, KA: 0.081 mM, Ki: 0.28 mM
CTPS2	6.3.4.2		GTP	702613	35	GTP acts a positive allosteric effector for Gln-dependent CTP formation. However, at concentrations exceeding 0.15 mM, GTP inhibits Gln-dependent CTP formation. Moreover, GTP is an inhibitor of NH3-dependent CTP formation at all concentrations
CTPS2	6.3.4.2		guanosine	674909	256	
CTPS2	6.3.4.2		guanosine 5'-tetraphosphate	674909	1332	; no guanosine, kact: 4/sec, KA: 0.19 mM, Ki: 0.5 mM; the GTP analogue is capable of inhibiting Gln-dependent CTP formation at over 0.15 mM
CTPS2	6.3.4.2		Inosine	674909	154	
CTPS2	6.3.4.2		ITP	674909	203	no guanosine, kact: 5.2/sec, KA: 2.9 mM, Ki: 4.5 mM; the GTP analogue is capable of inhibiting Gln-dependent CTP formation at over 0.15 mM
CTPS2	6.3.4.2		L-2-pyrrolidone 5-carboxylate	648963	784	weak competitive inhibition of the reaction with ammonia as substrate, no significant inhibition with glutamine as substrate
CTPS2	6.3.4.2		Mn2+	649002	26	above 2 mM
CTPS2	6.3.4.2		N-methylguanosine	674909	24353	
CTPS2	6.3.4.2		Ni2+	649002	36	in presence of dithiothreitol inhibition at concentrations below 0.2 mM
CTPS2	6.3.4.2		O-methylguanosine	674909	7910	
CTPS2	6.3.4.2		O-methylguanosine 5'-triphosphate	674909	12119	no guanosine, kact: 2.8/sec, KA: 0.13 mM, Ki: 0.29 mM
CTPS2	6.3.4.2		O6-methyl-GTP	674909	25770	the GTP analogue is capable of inhibiting Gln-dependent CTP formation at over 0.15 mM
CTPS2	6.3.4.2		paraxanthine	702613	2781	pH-dependent inhibition, overview
CTPS2	6.3.4.2		pyrrole-2-carboxylate	648963	3361	weak competitive inhibition of the reaction with ammonia as substrate, no significant inhibition with glutamine as substrate
CTPS2	6.3.4.2		S-nitroso-L-cysteine	677028	5700	specific irreversible inhibitor,inhibits the activity by 94%
CTPS2	6.3.4.2		S-nitroso-L-homocysteine	677028	6628	specific irreversible inhibitor, inhibits the activity by 90%
CTPS2	6.3.4.2		s4UTP	648986, 648993	14515	
CTPS2	6.3.4.2		SO42-	648963	148	
CTPS2	6.3.4.2		Theobromine	702613	1996	
CTPS2	6.3.4.2		theophylline	702613	926	pH-dependent inhibition, overview
CTPS2	6.3.4.2		Uracil	702613	287	
CTPS2	6.3.4.2		uracil-4-acetic acid	702613	27035	
CTPS2	6.3.4.2		Uric acid	702613	570	pH-dependent inhibition, overview
CTPS2	6.3.4.2		uridine	702613	227	
CTPS2	6.3.4.2		xanthine	702613	208	; pH-dependent inhibition, overview
CTPS2	6.3.4.2		Xanthosine	674909	927	
CTPS2	6.3.4.2		Zn2+	649002	19	inhibition is reversed by EDTA, in presence of dithiothreitol inhibition at concentrations below 0.2 mM
CTPS2	6.3.4.2	2'-deoxy-GTP		674909	194	0 mM guanosine, kact: 1.5/sec, KA: 0.21 mM, Ki: 0.36 mM; the GTP analogue is capable of activating Gln-dependent CTP formation
CTPS2	6.3.4.2	6-thio-GTP		674909	12548	the GTP analogue is capable of activating Gln-dependent CTP formation
CTPS2	6.3.4.2	6-thioguanosine 5'-triphosphate		674909	12118	0 mM guanosine, kact: 8.5/sec, KA: 0.035 mM, Ki: 0.27 mM
CTPS2	6.3.4.2	GTP		648962	35	required as an allosteric effector to promote glutamine hydrolysis
CTPS2	6.3.4.2	GTP		648963	35	required as allosteric effector to promote reaction with glutamine as substrate, GTP functions by stabilizing the protein conformation that binds the tetrahedral intermediate(s) formed during glutamine hydrolysis
CTPS2	6.3.4.2	GTP		661241	35	activates enzyme-catalyzed glutamine hydrolysis
CTPS2	6.3.4.2	GTP		674909	35	0.1 mM guanosine, kact: 10.3/sec, KA: 0.088 mM, Ki: 0.22 mM; 0.2 mM guanosine, kact: 8.2/sec, KA: 0.078 mM, Ki: 0.12 mM; 0 mM guanosine, kact: 10.6/sec, KA: 0.081 mM, Ki: 0.28 mM; allosteric effector, structural requirements for activation are stringent, but requirements for inhibition are lax. GTP promotes Gln hydrolysis but inhibits Gln-dependent CTP formation at concentrations of over 0.15 mM
CTPS2	6.3.4.2	GTP		690817	35	required, activates
CTPS2	6.3.4.2	GTP		702613	35	GTP acts a positive allosteric effector for Gln-dependent CTP formation. However, at concentrations exceeding 0.15 mM, GTP inhibits Gln-dependent CTP formation. Moreover, GTP is an inhibitor of NH3-dependent CTP formation at all concentrations
CTPS2	6.3.4.2	guanosine 5'-tetraphosphate		674909	1332	0 mM guanosine, kact: 4/sec, KA: 0.19 mM, Ki: 0.5 mM; the GTP analogue is capable of activating Gln-dependent CTP formation
CTPS2	6.3.4.2	ITP		674909	203	0 mM guanosine, kact: 5.2/sec, KA: 2.9 mM, Ki: 4.5 mM; the GTP analogue is capable of activating Gln-dependent CTP formation
CTPS2	6.3.4.2	O-methylguanosine 5'-triphosphate		674909	12119	0 mM guanosine, kact: 2.8/sec, KA: 0.13 mM, Ki: 0.29 mM
CTPS2	6.3.4.2	O6-methyl-GTP		674909	25770	the GTP analogue is capable of activating Gln-dependent CTP formation
ADSS	6.3.4.4		6-(4-bromo-2,3-dioxobutyl)thioadenosine 5'-monophosphate	649897	35672	
ADSS	6.3.4.4		6-mercaptopurine riboside 5'-phosphate	1537	13256	
ADSS	6.3.4.4		adenylosuccinate	1537	113171	
ADSS	6.3.4.4		beta,gamma-5'-Guanylylmethylene diphosphate	1537	13746	
ADSS	6.3.4.4		fumarate	652356	156	
ADSS	6.3.4.4		GDP	1537, 1557	49	
ADSS	6.3.4.4		guanosine 5'-diphosphate	651925	49	
ADSS	6.3.4.4		Guanosine 5'-diphosphate-3'-diphosphate	1542	2614	competitive with respect to GTP and noncompetitive with respect to L-Asp and IMP
ADSS	6.3.4.4		Guanosine 5'-O-[S-(4-bromo-2,3-dioxobutyl)thio]phosphate	1555	64618	
ADSS	6.3.4.4		Hadacidin	1537, 1557, 1558, 649264, 649423, 651925, 652347, 672068	2290	
ADSS	6.3.4.4		IMP	1557	206	
ADSS	6.3.4.4		Maleate	652356	474	
ADSS	6.3.4.4		NO3-	1557	263	
ADSS	6.3.4.4		Phenylglyoxal	1560	258	GTP or IMP partially protect
ADSS	6.3.4.4		succinate	649423	54	poor inhibitor
ADSS	6.3.4.4		succinate	1537, 652356	54	
GMPS2	6.3.5.2		(5R)-acivicin	650087	35674	
GMPS2	6.3.5.2		(alpha-S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid	650087	35673	trivial name acivicin
GMPS2	6.3.5.2		1-methyladenosine	1362	7054	
GMPS2	6.3.5.2		1-Ribosyl-4-hydroxy-6-aminopyrazolo[3,4-d]pyrimidine 5'-phosphate	1364	29068	
GMPS2	6.3.5.2		1-Ribosyl-4,6-dihydroxypyrazolo[3,4-d]-pyrimidine 5'-phosphate	1364	28614	
GMPS2	6.3.5.2		1,N6-Ethenoadenosine	1362	17043	
GMPS2	6.3.5.2		2-Amino-6-methylthiopurine ribonucleoside	1362	63011	
GMPS2	6.3.5.2		2-fluoroadenosine	1362	3754	
GMPS2	6.3.5.2		2-fluoroinosine 5'-monophosphate	649891	21290	50% inhibition above 2 mM
GMPS2	6.3.5.2		2,6-Diaminopurine ribonucleoside	1362	8830	
GMPS2	6.3.5.2		2'-deoxyadenosine	1362	304	
GMPS2	6.3.5.2		3'-deoxyadenosine	1362	1579	
GMPS2	6.3.5.2		5'-Azido-5'-deoxyadenosine	1362	63541	
GMPS2	6.3.5.2		5'-Thioethyl-5'-deoxyadenosine	1362	3126	
GMPS2	6.3.5.2		6-Amino-9-D-psicofuranosylpurine	1360	13251	i.e. psicofuranine, irreversible inhibition, dependent on presence of XMP and diphosphate
GMPS2	6.3.5.2		6-Chloropurine ribonucleoside	1362	4379	
GMPS2	6.3.5.2		6-diazo-5-oxo-L-norleucine	1365	666	irreversible inhibition is dependent on presence of XMP, ATP and Mg2+
GMPS2	6.3.5.2		6-diazo-5-oxo-L-norleucine	1380	666	irreversible inhibition of Gln-dependent activity
GMPS2	6.3.5.2		6-diazo-5-oxo-L-norleucine	1381	666	inhibition of Gln-dependent activity and NH4+-dependent activity
GMPS2	6.3.5.2		6-diazo-5-oxo-L-norleucine	1382	666	Gln-dependent activity is more sensitive than NH4+-dependent activity; inhibition of Gln-dependent activity and NH4+-dependent activity
GMPS2	6.3.5.2		6-diazo-5-oxo-L-norleucine	1360, 650087	666	
GMPS2	6.3.5.2		6-Methylmercaptopurine ribonucleoside	1362	4036	
GMPS2	6.3.5.2		6-Methylpurine ribonucleoside	1362	25372	
GMPS2	6.3.5.2		6-Methylpurine ribonucleotide	1362	63700	
GMPS2	6.3.5.2		6-Thio-GMP	649891	7110	
GMPS2	6.3.5.2		6-ThioGMP	1364	7110	
GMPS2	6.3.5.2		6-thioXMP	1364	10457	
GMPS2	6.3.5.2		8-aza-GMP	649891	10463	
GMPS2	6.3.5.2		8-azaadenosine	1362	6109	
GMPS2	6.3.5.2		8-azaGMP	1364	10463	
GMPS2	6.3.5.2		8-Bromoadenosine	1362	6111	
GMPS2	6.3.5.2		adenine arabinoside	1362	8319	
GMPS2	6.3.5.2		adenosine	1362	116	
GMPS2	6.3.5.2		ADP	1362	8	
GMPS2	6.3.5.2		azaserine	1375	1381	
GMPS2	6.3.5.2		Bromopyruvate	1380	1425	
GMPS2	6.3.5.2		Decoyinine	1362	6147	
GMPS2	6.3.5.2		diphosphate	1362	13	competitive with respect to ATP; kinetic parameters for the two progressively formed inhibitory complexes
GMPS2	6.3.5.2		DTNB	1380	196	
GMPS2	6.3.5.2		Glucofuranosyladenine	1362	64563	
GMPS2	6.3.5.2		GMP	649891	150	0.33 mM, 50% inhibition
GMPS2	6.3.5.2		guanidine hydrochloride	1360	804	
GMPS2	6.3.5.2		iodoacetamide	1381	63	inhibition of Gln-dependent activity, no inhibition of NH4+-dependent activity
GMPS2	6.3.5.2		Kinetin ribonucleoside	1362	64713	
GMPS2	6.3.5.2		L-2-Amino-4-oxo-5-chloropentanoic acid	1381	4073	inhibition of Gln-dependent activity and NH4+-dependent activity
GMPS2	6.3.5.2		mycophenolate	1362	470	
GMPS2	6.3.5.2		N2-hydroxyguanosine 5'-monophosphate	649891	35675	0.0003-0.0005 mM, 50% inhibition
GMPS2	6.3.5.2		N6-Allyladenosine	1362	65140	
GMPS2	6.3.5.2		N6-Benzyladenosine	1362	20509	
GMPS2	6.3.5.2		N6-Hydroxyaminopurine ribonucleoside	1362	65145	
GMPS2	6.3.5.2		N6-isopentenyladenosine	1362	4888	
GMPS2	6.3.5.2		N6-methyladenosine	1362	4448	
GMPS2	6.3.5.2		N6,N6-Dimethyladenosine	1362	63683	
GMPS2	6.3.5.2		Nucleodide inhibitors	1362		overview
GMPS2	6.3.5.2		oxanosine	649891	35676	
GMPS2	6.3.5.2		p-chloromercuribenzoate	1380	40	
GMPS2	6.3.5.2		tubercidin	1362	2600	
GMPS2	6.3.5.2		XMP	727023	772	substrate inhibition above 0.2 mM
GMPS2	6.3.5.2		Zeatin ribonucleoside	1362	65699	
PRFGS	6.3.5.3		albizziin	1670	7122	
PRFGS	6.3.5.3		Glu	1670	38	
